PostingID|Sponsor|StudyTitle|Disorder|Phase|LinkToSponsorStudyRegistry|LinkToClinicalTrials|drug_cui|drug_names
1|GSK|U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects with Acne|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114550|http://clinicaltrials.gov/show/NCT01706250|[C0005088, C0036079]|[benzoyl peroxide, salicylic acid]
3|GSK|GSK1550188, A randomised, single-blind, placebo controlled, dose ascending, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114243|http://clinicaltrials.gov/show/NCT01381536|[C1723401]|[belimumab]
4|GSK|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, versus Vehicle in Subjects with Plaque-type Psoriasis|Psoriasis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114741|http://clinicaltrials.gov/show/NCT00688519|[C0065767]|[calcipotriene]
8|GSK|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (clindamycin 1% and benzoyl peroxide 5%) to ACANYA™ Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) Topical Acne Medications|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114546|http://clinicaltrials.gov/show/NCT01015638|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
9|GSK|A single-blind, randomized, comparative split-face study evaluating the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of acne vulgaris.|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114547|http://clinicaltrials.gov/show/NCT00964223|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
10|GSK|A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream when used in Combination with Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114566|http://clinicaltrials.gov/show/NCT01016977|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
11|GSK|A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris|Acne Vulgaris|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114677|http://clinicaltrials.gov/show/NCT00776919|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
12|GSK|A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis|Psoriasis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114743|http://clinicaltrials.gov/show/NCT01139580|[C0065767]|[calcipotriene]
13|GSK|A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and lisinopril|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CFD109701|http://clinicaltrials.gov/show/NCT00508365|[C0054836]|[carvedilol]
14|GSK|COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy|Hypertension|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=COR111096|http://clinicaltrials.gov/show/NCT00624065|[C0054836]|[carvedilol]
16|GSK|A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV100781|http://clinicaltrials.gov/show/NCT00440128|[C2347566]|[casopitant]
19|GSK|A single-blind, randomized, comparative pilot study evaluating the tolerability of two topical combination therapies in the treatment of acne vulgaris|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114544|http://clinicaltrials.gov/show/NCT00887484|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
20|GSK|Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.|Dermatitis, Chronic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115054|http://clinicaltrials.gov/show/NCT01323673|[C0008992]|[clobetasol]
21|GSK|A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AC2108378|http://clinicaltrials.gov/show/NCT00453479|[C2699560]|[Darotropium Bromide]
22|GSK|Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AC2110664|http://clinicaltrials.gov/show/NCT00676052|[C2699560]|[Darotropium Bromide]
23|GSK|A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=DB1111581|http://clinicaltrials.gov/show/NCT00749411|[C2935023, C2699560]|[vilanterol, Darotropium Bromide]
32|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFR101782|http://clinicaltrials.gov/show/NCT00570492|[C1948374]|[fluticasone furoate]
33|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFR110537|http://clinicaltrials.gov/show/NCT00682643|[C1948374]|[fluticasone furoate]
34|GSK|A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis|Rhinitis, Allergic, Perennial|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFR111158|http://clinicaltrials.gov/show/NCT00730756|[C1948374]|[fluticasone furoate]
35|GSK|A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFU105924|http://clinicaltrials.gov/show/NCT00539006|[C1948374]|[fluticasone furoate]
36|GSK|A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFU105927|http://clinicaltrials.gov/show/NCT00519636|[C1948374]|[fluticasone furoate]
37|GSK|A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis|Rhinitis, Allergic, Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFU109047|http://clinicaltrials.gov/show/NCT00502775|[C1948374]|[fluticasone furoate]
38|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFU111439|http://clinicaltrials.gov/show/NCT00609674|[C1948374]|[fluticasone furoate]
39|GSK|A randomised, double-blind, placebo-controlled, 4-period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 g, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=110341|http://clinicaltrials.gov/show/NCT00848965|[C0117996]|[fluticasone propionate]
40|GSK|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ADA109055|http://clinicaltrials.gov/show/NCT00452699|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
41|GSK|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ADA109057|http://clinicaltrials.gov/show/NCT00452348|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
42|GSK|A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=113872|http://clinicaltrials.gov/show/NCT01192178|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
43|GSK|A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111114|http://clinicaltrials.gov/show/NCT00784550|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
44|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50mcg twice-daily in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111117|http://clinicaltrials.gov/show/NCT00633217|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
45|GSK|A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=112355|http://clinicaltrials.gov/show/NCT00857766|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
46|GSK|A study of fluticasone propionate/salmeterol DISKUS combination product 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=113877|http://clinicaltrials.gov/show/NCT01124422|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
47|GSK|A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFA106484|http://clinicaltrials.gov/show/NCT00441441|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
48|GSK|FondaparinUx Trial with Unfractionated Heparin (UFH) during Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with Unstable Angina/Non ST segment elevation myocardial infarction (UA/NSTEMI) initially treated with subcutaneous fondaparinux and referred for early coronary angiography (OASIS 8)|Acute Coronary Syndrome|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=108888|http://clinicaltrials.gov/show/NCT00790907|[C1099664]|[fondaparinux sodium]
49|GSK|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)|Embolism, Pulmonary|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106206|http://clinicaltrials.gov/show/NCT00981409|[C1099664]|[fondaparinux sodium]
50|GSK|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)|Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111436|http://clinicaltrials.gov/show/NCT00911157|[C1099664]|[fondaparinux sodium]
51|GSK|An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=IPR110723|http://clinicaltrials.gov/show/NCT00612820|[C2934026]|[GSK-256066]
52|GSK|A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asthmatic response in subjects with mild asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110762|http://clinicaltrials.gov/show/NCT00857857|[C3659427]|[GW870086X]
53|GSK|An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder|Mood Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LBI108884|http://clinicaltrials.gov/show/NCT00579982|[C0064636]|[lamotrigine]
54|GSK|Lamotrigine Extended-Release in Elderly Patients with Epilepsy|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LEP105972|http://clinicaltrials.gov/show/NCT00516139|[C0064636]|[lamotrigine]
55|GSK|Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA104779|http://clinicaltrials.gov/show/NCT00550407|[C0064636]|[lamotrigine]
56|GSK|Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA106052|http://clinicaltrials.gov/show/NCT00566020|[C0064636]|[lamotrigine]
74|GSK|A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects|Hypertriglyceridemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=OM9L|http://clinicaltrials.gov/show/NCT00435045|[C1532673]|['omega-3 acid ethyl esters (USP)']
79|GSK|Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND|Diabetes Mellitus, Type 1|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115495|http://clinicaltrials.gov/show/NCT00678886|[C2935224]|[otelixizumab]
80|GSK|A randomised, single-blind, placebo-controlled, study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending administration of otelixizumab in subjects with Type 1 Diabetes Mellitus|Diabetes Mellitus, Type 1|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112438|http://clinicaltrials.gov/show/NCT00946257|[C2935224]|[otelixizumab]
82|GSK|A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study>|Depressive Disorder|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=112487|http://clinicaltrials.gov/show/NCT00812812|[C0070122]|[paroxetine]
101|GSK|Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus|Infections, Bacterial|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ALB110247|http://clinicaltrials.gov/show/NCT00539994|[C1703334]|[retapamulin]
102|GSK|An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months|Skin Infections, Bacterial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=TOC106489|http://clinicaltrials.gov/show/NCT00555061|[C1703334]|[retapamulin]
103|GSK|A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL|Skin Infections, Bacterial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=110977|http://clinicaltrials.gov/show/NCT00684177|[C1703334]|[retapamulin]
104|GSK|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus|Skin Infections, Bacterial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=110978|http://clinicaltrials.gov/show/NCT00852540|[C1703334]|[retapamulin]
105|GSK|An open label, single-dose, fixed sequence, two treatment period study to assess the effect of haemodialysis on the pharmacokinetics of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR).|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115214|http://clinicaltrials.gov/show/NCT01480609|[C0530684]|[ezogabine]
106|GSK|A multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIa study using 18F fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on macrophage activity in subjects with atherosclerosis|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=LP2105521|http://clinicaltrials.gov/show/NCT00695305|[C2699087]|[rilapladib]
107|GSK|A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius|Fracture Healing|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=CR9108914|http://clinicaltrials.gov/show/NCT00548496|[C2825588]|[ronacaleret]
108|GSK|Study CR9108963: A 12-month, randomized, double-blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with osteoporosis|Osteoporosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=CR9108963|http://clinicaltrials.gov/show/NCT00471237|[C2825588]|[ronacaleret]
110|GSK|Clinical Evaluation of ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in subjects with advanced Parkinson’s disease|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106066|http://clinicaltrials.gov/show/NCT00823836|[C0244821]|[ropinirole]
111|GSK|An open label, repeat dose, dose escalation study conducted in Parkinson's Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets.|Parkinson Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ROP109087|http://clinicaltrials.gov/show/NCT00460148|[C0244821]|[ropinirole]
112|GSK|Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration)|Restless Legs Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113079|http://clinicaltrials.gov/show/NCT00996944|[C0244821]|[ropinirole]
113|GSK|Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory|Restless Legs Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=107846|http://clinicaltrials.gov/show/NCT00530790|[C0244821]|[ropinirole]
114|GSK|An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4).|Alzheimer's Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVA102675|http://clinicaltrials.gov/show/NCT00490568|[C0289313]|[rosiglitazone]
115|GSK|An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5)|Alzheimer's Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVA102677|http://clinicaltrials.gov/show/NCT00550420|[C0289313]|[rosiglitazone]
116|GSK|A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)|Alzheimer's Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105640|http://clinicaltrials.gov/show/NCT00428090|[C0289313]|[rosiglitazone]
117|GSK|An open label single oral dose study in patients with mild Alzheimer's disease to assess the pharmacokinetics of extended release formulation of Rosiglitazone (RSG XR) in this population|Alzheimer's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AVA109941|http://clinicaltrials.gov/show/NCT00688207|[C0289313]|[rosiglitazone]
118|GSK|A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AVD111179|http://clinicaltrials.gov/show/NCT00679939|[C0289313]|[rosiglitazone]
119|GSK|Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111960|http://clinicaltrials.gov/show/NCT00879970|[C0289313]|[rosiglitazone]
120|GSK|A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administered alone or in conjunction with intranasal fluticasone propionate on the symptoms of rhinitis in the Vienna allergen challenge chamber|Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111924|http://clinicaltrials.gov/show/NCT01424397|[C1744311]|[SB 705498]
121|GSK|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2|Migraine Disorders|Phase 3|nan|http://clinicaltrials.gov/show/NCT01812408|[C0075632, C0027396]|[sumatriptan, naproxen]
122|GSK|A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2|Migraine Disorders|Phase 3|nan|http://clinicaltrials.gov/show/NCT00599157|[C0075632, C0027396]|[sumatriptan, naproxen]
123|GSK|Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=110948|http://clinicaltrials.gov/show/NCT00792636|[C0075632, C0027396]|[sumatriptan, naproxen]
124|GSK|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris|Acne Vulgaris|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114575|http://clinicaltrials.gov/show/NCT01017146|[C0288792]|[tazarotene]
125|GSK|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris|Acne Vulgaris|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114576|http://clinicaltrials.gov/show/NCT01017120|[C0288792]|[tazarotene]
127|GSK|A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia|Sleep Initiation and Maintenance Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKI110334|http://clinicaltrials.gov/show/NCT00606697|[C2607417]|[vestipitant]
128|GSK|A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients|Sleep Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111364|http://clinicaltrials.gov/show/NCT00992160|[C2607417]|[vestipitant]
141|GSK|Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=104977|http://clinicaltrials.gov/show/NCT00473668|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
142|GSK|Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals’ GSK2036874A vaccine in healthy toddlers|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113264|http://clinicaltrials.gov/show/NCT01106092|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
151|GSK|Evaluation of GSK Biological’s dTpa-IPV booster vaccine in children and adolescents, 5 years after previous dTpa-IPV boosting.|Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=110947|http://clinicaltrials.gov/show/NCT00635128|[C5233092, C0305062, C0982332, C0718003]|[Reduced cysteine content, 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', 'Poliovirus Vaccine, Inactivated']
152|GSK|Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 5 to 6-year-old children.|Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111815|http://clinicaltrials.gov/show/NCT00871000|[C5233092, C0305062, C0982332, C0718003]|[Reduced cysteine content, 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', 'Poliovirus Vaccine, Inactivated']
281|GSK|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD)|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30008|nan|[C0216660]|[zanamivir]
282|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30009|nan|[C0216660]|[zanamivir]
283|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30010|nan|[C0216660]|[zanamivir]
284|GSK|A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30012|nan|[C0216660]|[zanamivir]
285|GSK|A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel.|Influenza, Human|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30015|nan|[C0216660]|[zanamivir]
286|GSK|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30020|nan|[C0216660]|[zanamivir]
287|GSK|A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30028|nan|[C0216660]|[zanamivir]
288|GSK|A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30031|nan|[C0216660]|[zanamivir]
289|GSK|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk …|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30034|nan|[C0216660]|[zanamivir]
290|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3002|nan|[C0216660]|[zanamivir]
291|GSK|A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3003|nan|[C0216660]|[zanamivir]
292|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3004|nan|[C0216660]|[zanamivir]
293|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA3005|nan|[C0216660]|[zanamivir]
294|GSK|A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB3001|nan|[C0216660]|[zanamivir]
295|GSK|A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB3002|nan|[C0216660]|[zanamivir]
296|GSK|A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115902|http://clinicaltrials.gov/show/NCT01132443|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
297|GSK|Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-101|nan|[C0530684]|[ezogabine]
298|GSK|Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-102|nan|[C0530684]|[ezogabine]
299|GSK|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia|Neuralgia, Postherpetic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-NP201|http://clinicaltrials.gov/show/NCT00612105|[C0530684]|[ezogabine]
312|GSK|An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV110483|http://clinicaltrials.gov/show/NCT00511823|[C2347566]|[casopitant]
313|GSK|A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AC2106213|http://clinicaltrials.gov/show/NCT00500461|[C2699560]|[Darotropium Bromide]
314|GSK|A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AC2108380|http://clinicaltrials.gov/show/NCT00453687|[C2699560]|[Darotropium Bromide]
320|GSK|A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM105379|http://clinicaltrials.gov/show/NCT00412191|[C0064636]|[lamotrigine]
321|GSK|An open-label, randomised, single-dose, parallel-group study to demonstrate bioequivalence of two formulations and the effect of food and water on one formulation of lamotrigine in healthy male and female volunteers|Mental Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LBI108617|http://clinicaltrials.gov/show/NCT00449774|[C0064636]|[lamotrigine]
322|GSK|A randomised, double-blind study in healthy volunteers to compare the properties and characteristics of an investigational formulation of lamotrigine with placebo|Mental Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111649|http://clinicaltrials.gov/show/NCT01607086|[C0064636]|[lamotrigine]
323|GSK|An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LEP108937|http://clinicaltrials.gov/show/NCT00627575|[C0064636]|[lamotrigine]
324|GSK|A pivotal single-dose, randomised, parallel-group, open-label study to demonstrate bioequivalence of 250mg lamotrigine XR relative to 200mg + 50mg lamotrigine XR and to demonstrate lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LEP111102|http://clinicaltrials.gov/show/NCT00605371|[C0064636]|[lamotrigine]
325|GSK|An open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of retigavine given as the Market Image tablet compared to the retigavine clinical trial tablets.|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113287|nan|[C0530684]|[ezogabine]
326|GSK|An open label study conducted in healthy subjects to demonstrate bioequivalence between ropinirole prolonged release tablets (ropinirole XL, marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) manufactured at Crawley and Aranda|Parkinson Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112771|http://clinicaltrials.gov/show/NCT01371682|[C0244821]|[ropinirole]
327|GSK|A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM)|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=DIX110434|http://clinicaltrials.gov/show/NCT00551564|[C0289313]|[rosiglitazone]
328|GSK|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114571|http://clinicaltrials.gov/show/NCT01112787|[C0288792]|[tazarotene]
329|GSK|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114572|http://clinicaltrials.gov/show/NCT01114841|[C0288792]|[tazarotene]
330|GSK|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114573|http://clinicaltrials.gov/show/NCT01115322|[C0288792]|[tazarotene]
331|GSK|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114574|http://clinicaltrials.gov/show/NCT01119651|[C0288792]|[tazarotene]
332|GSK|Carvedilol Prospective Randomized Cumulative Survival Trial.|Heart failure, Congestive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105517/287|nan|[C0054836]|[carvedilol]
369|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer|Neoplasms, Prostate|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40006|http://clinicaltrials.gov/show/NCT00056407|[C0754659]|[dutasteride]
370|GSK|A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40005|http://clinicaltrials.gov/show/NCT00090103|[C0754659]|[dutasteride]
371|GSK|A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management|Neoplasms, Prostate|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AVO105948|http://clinicaltrials.gov/show/NCT00363311|[C0754659]|[dutasteride]
372|GSK|HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=102871|http://clinicaltrials.gov/show/NCT01009463|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
373|GSK|A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HZA102928|http://clinicaltrials.gov/show/NCT00522678|[C1948374]|[fluticasone furoate]
374|GSK|An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102932|http://clinicaltrials.gov/show/NCT01213849|[C1948374]|[fluticasone furoate]
375|GSK|A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102936|http://clinicaltrials.gov/show/NCT01209026|[C1948374]|[fluticasone furoate]
376|GSK|A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HZA102940|http://clinicaltrials.gov/show/NCT00625196|[C1948374]|[fluticasone furoate]
377|GSK|A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800?g) with and without magnesium stearate, in mild/moderate asthmatic patients.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HZA108799|http://clinicaltrials.gov/show/NCT00444509|[C1948374]|[fluticasone furoate]
378|GSK|A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent an|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFA109684|http://clinicaltrials.gov/show/NCT00603746|[C1948374]|[fluticasone furoate]
379|GSK|A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFA109685|http://clinicaltrials.gov/show/NCT00603278|[C1948374]|[fluticasone furoate]
380|GSK|A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFA109687|http://clinicaltrials.gov/show/NCT00603382|[C1948374]|[fluticasone furoate]
381|GSK|An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepatic impairment|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111789|http://clinicaltrials.gov/show/NCT01266941|[C1948374]|[fluticasone furoate]
382|GSK|Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112018|http://clinicaltrials.gov/show/NCT00972673|[C1948374]|[fluticasone furoate]
383|GSK|A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112202|http://clinicaltrials.gov/show/NCT00766090|[C1948374]|[fluticasone furoate]
384|GSK|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112206|http://clinicaltrials.gov/show/NCT01053988|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
385|GSK|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112207|http://clinicaltrials.gov/show/NCT01054885|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
386|GSK|A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113107|http://clinicaltrials.gov/show/NCT01342913|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
387|GSK|An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113477|http://clinicaltrials.gov/show/NCT01000597|[C1948374]|[fluticasone furoate]
388|GSK|An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102934|http://clinicaltrials.gov/show/NCT01299558|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
389|GSK|HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106829|http://clinicaltrials.gov/show/NCT01134042|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
390|GSK|A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106839|http://clinicaltrials.gov/show/NCT01018186|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
391|GSK|Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106851|http://clinicaltrials.gov/show/NCT01086410|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
392|GSK|A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113091|http://clinicaltrials.gov/show/NCT01147848|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
394|GSK|A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FLTA3025|nan|[C0117996]|[fluticasone propionate]
396|GSK|HZC102970: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=102970|http://clinicaltrials.gov/show/NCT01017952|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
397|GSK|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ADA103575|http://clinicaltrials.gov/show/NCT00296491|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
398|GSK|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ADA103578|http://clinicaltrials.gov/show/NCT00296530|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
399|GSK|A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ADC105931|http://clinicaltrials.gov/show/NCT00346749|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
400|GSK|A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40031|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
401|GSK|Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40056|http://clinicaltrials.gov/show/NCT00479739|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
402|GSK|A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic)|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40065|http://clinicaltrials.gov/show/NCT01324362|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
403|GSK|A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic)|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40086|http://clinicaltrials.gov/show/NCT00920543|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
404|GSK|Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40100|http://clinicaltrials.gov/show/NCT00169546|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
405|GSK|A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40101|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
406|GSK|Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40104|http://clinicaltrials.gov/show/NCT00370591|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
407|GSK|A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10006|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
408|GSK|A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10007|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
409|GSK|A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg)|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10016|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
410|GSK|A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10019|http://clinicaltrials.gov/show/NCT00364442|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
411|GSK|A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SAS104449|http://clinicaltrials.gov/show/NCT00369993|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
412|GSK|A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS105519|http://clinicaltrials.gov/show/NCT00400608|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
413|GSK|A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30021|http://clinicaltrials.gov/show/NCT00920959|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
414|GSK|A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg Twice Daily with Salmeterol Diskus 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100250|http://clinicaltrials.gov/show/NCT00115492|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
415|GSK|A randomized, double-blind placebo-controlled study of treatments with salmeterol, fluticasone propionate and their combination to evaluate novel endpoints in patients with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=104925|http://clinicaltrials.gov/show/NCT00358358|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
416|GSK|A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE® inhaler) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the DISKUS®/ACCUHALER® inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCO30003|http://clinicaltrials.gov/show/NCT00268216|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
417|GSK|A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCO30005|http://clinicaltrials.gov/show/NCT00268177|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
418|GSK|A Randomized, Double Blind, Placebo Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone/Salmeterol Combination Product 250/50mcg twice daily via DISKUS and Salmeterol 50 mcg twice daily via DISKUS on Lung Hyperinflation in Subjects with COPD.|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40030|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
419|GSK|A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS® inhaler versus salmeterol 50mcg twice daily via DISKUS® inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40041|http://clinicaltrials.gov/show/NCT00355342|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
420|GSK|A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 250/50mcg twice daily with Salmeterol DISKUS® inhaler 50mcg twice daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40043|http://clinicaltrials.gov/show/NCT00144911|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
421|GSK|Randomized, Double-Blind Comparison of ADVAIR® medication 100/50 Twice Daily vs Salmeterol Twice Daily vs Albuterol QID in subjects with ARG/ARG genotype 12 years of Age and Older with Presistent Asthma on Short-Acting Beta2-Agonists Alone|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100062|http://clinicaltrials.gov/show/NCT00102882|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
422|GSK|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm|Bronchospasm|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100314|http://clinicaltrials.gov/show/NCT00118716|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
423|GSK|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS® inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS® inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm|Bronchospasm|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100316|http://clinicaltrials.gov/show/NCT00118690|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
424|GSK|A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® Inhaler Twice Daily or Fluticasone Propionate 100mcg DISKUS® Inhaler Twice Daily Alone.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SFA103153|http://clinicaltrials.gov/show/NCT00102765|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
425|GSK|A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the Salmeterol/Fluticasone combination product (50/500mg strength) twice daily with Salmeterol 50mg twice daily alone and Fluticasone Propionate 500mg twice daily alone, all delivered via the Diskus/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFCB3024|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
426|GSK|A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3007|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
427|GSK|A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulations of salmeterol 50mcg twice daily and fluticasone propionate 500mcg twice daily individually and in combination as compared to placebo in COPD patients.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3006|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
428|GSK|A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100470|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
429|GSK|A multicentre randomised double-blind parallel group placebo controlled study assessing the efficacy and safety of inhaled salmeterol/fluticasone 50/500mcg twice daily, inhaled fluticasone 500mcg twice daily and placebo all administered via MDI in the treatment of patients with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCO30002|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
430|GSK|An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10013|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
433|GSK|An open-label, randomised, crossover study to assess the relative bioavailability of different 2mg formulations of GSK2018682(S1P1 agonist) in healthy volunteers|Multiple Sclerosis, Relapsing-Remitting|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114919|http://clinicaltrials.gov/show/NCT01466322|[C4549166]|[GSK2018682]
457|GSK|A Double-blind, Double-dummy, Parallel-group Comparison of Lamotrigine and Divalproex Sodium Initial Monotherapy in Patients with Epilepsy|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCAA4001|nan|[C0064636]|[lamotrigine]
474|GSK|An open label, randomized, up-titration study to assess the effect of urine sample handling procedures on the safety results of urine obtained from healthy subjects receiving repeat doses of ezogabine/retigabine.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114137|nan|[C0530684]|[ezogabine]
475|GSK|A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/048|http://clinicaltrials.gov/show/NCT00279045|[C0289313]|[rosiglitazone]
476|GSK|A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=BRL-49653/137|http://clinicaltrials.gov/show/NCT00500955|[C0289313]|[rosiglitazone]
477|GSK|A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II)|Heart failure, Congestive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/211|nan|[C0289313]|[rosiglitazone]
478|GSK|A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=BRL-049653/231|http://clinicaltrials.gov/show/NCT00379769|[C0289313]|[rosiglitazone]
479|GSK|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Rosiglitazone in Combination with Glimepiride Compared to Glimepiride Plus Placebo for 24 Weeks in Subjects with Type 2 DiabetesMellitus Who are Inadequately Controlled on Non-TZD Oral Monotherapy|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/325|nan|[C0289313]|[rosiglitazone]
480|GSK|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis|Psoriasis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/330|nan|[C0289313]|[rosiglitazone]
481|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis|Psoriasis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/331|nan|[C0289313]|[rosiglitazone]
482|GSK|Effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/334|http://clinicaltrials.gov/show/NCT00306644|[C0289313]|[rosiglitazone]
483|GSK|A Study to Investigate the Mechanism of Fluid Retention with AVANDIA™ in Combination with a Euglycaemic/Hyperinsulinaemic Clamp.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/339|nan|[C0289313]|[rosiglitazone]
484|GSK|A Randomised study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated with Avandia|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/342|http://clinicaltrials.gov/show/NCT00306696|[C0289313]|[rosiglitazone]
485|GSK|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/347|http://clinicaltrials.gov/show/NCT00329225|[C0289313]|[rosiglitazone]
486|GSK|A 12 month randomized, double-blind, placebo-controlled, magnetic resonance imaging study to evaulate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=BRL-049563/351|nan|[C0289313]|[rosiglitazone]
487|GSK|A 16 Week Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Rosiglitazone on Myocardial Glucose Uptake in Subjects with Type 2 Diabetes Mellitus and Stable Coronary Heart Disease|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/352|nan|[C0289313]|[rosiglitazone]
489|GSK|A 16-week, randomised, double-blind, placebo-controlled, single-centre study to investigate fluid retention in insulin-treated subjects with type 2 diabetes mellitus and varying degrees of autonomic neuropathy when administered rosiglitazone 4mg twice daily|Neuropathy, Diabetic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/376|http://clinicaltrials.gov/show/NCT00422955|[C0289313]|[rosiglitazone]
490|GSK|A Study to Evaluate the Effect of Single and Repeat Doses of Rosiglitazone on the Pharmacokinetics of Methotrexate in Patients Receiving Methotrexate for Psoriasis|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/411|nan|[C0289313]|[rosiglitazone]
491|GSK|A study to evaluate the effect of repeat doses of rosiglitazone on the pharmacokinetics of repeat doses of acitretin in patients receiving acitretin for psoriasis.|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/413|nan|[C0289313]|[rosiglitazone]
492|GSK|An open-label, non-randomized, two period study to investigate the pharmacokinetics of rosiglitazone and glibenclamide when administered alone and concomitantly in healthy male Japanese and Caucasian subjects.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/414|nan|[C0289313]|[rosiglitazone]
494|GSK|A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS)|Multiple Sclerosis, Relapsing-Remitting|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=49653/452|nan|[C0289313]|[rosiglitazone]
495|GSK|A double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilization and cognition in subjects with mild to moderate Alzheimer's Disease (AD)|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=BRL-49653/461|http://clinicaltrials.gov/show/NCT00265148|[C0289313]|[rosiglitazone]
496|GSK|An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosiglitazone when Co-administered with Gemfibrozil in Healthy Adult Subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/902|nan|[C0289313]|[rosiglitazone]
497|GSK|A randomized, open-label, two-period crossover study to demonstrate the bioequivalence of twice-daily immediate release and once-daily extended release rosiglitazone dosing over five days in healthy volunteers.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/903|nan|[C0289313]|[rosiglitazone]
498|GSK|A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ARA102198|http://clinicaltrials.gov/show/NCT00379600|[C0289313]|[rosiglitazone]
499|GSK|A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=100193|nan|[C0289313]|[rosiglitazone]
500|GSK|An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=100468|nan|[C0289313]|[rosiglitazone]
501|GSK|A 54-week, study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-3)|Alzheimer's Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVA102670|http://clinicaltrials.gov/show/NCT00348140|[C0289313]|[rosiglitazone]
502|GSK|An open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AVA104617|http://clinicaltrials.gov/show/NCT00381238|[C0289313]|[rosiglitazone]
503|GSK|A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)|Atherosclerosis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVD100521|http://clinicaltrials.gov/show/NCT00116831|[C0289313]|[rosiglitazone]
507|GSK|A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104385|http://clinicaltrials.gov/show/NCT00318630|[C0289313]|[rosiglitazone]
508|GSK|A Randomized, Single-Blind, Placebo-Controlled, Parallel Group, Exploratory Research Study to Describe the Pharmacodynamic Effects of Glyburide, Metformin, and Rosiglitazone versus Placebo for 8 Weeks in Adult Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=RES11098|nan|[C0289313]|[rosiglitazone]
511|GSK|A Randomized, Double-Blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin®) in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SLGA4005|nan|[C0073992]|[salmeterol]
512|GSK|A Randomized, Double-blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin) in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SLGA4004|nan|[C0073992]|[salmeterol]
514|GSK|A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects with Acne Vulgaris|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114565|http://clinicaltrials.gov/show/NCT01019603|[C0288792]|[tazarotene]
520|GSK|A double-blind, randomized, placebo-controlled, repeat dose, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following administration of fluticasone furoate/GW642444M Inhalation Powder with ketoconazole|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105548|http://clinicaltrials.gov/show/NCT01165125|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
521|GSK|A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C109575|http://clinicaltrials.gov/show/NCT00600171|[C2935023]|[vilanterol]
522|GSK|A three-way incomplete block crossover study to investigate the 24-hour pulmonary function of three dosage strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=110946|http://clinicaltrials.gov/show/NCT01072149|[C2935023]|[vilanterol]
523|GSK|Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=HZC111348|http://clinicaltrials.gov/show/NCT00731822|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
524|GSK|A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113090|http://clinicaltrials.gov/show/NCT01128569|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
525|GSK|A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113126|http://clinicaltrials.gov/show/NCT01128595|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
526|GSK|A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry powder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113310|http://clinicaltrials.gov/show/NCT00980200|[C2935023]|[vilanterol]
527|GSK|An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113970|http://clinicaltrials.gov/show/NCT01266980|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
529|GSK|Phase III Clinical Study of GG167: An open trial of GG167 in the treatment of influenza viral infection in children (open-label study). A survey on time course of influenza-like symptoms in pediatric patients with influenza viral infection treated without an influenza antiviral.|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=167T3-11|nan|[C0216660]|[zanamivir]
533|GSK|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled zanamivir Treatment on Workplace Attendance Due to Influenza A and B Infections|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NAI30011|nan|[C0216660]|[zanamivir]
534|GSK|Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1009|nan|[C0216660]|[zanamivir]
535|GSK|A Double-Blind, Randomized Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 in the Treatment of Influenza A and B Viral Infection|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2005|nan|[C0216660]|[zanamivir]
536|GSK|A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 (zanamivir) Therapy in the Prevention of Progression of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2006|nan|[C0216660]|[zanamivir]
537|GSK|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2008|nan|[C0216660]|[zanamivir]
538|GSK|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2009|nan|[C0216660]|[zanamivir]
539|GSK|Efficacy of zanamivir (GG167) In Controlling Nursing Home Influenza Outbreaks|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA2010|nan|[C0216660]|[zanamivir]
540|GSK|Pharmacoscintigraphic Evalutaion of Lung Deposition of GG167 Inhaled from the Diskhaler and the Free Flow Powder System (FFPS) in Healthy Volunteers.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1001|nan|[C0216660]|[zanamivir]
541|GSK|A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects|Hyperreactivity, Bronchial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1002|nan|[C0216660]|[zanamivir]
542|GSK|A GG167 Pharmacokinetic Study to Select a Regimen for Prophylaxis.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB1007|nan|[C0216660]|[zanamivir]
543|GSK|A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Intranasal GG167 in the Treatment of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2005|nan|[C0216660]|[zanamivir]
544|GSK|Double-Blind,Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of inhaled zanamivir in Preventing Progression of Influenza|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2006|nan|[C0216660]|[zanamivir]
545|GSK|Double-Blind, Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Inhaled plus Intranasal GG167 in the Treatment of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2007|nan|[C0216660]|[zanamivir]
546|GSK|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections.|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2008|nan|[C0216660]|[zanamivir]
547|GSK|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NAIB2009|nan|[C0216660]|[zanamivir]
548|GSK|A randomized double-blind placebo-controlled study to evaluate the inhibitory effect against the onset of influenza virus-infected patients|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=PE-01|nan|[C0216660]|[zanamivir]
1276|GSK|ARI103094-Follow-Up Study for REDUCE Study Subjects|Neoplasms, Prostate|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=103094|http://clinicaltrials.gov/show/NCT00883909|[C0754659]|[dutasteride]
1277|GSK|A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105871|http://clinicaltrials.gov/show/NCT00538057|[C1948374]|[fluticasone furoate]
1278|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40020|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1279|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40021|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1280|GSK|A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/329|nan|[C0070122]|[paroxetine]
1281|GSK|An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116216|http://clinicaltrials.gov/show/NCT01583036|[C0530684]|[ezogabine]
1282|GSK|A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Three Dose Levels of Rosiglitazone Maleate in the Treatment of Moderate to Severe Plaque Psoriasis.|Psoriasis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=49653/292|nan|[C0289313]|[rosiglitazone]
1306|GSK|A dose ranging study to assess the effect of pre-treatment with a single dose of inhaled fluticasone propionate (2 mg, 0.5 mg) on lung inflammation following challenge with inhaled ozone and intermittent exercise in healthy volunteers, relative to placebo.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CR219039|nan|[C0117996]|[fluticasone propionate]
1372|ViiV|Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects|Infection, Human Immunodeficiency Virus I|Phase 4|https://www.viiv-studyregister.com/study/19745|http://clinicaltrials.gov/show/NCT00549198|[C0663655]|[abacavir]
1373|ViiV|A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus I|Phase 4|https://www.viiv-studyregister.com/study/19788|http://clinicaltrials.gov/show/NCT00244712|[C0663655]|[abacavir]
1374|ViiV|A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19740|http://clinicaltrials.gov/show/NCT00044577|[C0663655]|[abacavir]
1375|ViiV|A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity|Infection, Human Immunodeficiency Virus|Phase 4|http://www.viiv-clinicalstudyregister.com/study/CNA106030|http://clinicaltrials.gov/show/NCT00340080|[C0663655]|[abacavir]
1376|ViiV|A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects|Infection, Human Immunodeficiency Virus|Phase 4|https://www.viiv-studyregister.com/study/19538|http://clinicaltrials.gov/show/NCT01102972|[C0663655, C0209738]|[abacavir, lamivudine]
1377|ViiV|A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19791|http://clinicaltrials.gov/show/NCT00046176|[C0663655, C0209738]|[abacavir, lamivudine]
1378|ViiV|A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects.|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19792|http://clinicaltrials.gov/show/NCT00053638|[C0663655, C0209738]|[abacavir, lamivudine]
1379|ViiV|A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.|Infection, Human Immunodeficiency Virus|Phase 3|http://www.viiv-clinicalstudyregister.com/study/AZL30006|http://clinicaltrials.gov/show/NCT00043888|[C0663655, C0209738, C0043474]|[abacavir, lamivudine, zidovudine]
1380|ViiV|A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)|Infection, Human Immunodeficiency Virus I|Phase 4|https://www.viiv-studyregister.com/study/19790|http://clinicaltrials.gov/show/NCT00038506|[C0663655, C0209738, C0043474]|[abacavir, lamivudine, zidovudine]
1381|ViiV|A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks|Infection, Human Immunodeficiency Virus|Phase 4|http://www.viiv-clinicalstudyregister.com/study/100327|http://clinicaltrials.gov/show/NCT00082394|[C0663655, C0209738, C0043474]|[abacavir, lamivudine, zidovudine]
1382|ViiV|A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19475|http://clinicaltrials.gov/show/NCT01231516|[C3253985]|[dolutegravir]
1383|ViiV|A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19471|http://clinicaltrials.gov/show/NCT00708110|[C3253985]|[dolutegravir]
1384|ViiV|A Phase IIb study to select a once daily dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naive adult subjects|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19484|http://clinicaltrials.gov/show/NCT00951015|[C3253985]|[dolutegravir]
1385|ViiV|A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen.|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19497|http://clinicaltrials.gov/show/NCT01328041|[C3253985]|[dolutegravir]
1386|ViiV|A pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19514|http://clinicaltrials.gov/show/NCT00950859|[C3253985]|[dolutegravir]
1387|ViiV|A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19519|http://clinicaltrials.gov/show/NCT01227824|[C3253985]|[dolutegravir]
1388|ViiV|A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19545|http://clinicaltrials.gov/show/NCT01263015|[C3253985]|[dolutegravir]
1389|ViiV|An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19721|http://clinicaltrials.gov/show/NCT00296504|[C1176315]|[fosamprenavir]
1390|ViiV|A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19453|http://clinicaltrials.gov/show/NCT00094523|[C1176315]|[fosamprenavir]
1391|ViiV|A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks|Infection, Human Immunodeficiency Virus|Phase 3|http://www.viiv-clinicalstudyregister.com/study/100732|http://clinicaltrials.gov/show/NCT00085943|[C1176315]|[fosamprenavir]
1392|ViiV|Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19714|http://clinicaltrials.gov/show/NCT00450580|[C1176315]|[fosamprenavir]
1393|ViiV|A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19802|http://clinicaltrials.gov/show/NCT00363142|[C1176315]|[fosamprenavir]
1394|ViiV|A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19713|http://clinicaltrials.gov/show/NCT00144833|[C1176315]|[fosamprenavir]
1395|ViiV|A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19718|nan|[C1176315]|[fosamprenavir]
1396|ViiV|A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with Abacavir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy Naïve HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19719|nan|[C1176315]|[fosamprenavir]
1397|ViiV|A Phase III, Randomized, Multicenter, Parallel Group, Open-label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg twice daily or 1400mg/200mg once daily) versus lopinavir/ritonavir (400mg/100mg twice daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure|Infection, Human Immunodeficiency Virus|Phase 3|nan|nan|[C1176315]|[fosamprenavir]
1398|ViiV|Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19789|http://clinicaltrials.gov/show/NCT00440947|[C0209738]|[lamivudine]
1399|ViiV|A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)|Infection, Human Immunodeficiency Virus|Phase 3|http://www.viiv-clinicalstudyregister.com/study/101822|http://clinicaltrials.gov/show/NCT00094367|[C0209738]|[lamivudine]
1400|ViiV|A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients|Infection, Human Immunodeficiency Virus|Phase 2|nan|http://ClinicalTrials.gov/show/NCT00827112|[C1667052]|[maraviroc]
1401|ViiV|Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|Infection, Human Immunodeficiency Virus|Phase 2|nan|http://ClinicalTrials.gov/show/NCT00634959|[C1667052]|[maraviroc]
1402|ViiV|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus|Phase 2/3|nan|http://ClinicalTrials.gov/show/NCT00098748|[C1667052]|[maraviroc]
1403|ViiV|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus|Phase 2/3|nan|http://ClinicalTrials.gov/show/NCT00098722|[C1667052]|[maraviroc]
1404|ViiV|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|Infection, Human Immunodeficiency Virus|Phase 2/3|nan|http://ClinicalTrials.gov/show/NCT00098306|[C1667052]|[maraviroc]
1405|ViiV|Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|Infection, Human Immunodeficiency Virus|Phase 2|nan|http://ClinicalTrials.gov/show/NCT00643643|[C1667052]|[maraviroc]
1406|ViiV|Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19675|http://ClinicalTrials.gov/show/NCT00098293|[C1667052]|[maraviroc]
1415|GSK|A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate|Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FRX106365|http://clinicaltrials.gov/show/NCT00312013|[C5848169]|[Nadroparin Calcium]
1416|GSK|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HGS1006-C1056|http://clinicaltrials.gov/show/NCT00410384|[C1723401]|[belimumab]
1417|GSK|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HGS1006-C1057|http://clinicaltrials.gov/show/NCT00424476|[C1723401]|[belimumab]
1426|GSK|A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines|Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=711866/006|nan|[C5233092, C0305062, C0982332, C0718003]|[Reduced cysteine content, 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', 'Poliovirus Vaccine, Inactivated']
1427|GSK|A double-blind, placebo-controlled, randomized, parallel group study to investigate the changes in corrected QT interval following repeat oral doses of GI198745 in healthy male subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARI10019|nan|[C0754659]|[dutasteride]
1429|GSK|An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART™ 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARI109882|http://clinicaltrials.gov/show/NCT00537654|[C0754659]|[dutasteride]
1430|GSK|An open label, randomized, repeat dose, 3 period crossover study to determine the bioequivalence of 3 different formulations of tamsulosin at steady state in healthy male volunteers|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARI111402|http://clinicaltrials.gov/show/NCT00609596|[C0754659]|[dutasteride]
1433|GSK|A multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy of GI198745 0.5mg Once Daily versus finasteride 5mg Once Daily for 12 months in the treatment of subjects with benign prostatic hyperplasia (BPH). (EPICS)|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40001|nan|[C0754659]|[dutasteride]
1434|GSK|A pilot multi-centre, double-blind, parallel group, randomised study to investigate the effect on symptoms 3 months after discontinuing tamsulosin, following 6 months combination treatment with 0.5mg GI198745 and 0.4mg tamsulosin daily in patients with symptomatic Benign Prostatic Hyperplasia (BPH).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40002|nan|[C0754659]|[dutasteride]
1435|GSK|An Investigation of the Pharmacokinetics of GI198745 and of the Effects of GI198745 on Semen Characteristics When Administered Daily for 12 Months to Healthy Male Subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA1009|nan|[C0754659]|[dutasteride]
1436|GSK|Investiagtion of the Metabolic Fate and Routes of Excretion of GI198745 at Steady State in Healthy Male Subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA1012|nan|[C0754659]|[dutasteride]
1437|GSK|A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002|nan|[C0754659]|[dutasteride]
1438|GSK|A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3003|nan|[C0754659]|[dutasteride]
1439|GSK|A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3004|nan|[C0754659]|[dutasteride]
1440|GSK|A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112186|http://clinicaltrials.gov/show/NCT01147744|[C4550339]|[Fiboflapon]
1441|GSK|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114255|http://clinicaltrials.gov/show/NCT01156792|[C4550339]|[Fiboflapon]
1442|GSK|PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAS106533|http://clinicaltrials.gov/show/NCT00370097|[C0117996]|[fluticasone propionate]
1443|GSK|Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAP10001|nan|[C0117996]|[fluticasone propionate]
1444|GSK|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAP30007|nan|[C0117996]|[fluticasone propionate]
1445|GSK|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAP30008|nan|[C0117996]|[fluticasone propionate]
1446|GSK|A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAP30010|nan|[C0117996]|[fluticasone propionate]
1447|GSK|A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAS30007|nan|[C0117996]|[fluticasone propionate]
1448|GSK|A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAS30009|nan|[C0117996]|[fluticasone propionate]
1449|GSK|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FAS30030|nan|[C0117996]|[fluticasone propionate]
1450|GSK|A randomised, open label, 4-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of single inhaled and intravenous doses of fluticasone propionate and mometasone furoate in healthy subjects|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FMS10026|nan|[C0117996]|[fluticasone propionate]
1452|GSK|A study to compare PK of a single doe of fluticasone propionate in healthy male Japanse and Caucasian subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FMS10032|nan|[C0117996]|[fluticasone propionate]
1453|GSK|A randomised, single-blind, placebo-controlled study with 5-way cross-over design to investigate the systemic pharmacokinetics and pharmacodynamics of single inhaled doses (800mcg and 1600mcg) of Fluticasone Propionate and Mometasone Furoate in healthy subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FMS10033|nan|[C0117996]|[fluticasone propionate]
1454|GSK|A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 24 months to 47 months|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FMS30058|nan|[C0117996]|[fluticasone propionate]
1455|GSK|A multicenter, randomized, double-blind, parallel group, placebo-controlled, 12 week study of Fluticasone Propionate 44mcg BID and 88mcg BID delivered via CFC MDI and a valved holding chamber with facemask in subjects with asthma age 6 months to 2 years|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FMS30059|nan|[C0117996]|[fluticasone propionate]
1456|GSK|A randomised, double-blind, double-dummy, parallel group, multicentre study to compare the effect on growth measured by stadiometry of fluticasone propionate (100µg bd) administered via DISKUS™ with budesonide (200µg bd) administered via Turbuhaler in prepubescent children.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FMS40001|nan|[C0117996]|[fluticasone propionate]
1457|GSK|An open study to investigate the nasal bioavailability of intra-nasally administered fluticasone propionate administered as a solution formulation, HFA nasal MDI formulation and as the aqueous nasal spray during charcoal block in healthy subjects.|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FNM10003|nan|[C0117996]|[fluticasone propionate]
1458|GSK|An open, three-period, balanced, incomplete block crossover study in healthy subjects to investigate the effect of 7 days co-administration of fluticasone propionate aqueous nasal spray (FPANS) with ritonavir, ketoconazole, or erythromycin on serum cortisol levels|Rhinitis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FNM10004|nan|[C0117996]|[fluticasone propionate]
1459|GSK|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Systems Commonly Associated with Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FNM30033|nan|[C0117996]|[fluticasone propionate]
1460|GSK|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FNM30034|nan|[C0117996]|[fluticasone propionate]
1461|GSK|A Multi-Center, Randomized, Double-Blind, Parallel Gruop Study to Assess the Potential Growth Effects of a One-year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) versus Placebo in Pre-pubescent, Pediatric Subjects with Perennial Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FNM40017|nan|[C0117996]|[fluticasone propionate]
1462|GSK|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)|Rhinitis, Allergic, Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FNM40194|nan|[C0117996]|[fluticasone propionate]
1463|GSK|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day Versus Montelukast 10mg every day in Subjects ≥15 Years Old with Seasonal Allergic Rhinitis (SAR)|Rhinitis, Allergic, Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FNM40195|nan|[C0117996]|[fluticasone propionate]
1464|GSK|A single centre, randomised, double blind, parallel group study to determine the efficacy and tolerability of Fluticasone propionate nasal drops (Nasules) 400mcg bd, 400mcg od and placebo nasal drops in adult patients with bilateral polyposis.|Polyps, Nasal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FNP40010|nan|[C0117996]|[fluticasone propionate]
1465|GSK|A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40009|nan|[C0117996]|[fluticasone propionate]
1466|GSK|A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteroids|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40010|nan|[C0117996]|[fluticasone propionate]
1467|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 Years of Age with Persistant Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40012|nan|[C0117996]|[fluticasone propionate]
1468|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Proprionate Inhalation Powder (50mcg BID) with Oral Montelukast (5mg QD) in Children 6-12 with Persistant Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40013|nan|[C0117996]|[fluticasone propionate]
1469|GSK|A Randomized, Double-Blind 12-Week Comparative Trial of Fluticasone Propionate DISKUS 100mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID And Oral Montelukast 10mg QD In Adults With Persistent Asthma.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40014|nan|[C0117996]|[fluticasone propionate]
1470|GSK|A Randomized, Open-Label, Cross Over Trial, Assessing Ease of Use, Correctness of Use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the Diskus versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40015|nan|[C0117996]|[fluticasone propionate]
1471|GSK|A Randomized, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Fluticasone Propionate Inhalation Powder (100mcg BID) via the DISKUS™ versus Fluticasone Propionate Aerosol via the Metered Dose Inhaler (88mcg BID) in Subjects at Least 12 Years of Age with Persistent Asthma Currently Receiving Short Acting Beta Agonists Alone.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FPD40016|nan|[C0117996]|[fluticasone propionate]
1472|GSK|A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover, study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine 5-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SIG103337|http://clinicaltrials.gov/show/NCT00400855|[C0117996]|[fluticasone propionate]
1473|GSK|An exploratory study to evaluate the response of salmeterol plus fluticasone propionate vs fluticasone propionate alone to experimental nasal inoculation with rhinovirus|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HZA109895|http://clinicaltrials.gov/show/NCT00503009|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1474|GSK|A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HZA109912|http://clinicaltrials.gov/show/NCT00517634|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1475|GSK|A Multicentre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination diskus (Accuhaler) dry powder inhaler compared with fluticasone propionate Diskus alone in adults and adolescents.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40027|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1476|GSK|A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40036|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1477|GSK|A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40040|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1478|GSK|A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40042|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1479|GSK|A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40058|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1480|GSK|A Muticenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day versus Montelukast 10mg every day in Adolescent and Adult subjects with Asthma and Seasonal allergic rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg twice daily|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40066|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1481|GSK|A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10014|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1482|GSK|A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10015|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1483|GSK|A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30017|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1484|GSK|A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30019|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1485|GSK|A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30022|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1486|GSK|A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30023|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1487|GSK|A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30031|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1488|GSK|An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30033|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1490|GSK|A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30039|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1491|GSK|A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30040|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1492|GSK|A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Versus Fluticasone Propinate 250 mcg twice daily Diskus in Adolescents and Adults With Moderate To Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40026|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1493|GSK|A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Diskus Fluticasone Propinate 250 mcg twice daily Diskus In Adolescents and Adults With Moderate to Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40027|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1494|GSK|An Open-Label, 12-Week Study to Evaluate the Effects of a Corticosteroid-Sparing Dose of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg twice daily Via the DISKUS Inhaler on Airway Inflammation, Airway Remodeling, and Bronchial Hyperresponsiveness in Adults with Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40028|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1495|GSK|A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescent and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40036|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1496|GSK|A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50mcg twice daily, fluticasone propionate Diskus 100mcg twice daily, salmeterol xinafoate 50mcg twice daily, or oral montelukast 10mg every day|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40037|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1497|GSK|A Randomized, Open Label, Pilot Crossover Trial, Assessing Patient Preference for Efficacy of Advair Diskus 100/50 (Fluticasone Propionate 100mcg and Salmeterol 50mcg Combination Product 100/50mcg twice daily) and Singulair (Montelukast 10mg every day) in Subjects>15 years of Age with Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40066|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1498|GSK|A randomised, double-blind, double dummy, 3 way crossover study evaluating the effects of a combination of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual agents (tiotropium bromide 18mcg alone and Seretide50/500mcg alone) in the treatment of subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104962|http://clinicaltrials.gov/show/NCT00325169|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1499|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40011|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1500|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol Xinafoate (250/50mcg twice daily via Diskus) to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmondary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40012|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1501|GSK|A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3002|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1502|GSK|A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SFCA3003|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
1547|GSK|A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SB020001|nan|[C0001927]|[albuterol]
1548|GSK|A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ HFA MDI delivered TID with facemask and valved holding chamber Aerochamber Plus in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SB030001|nan|[C0001927]|[albuterol]
1549|GSK|A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airways disease|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SB030002|http://clinicaltrials.gov/show/NCT00144846|[C0001927]|[albuterol]
1550|GSK|An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Albuterol HFA with Counter in Asthma or COPD Subjects at Least 4 Years of Age.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SB030003|nan|[C0001927]|[albuterol]
1551|GSK|Phase I study of GSK573719 -A randomized, double blind, placebo controlled, dose ascending, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 from a novel dry powder device in healthy Japanese male subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113377|http://clinicaltrials.gov/show/NCT01013974|[C3709474]|[umeclidinium bromide]
1552|GSK|Randomized, double-blind, 5 period cross over study assessing lung function in healthy volunteers following single inhalations of GSK573719 Inhalation Powder from two configurations of the Novel Dry Powder Inhaler|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115487|http://clinicaltrials.gov/show/NCT01521390|[C3709474]|[umeclidinium bromide]
1553|GSK|Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113120|http://clinicaltrials.gov/show/NCT01039675|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
1554|GSK|A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 and GW642444 as monotherapies and concurrently in healthy Japanese subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113208|http://clinicaltrials.gov/show/NCT00976144|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
1555|GSK|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113361|http://clinicaltrials.gov/show/NCT01313637|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
1556|GSK|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113373|http://clinicaltrials.gov/show/NCT01313650|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
1557|GSK|A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination with GW642444|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113950|http://clinicaltrials.gov/show/NCT01128634|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
1612|GSK|An adaptive design study for the assessment of the pharmacokinetics of albiglutide in subjects with normal renal function and subjects with moderate-to-severe renal impairment and hemodialysis.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=108370|http://clinicaltrials.gov/show/NCT00938158|[C2607479]|[albiglutide]
1613|GSK|A multicentre, double-blind, placebo-controlled, parallel group study of the efficacy and tolerability of long-term inhaled fluticasone propionate 500mg twice daily via a Volumatic Spacer device in patients with non-asthmatic chronic obstructive pulmonary disease, including…|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FLTB3054|nan|[C0117996]|[fluticasone propionate]
1617|GSK|A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=29060/785|nan|[C0070122]|[paroxetine]
1623|GSK|A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder.|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/115|nan|[C0070122]|[paroxetine]
1632|GSK|A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression.|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/377|nan|[C0070122]|[paroxetine]
1633|GSK|A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/448|nan|[C0070122]|[paroxetine]
1634|GSK|A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/449|nan|[C0070122]|[paroxetine]
1637|GSK|A multi-center, double blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of Paroxetine in children with major depression.|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/701|nan|[C0070122]|[paroxetine]
1638|GSK|A double-blind, placebo-controlled, 3-arm, fixed-dose study of 12.5 mg/day and 25mg/day Paroxetine CR in the treatment of Major Depression.|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=29060/810|nan|[C0070122]|[paroxetine]
1639|GSK|Assessment of Paxil CR, 12.5 and 25 mg/day in treating elderly patients with major depression|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/874|http://clinicaltrials.gov/show/NCT00067444|[C0070122]|[paroxetine]
1641|GSK|A multi-center trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113374|http://clinicaltrials.gov/show/NCT01316913|[C3709474]|[umeclidinium bromide]
1642|GSK|A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113360|http://clinicaltrials.gov/show/NCT01316900|[C3709474]|[umeclidinium bromide]
1643|GSK|Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients treated with IV zanamivir in the Relenza Compassionate Use Program|Infections, Respiratory Tract|nan|https://www.gsk-studyregister.com/en/trial-details/?id=115008|http://clinicaltrials.gov/show/NCT01353768|[C0216660]|[zanamivir]
1644|ViiV|A Phase II, Open-Label, Randomized Study to Compare the Efficacy and Safety of EPIVIR/ZIAGEN/Zerit (3TC/ABC/d4T) Versus EPIVIR/ZIAGEN/Sustiva (3TC/ABC/EFV) Versus EPIVIR/ZIAGEN/GW433908/Norvir (3TC/ABC/908/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who are Antiretroviral Thera ...|Infection, Human Immunodeficiency Virus I|Phase 2|https://www.viiv-studyregister.com/study/19793|nan|[C1176315]|[fosamprenavir]
1657|GSK|A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=GLP106073|http://clinicaltrials.gov/show/NCT00354536|[C2607479]|[albiglutide]
1658|GSK|A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=GLP107030|http://clinicaltrials.gov/show/NCT00537719|[C2607479]|[albiglutide]
1659|GSK|A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105229|nan|[C2607479]|[albiglutide]
1660|GSK|An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107032|http://clinicaltrials.gov/show/NCT01077505|[C2607479]|[albiglutide]
1661|GSK|A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107085|http://clinicaltrials.gov/show/NCT01406262|[C2607479]|[albiglutide]
1662|GSK|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111680|http://clinicaltrials.gov/show/NCT01147718|[C2607479]|[albiglutide]
1663|GSK|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111681|http://clinicaltrials.gov/show/NCT01147731|[C2607479]|[albiglutide]
1664|GSK|A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114179|http://clinicaltrials.gov/show/NCT01128894|[C2607479]|[albiglutide]
1665|GSK|An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=GLP107724|http://clinicaltrials.gov/show/NCT00394030|[C2607479]|[albiglutide]
1666|GSK|The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance|Otitis Media|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/541|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1667|GSK|An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 7 days for the Treatment of Bacterial Community-Acquired Pneumonia in adults.|Pneumonia, Community-Acquired|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/547|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1668|GSK|Evaluating the Impact of Amoxicillin/Clavulanate Potassium Therapy on Carriage of Susceptible and Resistant Streptococcus pneumoniae.|Streptococcus pneumoniae|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/555|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1669|GSK|A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension.|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/601|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1670|GSK|A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children.|Otitis Media|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=25000/611|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1671|GSK|A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin.|Pneumonia, Community-Acquired|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/620|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1672|GSK|A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis.|Bronchitis, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/630|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1673|GSK|A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A)|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/643|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1674|GSK|An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension.|Streptococcus pneumoniae|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/665|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1675|GSK|A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AUG102821|http://clinicaltrials.gov/show/NCT00354965|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1676|GSK|A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults.|Pneumonia, Community-Acquired|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/557|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1677|GSK|An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.|Sinusitis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/592|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1678|GSK|A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers.|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/593|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1679|GSK|A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia.|Pneumonia, Community-Acquired|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/600|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1680|GSK|A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis|Bronchitis, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=25000/627|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
1681|GSK|A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients|Hypertension|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105517/367|nan|[C0054836]|[carvedilol]
1682|GSK|An open, non-randomized comparison of pharmacokinetic profiles of carvedilol (SK&F-105517) MR and IR on repeat dosing in chronic CHF subjects and survivors of an acute MI and LVD|Heart failure, Congestive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105517/369|nan|[C0054836]|[carvedilol]
1683|GSK|A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the B1-Blocking Effects of an investigational formulation of carvedilol to COREG Immediate Release Tablets at Steady-State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response to Bicycle Ergometry|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105517/902|nan|[C0054836]|[carvedilol]
1684|GSK|An Open-label, Single Dose, Three Session, Partially Randomized, Crossover Study to Assess Morning and Evening Dosing of Carvedilol Phosphate MR Capsules in Healthy Adult Subjects|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105517/906|nan|[C0054836]|[carvedilol]
1685|GSK|A randomized, single-blind, placebo-controlled, three-period parallel-group study to assess the pharmacokinetic and pharmacodynamic relationship of a 50 mg single oral dose of immediate release carvedilol in healthy subjects|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105517/908|nan|[C0054836]|[carvedilol]
1686|GSK|A randomized, open-label, single-dose, four-period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-encapsulated Zestril to Zestril|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105533|nan|[C0054836]|[carvedilol]
1687|GSK|A randomized, open-label, two period, period balanced, crossover study to estimate the relative bioavailability of an investigational drug compared to Coreg IR in healthy adult volunteers|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104257|nan|[C0054836]|[carvedilol]
1688|GSK|A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106904|nan|[C0054836]|[carvedilol]
1689|GSK|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG™ CR) or 10mg, 20mg, or 40mg QD doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication|Hypertension|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=CFD105453|http://clinicaltrials.gov/show/NCT00347360|[C0054836, C0065374]|[carvedilol, lisinopril]
1692|GSK|Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40014|http://clinicaltrials.gov/show/NCT00062790|[C0754659]|[dutasteride]
1693|GSK|A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase|Neoplasms, Prostate|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AVO108943|http://clinicaltrials.gov/show/NCT00470834|[C0754659]|[dutasteride]
1707|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with SARs.|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFR20001|nan|[C1948374]|[fluticasone furoate]
1708|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Perennial Allergic Rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR30002|http://clinicaltrials.gov/show/NCT00103454|[C1948374]|[fluticasone furoate]
1709|GSK|A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the effect of fluticasone furoate aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR20002|http://clinicaltrials.gov/show/NCT00116818|[C1948374]|[fluticasone furoate]
1710|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis|Rhinitis, Allergic, Seasonal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR30003|http://clinicaltrials.gov/show/NCT00115622|[C1948374]|[fluticasone furoate]
1711|GSK|A non-randomized, open label, two period cross-over study to determine the excretion balance and pharmacokinetics of [14C]-GW685698, administered as single doses of an oral solution and an intravenous infusion to healthy adult male subjects|Rhinitis, Allergic, Perennial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFR10008|nan|[C1948374]|[fluticasone furoate]
1712|GSK|A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112059|http://clinicaltrials.gov/show/NCT01159912|[C1948374]|[fluticasone furoate]
1713|GSK|A randomised, repeat-dose, placebo-controlled, double-blind study to evaluate and compare the efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, when administered either in the morning or in the evening, in male and female asthmatic subjects|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114624|http://clinicaltrials.gov/show/NCT01287065|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
1715|GSK|A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects.|Rhinitis, Allergic, Perennial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101888|nan|[C1948374]|[fluticasone furoate]
1716|GSK|A randomised, open label, 2-way cross-over study to assess the absolute bioavailability of GW685698X administered intranasally in healthy male and female subjects|Rhinitis, Allergic, Perennial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFR10010|nan|[C1948374]|[fluticasone furoate]
1717|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mg and 100mcg for 12 Weeks in Pediatric Subjects Ages 2 to <12 Years with Perennial Allergic Rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR30008|http://clinicaltrials.gov/show/NCT00108914|[C1948374]|[fluticasone furoate]
1718|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis|Rhinitis, Vasomotor|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR30006|http://clinicaltrials.gov/show/NCT00117325|[C1948374]|[fluticasone furoate]
1719|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis|Rhinitis, Vasomotor|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR30007|http://clinicaltrials.gov/show/NCT00118703|[C1948374]|[fluticasone furoate]
1720|GSK|A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR105693|http://clinicaltrials.gov/show/NCT00346775|[C1948374]|[fluticasone furoate]
1721|GSK|A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects 18 Years of Age with Perennial Allergic Rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR104503|http://clinicaltrials.gov/show/NCT00224523|[C1948374]|[fluticasone furoate]
1722|GSK|A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114496|http://clinicaltrials.gov/show/NCT01431950|[C1948374]|[fluticasone furoate]
1723|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 years of age and older) with Persistent Asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFA106783|http://clinicaltrials.gov/show/NCT00398645|[C1948374]|[fluticasone furoate]
1724|GSK|A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10022|nan|[C1948374]|[fluticasone furoate]
1725|GSK|A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10027|nan|[C1948374]|[fluticasone furoate]
1726|GSK|A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10028|nan|[C1948374]|[fluticasone furoate]
1727|GSK|A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10013|http://clinicaltrials.gov/show/NCT00419237|[C1948374]|[fluticasone furoate]
1728|GSK|A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis.|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=102123|nan|[C1948374]|[fluticasone furoate]
1729|GSK|A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 100ug (micrograms) in children aged 5-11 years with persistent asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=102942|http://clinicaltrials.gov/show/NCT01332292|[C1948374]|[fluticasone furoate]
1730|GSK|A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 years of age and older) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber|Rhinitis, Allergic, Seasonal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR101816|http://clinicaltrials.gov/show/NCT00118729|[C1948374]|[fluticasone furoate]
1731|GSK|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe|Rhinitis, Allergic, Seasonal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR103184|http://clinicaltrials.gov/show/NCT00225823|[C1948374]|[fluticasone furoate]
1732|GSK|A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg Once Daily on Short-Term Growth in Children Aged 6 to 11 Years with Seasonal and/or Perennial Allergic Rhinitis|Rhinitis, Allergic, Perennial and Seasonal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR101747|http://clinicaltrials.gov/show/NCT00109486|[C1948374]|[fluticasone furoate]
1733|GSK|A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR).|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR100012|http://clinicaltrials.gov/show/NCT00116883|[C1948374]|[fluticasone furoate]
1734|GSK|See Detailed Description|Rhinitis, Allergic, Seasonal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR104861|http://clinicaltrials.gov/show/NCT00197262|[C1948374]|[fluticasone furoate]
1735|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR100010|http://clinicaltrials.gov/show/NCT00107757|[C1948374]|[fluticasone furoate]
1736|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFR106080|http://clinicaltrials.gov/show/NCT00289198|[C1948374]|[fluticasone furoate]
1737|GSK|A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106837|http://clinicaltrials.gov/show/NCT01086384|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
1738|GSK|HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106827|http://clinicaltrials.gov/show/NCT01165138|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
1739|GSK|A two cohort, randomised, single-blind, two-way crossover design study to assess the effects of single doses of nasally administered fluticasone propionate (400 mcg) and a new chemical entity (NCE) on nuclear translocation of the glucocorticoid receptor, using biopsy, in male healthy volunteers.|Rhinitis, Allergic, Perennial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFR10006|nan|[C1948374, C0117996]|[fluticasone furoate, fluticasone propionate]
1740|GSK|A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE)|Thromboembolism|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104574|nan|[C1099664]|[fondaparinux sodium]
1741|GSK|An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.|Thromboembolism|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=103413|http://clinicaltrials.gov/show/NCT00064428|[C1099664]|[fondaparinux sodium]
1742|GSK|A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with Intermittent Pneumatic Compression (IPC) versus IPC used alone for the prevention of venous thromboembolic events in subjects at increased risk undergoing major abdomi|Thromboembolism|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=103414|http://clinicaltrials.gov/show/NCT00038961|[C1099664]|[fondaparinux sodium]
1743|GSK|An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes|Thromboembolism|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=103420|http://clinicaltrials.gov/show/NCT00139815|[C1099664]|[fondaparinux sodium]
1744|GSK|A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS).|Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=104619|nan|[C1099664]|[fondaparinux sodium]
1770|GSK|Evaluate the effect of risk factors that influence the immunogenicity of GSK Biologicals Twinrix compared to hepatitis A and hepatitis B vaccines given separately and to show the non-inferiority between the vaccines in adults|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111149|http://clinicaltrials.gov/show/NCT00603252|[C0593953]|[Twinrix]
1771|GSK|Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100566|http://clinicaltrials.gov/show/NCT00197119|[C0593953]|[Twinrix]
1772|GSK|Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100566|http://clinicaltrials.gov/show/NCT00197119|[C0593953]|[Twinrix]
1773|GSK|Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100566|http://clinicaltrials.gov/show/NCT00197119|[C0593953]|[Twinrix]
1774|GSK|Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100566|http://clinicaltrials.gov/show/NCT00197119|[C0593953]|[Twinrix]
1775|GSK|Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100566|http://clinicaltrials.gov/show/NCT00197119|[C0593953]|[Twinrix]
1799|GSK|A randomised, open-label, parallel-group design study to evaluate the pharmacokinetic characteristics, safety and tolerability of single oral doses of three prototype 300mg enteric coated - modified release formulations of Lamotrigine in healthy subjects.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105377|nan|[C0064636]|[lamotrigine]
1800|GSK|A two-part, open label study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single and repeat oral doses of Lamictal SR/XR prototype formulations and to study the effects of food on pharmacokinetic parameters.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM10005|nan|[C0064636]|[lamotrigine]
1801|GSK|An open-label study in healthy male and female volunteers to evaluate the repeat dose pharmacokinetics and dose strength equivalence of lamotrigine enteric coated modified release tablets over the dose range 25-200 mg.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM10017|nan|[C0064636]|[lamotrigine]
1802|GSK|Open label, safety study for use of lamictal in patients with diabetic neuropathy|Neuropathy, Diabetic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NPP30006|nan|[C0064636]|[lamotrigine]
1803|GSK|A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures|Epilepsy, Tonic-Clonic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LAM100036|http://clinicaltrials.gov/show/NCT00104416|[C0064636]|[lamotrigine]
1804|GSK|A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures|Epilepsy, Partial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LAM100034|http://clinicaltrials.gov/show/NCT00113165|[C0064636]|[lamotrigine]
1805|GSK|An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects|Mental Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LBI108614|http://clinicaltrials.gov/show/NCT00410371|[C0064636]|[lamotrigine]
1806|GSK|A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA100223|http://clinicaltrials.gov/show/NCT00274677|[C0064636]|[lamotrigine]
1807|GSK|Double blind placebo controlled study of lamictal in acute bipolar depression|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA30924|http://clinicaltrials.gov/show/NCT00056277|[C0064636]|[lamotrigine]
1808|GSK|Lamictal in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: Trial to Assess and Refine Global Epilepsy Treatment)|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40091|nan|[C0064636]|[lamotrigine]
1809|GSK|A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy|Neuropathy, Diabetic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NPP30004|nan|[C0064636]|[lamotrigine]
1810|GSK|A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy|Neuropathy, Diabetic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NPP30005|nan|[C0064636]|[lamotrigine]
1811|GSK|A Multicenter, Double-blind, Placebo-controlled, Randomized, Fixed-dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Subjects with Bipolar I Disorder|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCAB2003|nan|[C0064636]|[lamotrigine]
1812|GSK|Open-Label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects Initiating Lamotrigine or Valproate Either as Monotherapy for Newly Diagnosed Epilepsy or as Adjunctive Therapy for Inadequately Controlled Epilepsy|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LAM30007|nan|[C0064636]|[lamotrigine]
1813|GSK|A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures|Epilepsy, Partial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LAM30055|http://clinicaltrials.gov/show/NCT00355082|[C0064636]|[lamotrigine]
1814|GSK|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects wtih Primary Generalized Tonic-Clonic Seizures|Epilepsy, Tonic-Clonic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40097|http://clinicaltrials.gov/show/NCT00043901|[C0064636]|[lamotrigine]
1815|GSK|An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LEP103944|http://clinicaltrials.gov/show/NCT00264615|[C0064636]|[lamotrigine]
1816|GSK|A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months)|Epilepsy|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=LAM20006|http://clinicaltrials.gov/show/NCT00043875|[C0064636]|[lamotrigine]
1817|GSK|An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age)|Epilepsy|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=LAM20007|http://clinicaltrials.gov/show/NCT00044278|[C0064636]|[lamotrigine]
1818|GSK|Double-blind Randomized Trial of Cognitive Effects of LAMICTAL (lamotrigine) versus Topiramate in Epilepsy|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40112|nan|[C0064636]|[lamotrigine]
1819|GSK|A randomised, blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and risperidone in healthy, non-smoking, male volunteers.|Schizophrenia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101963|nan|[C0064636]|[lamotrigine]
1820|GSK|A study to evaluate the effect of repeat oral doses of lamotrigine on cardiac conduction as assessed by 12-Lead ECG as compared to placebo and single oral doses of moxifloxacin.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104648|nan|[C0064636]|[lamotrigine]
1821|GSK|Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.|Bipolar Disorder|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCA40917|http://clinicaltrials.gov/show/NCT00067938|[C0064636]|[lamotrigine]
1822|GSK|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Evaluation of LAMICTAL (lamotrigine) in Adult Subjects with HIV-Associated Peripheral Neuropathy|Peripheral Neuropathies|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40006|nan|[C0064636]|[lamotrigine]
1823|GSK|A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40013|http://clinicaltrials.gov/show/NCT00043914|[C0064636]|[lamotrigine]
1824|GSK|A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and olanzapine in healthy, non-smoking, male volunteers.|Bipolar Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SCA10908|nan|[C0064636]|[lamotrigine]
1825|GSK|A randomised, partially blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and oxcarbazepine in healthy, non-smoking, male volunteers.|Bipolar Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SCA10910|nan|[C0064636]|[lamotrigine]
1826|GSK|A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety, Efficacy, and Tolerability of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA40910|nan|[C0064636]|[lamotrigine]
1827|GSK|Double blind, double-dummy, randomised, placebo controlled study to evaluate the effect of single doses of drug A (lamotrigine) and drug B (vofopitant) alone and in combination on resting motor threshold in healthy subjects|Bipolar Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112676|http://clinicaltrials.gov/show/NCT00907985|[C0064636]|[lamotrigine]
1828|GSK|An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents|Seizure, Absence|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM100118|http://clinicaltrials.gov/show/NCT00144872|[C0064636]|[lamotrigine]
1829|GSK|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects with Schizophrenia|Schizophrenia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101464|http://clinicaltrials.gov/show/NCT00086593|[C0064636]|[lamotrigine]
1830|GSK|A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia|Schizophrenia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA30926|http://clinicaltrials.gov/show/NCT00071747|[C0064636]|[lamotrigine]
1831|GSK|An open, randomised, parallel group study in healthy, young, male and female volunteers to evaluate the pharmacokinetic characteristics of single oral does of new LAMICTAL™ formulations.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM10004|nan|[C0064636]|[lamotrigine]
1832|GSK|An open-label, non-randomised, single-sequence study to investigate the effects of the combined oral contraceptive pill on the pharmacokinetics of lamotrigine and the effects of lamotrigine on the pharamcokinetics of the combined oral contraceptive pill in healthy young female subjects.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LAM10016|nan|[C0064636]|[lamotrigine]
1881|GSK|A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100013|nan|[C0244821]|[ropinirole]
1882|GSK|A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100310|http://clinicaltrials.gov/show/NCT00225862|[C0244821]|[ropinirole]
1883|GSK|An open-label, randomised, two part study to investigate the relative bioavailability of Ropinirole new and standard, marketed formulations and the effect of food on the pharmacokinetics of Ropinirole new formulation in early stage Parkinson’s disease subjects|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/164|nan|[C0244821]|[ropinirole]
1884|GSK|An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies.|Parkinson Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=101468/165|nan|[C0244821]|[ropinirole]
1885|GSK|A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies|Parkinson Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=101468/166|nan|[C0244821]|[ropinirole]
1886|GSK|A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/168|nan|[C0244821]|[ropinirole]
1887|GSK|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/169|http://clinicaltrials.gov/show/NCT00381472|[C0244821]|[ropinirole]
1888|GSK|A Study of the Maintained Efficacy and Safety of Ropinirole Versus Placebo in the Long Term Treatment of Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/188|nan|[C0244821]|[ropinirole]
1889|GSK|A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/190|nan|[C0244821]|[ropinirole]
1890|GSK|A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/191|nan|[C0244821]|[ropinirole]
1891|GSK|A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/192|nan|[C0244821]|[ropinirole]
1892|GSK|A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/194|nan|[C0244821]|[ropinirole]
1893|GSK|101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/196|http://clinicaltrials.gov/show/NCT00650104|[C0244821]|[ropinirole]
1894|GSK|An open study to compare the PK and tolerability of ropinirole administered as 5 different new formulations with the standard, marketed formulation in healthy volunteers|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/197|nan|[C0244821]|[ropinirole]
1895|GSK|An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/198|nan|[C0244821]|[ropinirole]
1896|GSK|An open label study conducted in healthy volunteers to characterize the pharmacokinetics of a new unmarketed formulation of ropinirole|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/199|nan|[C0244821]|[ropinirole]
1897|GSK|A Single Blind, Parallel Group, Up-titration, Phase 1 Study in Healthy Volunteers to Determine a Starting Dose and Select an Up-titration Regimen for a new Formulation of Ropinirole|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/201|nan|[C0244821]|[ropinirole]
1898|GSK|A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/204|http://clinicaltrials.gov/show/NCT00314860|[C0244821]|[ropinirole]
1899|GSK|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/205|http://clinicaltrials.gov/show/NCT00197080|[C0244821]|[ropinirole]
1900|GSK|A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/206|http://clinicaltrials.gov/show/NCT00355641|[C0244821]|[ropinirole]
1901|GSK|A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS).|Restless Legs Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=101468/207|nan|[C0244821]|[ropinirole]
1902|GSK|A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase IIa Study to Determine the Pharmacokinetics and Tolerability of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=101468/218|nan|[C0244821]|[ropinirole]
1903|GSK|An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers|Parkinson Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/219|nan|[C0244821]|[ropinirole]
1904|GSK|A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/228|http://clinicaltrials.gov/show/NCT00363727|[C0244821]|[ropinirole]
1905|GSK|A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/243|nan|[C0244821]|[ropinirole]
1906|GSK|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/249|http://clinicaltrials.gov/show/NCT00363857|[C0244821]|[ropinirole]
1907|GSK|An open label, single dose, dose rising, multi-centre study to assess the tolerability and pharmacokinetics of Ropinirole Immediate Release in adolescent patients with RLS.|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/253|http://clinicaltrials.gov/show/NCT00140712|[C0244821]|[ropinirole]
1908|GSK|A study to evaluate the effect of repeated oral doses of ropinirole on cardiac conduction as assessed by 12-lead electrocardiogram compared to placebo and single oral doses of moxifloxacin (Bayer) as a positive control.|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101468/902|nan|[C0244821]|[ropinirole]
1910|GSK|A randomised, double blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24 mg) administered once daily for 12 weeks in subjects with fibromyalgia|Fibromyalgia Syndrome, Primary|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ROF102100|http://clinicaltrials.gov/show/NCT00256893|[C0244821]|[ropinirole]
1911|GSK|A parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome.|Restless Legs Syndrome|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ROR104836|http://clinicaltrials.gov/show/NCT00329602|[C0244821]|[ropinirole]
1912|GSK|An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)|Restless Legs Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=RRL103628|http://clinicaltrials.gov/show/NCT00422994|[C0244821]|[ropinirole]
1913|GSK|A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep|Restless Legs Syndrome|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=RRL103660|http://clinicaltrials.gov/show/NCT00373542|[C0244821]|[ropinirole]
1914|GSK|A Multicentre, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered to Patients With Type 2 Diabetes Mellitus.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/009|nan|[C0289313]|[rosiglitazone]
1915|GSK|A 26 Week Randomised, Double-Blind, Multicentre Study to Investigate the Effects of Rosiglitazone on Insulin Requirements in Insulin-Treated Type 2 Diabetic Patients|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/085|nan|[C0289313]|[rosiglitazone]
1916|GSK|A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/097|nan|[C0289313]|[rosiglitazone]
1917|GSK|An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/112|nan|[C0289313]|[rosiglitazone]
1918|GSK|An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Insulin to Patients with Type 2 Diabetes|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/114|nan|[C0289313]|[rosiglitazone]
1919|GSK|A Double-blind, Placebo-controlled, Parallel-group Study to Determine the Effect of BRL- 49653C Rosiglitazone, on Fat Distribution When Administered for 26 Weeks to Subjects With Impaired Glucose Tolerance (IGT)|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/131|nan|[C0289313]|[rosiglitazone]
1920|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SUM30047|nan|[C0075632]|[sumatriptan]
1921|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine (EU study).|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SUM30053|nan|[C0075632]|[sumatriptan]
1922|GSK|A randomized double-blind placebo-controlled crossover dose escalation study to examine the safety tolerability pharmacodynamics and pharmacokinetics of inhaled doses of GSK233719 in healthy normal volunteers (single and repeat dosing) and in healthy CYP2D6 poor metaboliser volunteers (single or repeat dosing).|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105209|nan|[C3709474]|[umeclidinium bromide]
1923|GSK|A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719 in healthy male volunteers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112008|http://clinicaltrials.gov/show/NCT01110018|[C3709474]|[umeclidinium bromide]
1924|GSK|An open-label, two period study to determine the excretion balance and pharmacokinetics of 14C-GSK573719, administered as single dose of an oral solution and an intravenous infusion, to healthy male adults|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112014|http://clinicaltrials.gov/show/NCT01362257|[C3709474]|[umeclidinium bromide]
1925|GSK|A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 formulated with the excipient Magnesium Stearatein COPD subjects for 7 days|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=105211|http://clinicaltrials.gov/show/NCT00732472|[C3709474]|[umeclidinium bromide]
1926|GSK|A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as singledoses (750 μg and 1000 μg) and repeat doses over 14 days (250 μg–1000 μg once-daily) of GSK573719 in healthy male and female subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AC4106889|http://clinicaltrials.gov/show/NCT00475436|[C3709474]|[umeclidinium bromide]
1927|GSK|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113073|http://clinicaltrials.gov/show/NCT00950807|[C3709474]|[umeclidinium bromide]
1928|GSK|A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113589|http://clinicaltrials.gov/show/NCT01030965|[C3709474]|[umeclidinium bromide]
1929|GSK|A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115321|http://clinicaltrials.gov/show/NCT01372410|[C3709474]|[umeclidinium bromide]
1930|GSK|A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115408|http://clinicaltrials.gov/show/NCT01387230|[C3709474]|[umeclidinium bromide]
1931|GSK|A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (250, 500 and 1000 μg) and tiotropium bromide (18 μg) via DPI in COPD patients.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AC4108123|http://clinicaltrials.gov/show/NCT00515502|[C3709474]|[umeclidinium bromide]
1932|GSK|A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110106|http://clinicaltrials.gov/show/NCT00803673|[C3709474]|[umeclidinium bromide]
1933|GSK|An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with VZV infection|Varicella|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HS210916|nan|[C0249458]|[valacyclovir]
1934|GSK|An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients|Herpes Genitalis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HS2100275|http://clinicaltrials.gov/show/NCT00158860|[C0249458]|[valacyclovir]
1935|GSK|An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children.|Herpes Simplex|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HS210914|http://clinicaltrials.gov/show/NCT00297206|[C0249458]|[valacyclovir]
1936|GSK|An open-label, multiple-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children with HSV infection|Herpes Simplex|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HS210915|nan|[C0249458]|[valacyclovir]
1938|GSK|A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Reduction of the Length of Cold Sore Episodes|Herpes Labialis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HS230027|nan|[C0249458]|[valacyclovir]
1939|GSK|A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development|Herpes Labialis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HS230028|nan|[C0249458]|[valacyclovir]
1940|GSK|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus (HSV) Transmission in Heterosexual Couples (Double-Blind Phase and Open-Label Suppression Phase)|Herpes Simplex|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HS2AB3009|nan|[C0249458]|[valacyclovir]
1941|GSK|An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects|Herpes Genitalis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=HS230018|nan|[C0249458]|[valacyclovir]
1942|GSK|A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes|Herpes Genitalis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100273|nan|[C0249458]|[valacyclovir]
1943|GSK|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection.|Infections, Herpesviridae|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=VLX103596|http://clinicaltrials.gov/show/NCT00116844|[C0249458]|[valacyclovir]
1944|GSK|The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection|Herpes Labialis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=VLX105832|http://clinicaltrials.gov/show/NCT00306293|[C0249458]|[valacyclovir]
1945|GSK|A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy With VALTREX™ on the Rate of HSV Shedding in Subjects With Recurrent Genital Herpes|Herpes Genitalis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HS240017|nan|[C0249458]|[valacyclovir]
1946|GSK|A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes|Herpes Genitalis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HS240018|nan|[C0249458]|[valacyclovir]
1947|GSK|A Randomized, Double-Blind, Multicenter Study of VALTREX 500mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes|Herpes Genitalis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=HS240021|nan|[C0249458]|[valacyclovir]
1948|GSK|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects with asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113989|http://clinicaltrials.gov/show/NCT01244984|[C2935023]|[vilanterol]
1982|GSK|A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD)|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKF100096|http://clinicaltrials.gov/show/NCT00413023|[C2347566]|[casopitant]
1983|GSK|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder|Anxiety Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKF100110|http://clinicaltrials.gov/show/NCT00273039|[C2347566]|[casopitant]
1986|GSK|A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis|Nausea and Vomiting, Postoperative|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NKT102552|http://clinicaltrials.gov/show/NCT00334152|[C2347566]|[casopitant]
1987|GSK|A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis|Nausea and Vomiting, Postoperative|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NKT102553|http://clinicaltrials.gov/show/NCT00326248|[C2347566]|[casopitant]
1988|GSK|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment|Vomiting|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKT102783|http://clinicaltrials.gov/show/NCT00358813|[C2347566]|[casopitant]
1989|GSK|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment|Vomiting|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKT102785|http://clinicaltrials.gov/show/NCT00359177|[C2347566]|[casopitant]
1990|GSK|A two-part, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of single intravenous doses of GW679769 when administered alone and in combination with intravenous or oral doses of dexamethasone in healthy adult subjects|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=100789|nan|[C2347566]|[casopitant]
2000|ViiV|A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naïve adult subjects|Infection, Human Immunodeficiency Virus I|Phase 3|https://www.viiv-studyregister.com/study/19549|http://clinicaltrials.gov/ct2/show/NCT01449929|[C3253985]|[dolutegravir]
2062|GSK|An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers.|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AK110022|nan|[C0085208]|[bupropion]
2063|GSK|A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AK130939|nan|[C0085208]|[bupropion]
2064|GSK|A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101497|nan|[C0085208]|[bupropion]
2065|GSK|An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103106|nan|[C0085208]|[bupropion]
2066|GSK|Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AK110021|nan|[C0085208]|[bupropion]
2067|GSK|A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension|Depressive Disorder|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40021|nan|[C0085208]|[bupropion]
2070|GSK|A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103447|nan|[C2347566]|[casopitant]
2071|GSK|A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103933|nan|[C2347566]|[casopitant]
2072|GSK|An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769]|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV105093|http://clinicaltrials.gov/show/NCT00404378|[C2347566]|[casopitant]
2073|GSK|An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin when Co-administered with Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV105097|http://clinicaltrials.gov/show/NCT00404274|[C2347566]|[casopitant]
2074|GSK|A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant [GW679769] in Healthy Subjects|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV109990|http://clinicaltrials.gov/show/NCT00460707|[C2347566]|[casopitant]
2084|GSK|A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/125|nan|[C0244821]|[ropinirole]
2085|GSK|A Multicentre, Double-Blind, Parallel Group Study to Determine the Effects of Rosiglitazone on Insulin Sensitivity, Endothelial Function and Vascular Reactivity in Comparison With Metformin and Placebo When Administered to Patients With Non-insulin Dependent Diabetes Mellitus.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/025|nan|[C0289313]|[rosiglitazone]
2112|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Year 1 Data)|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001|nan|[C0754659]|[dutasteride]
2113|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001|nan|[C0754659]|[dutasteride]
2114|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3001|nan|[C0754659]|[dutasteride]
2115|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002|nan|[C0754659]|[dutasteride]
2116|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA3002|nan|[C0754659]|[dutasteride]
2117|GSK|A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3003|nan|[C0754659]|[dutasteride]
2118|GSK|A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension.|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARIB3004|nan|[C0754659]|[dutasteride]
2119|GSK|A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Compare the Efficacy of Dutasteride/GI198745 0.5mg Once Daily Versus Finasteride 5mg Once Daily for 12 Months in the Treatment of Subjects with Benign Prostatic Hyperplasia (BPH), Followed by an Optional 24 Months Open Label Phase.|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40001|nan|[C0754659]|[dutasteride]
2122|GSK|A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/01/001|nan|[C0070122]|[paroxetine]
2123|GSK|A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/02/001|nan|[C0070122]|[paroxetine]
2124|GSK|A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/03/001|nan|[C0070122]|[paroxetine]
2125|GSK|A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/07/001|nan|[C0070122]|[paroxetine]
2126|GSK|A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/009|nan|[C0070122]|[paroxetine]
2127|GSK|A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/057|nan|[C0070122]|[paroxetine]
2128|GSK|A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD)|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/106|nan|[C0070122]|[paroxetine]
2129|GSK|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/128|nan|[C0070122]|[paroxetine]
2130|GSK|A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/251|nan|[C0070122]|[paroxetine]
2132|GSK|A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=26090/007|nan|[C0070122]|[paroxetine]
2133|GSK|A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/276|nan|[C0070122]|[paroxetine]
2134|GSK|A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/012_3|nan|[C0070122]|[paroxetine]
2135|GSK|A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/282|nan|[C0070122]|[paroxetine]
2136|GSK|A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia.|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/327|nan|[C0070122]|[paroxetine]
2137|GSK|A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/487|nan|[C0070122]|[paroxetine]
2138|GSK|A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression.|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/625|nan|[C0070122]|[paroxetine]
2139|GSK|A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Continuation Phase.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/329|nan|[C0070122]|[paroxetine]
2158|GSK|Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=104065|http://clinicaltrials.gov/show/NCT00169442|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
2159|GSK|Study to assess immunogenicity and safety of GlaxoSmithKline Biologicals' Kft’s DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs concomitant administration of CSL’s Triple Antigen and GlaxoSmithKline Biologicals’ Hiberix, to infants at 2, 4, 6 months of age, after a birth dose of hepatitis B|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=104489|http://clinicaltrials.gov/show/NCT00316680|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
2160|GSK|Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals’ DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals’ DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106602|http://clinicaltrials.gov/show/NCT00332566|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
2175|GSK|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100382|http://clinicaltrials.gov/show/NCT00289731|[C0593953]|[Twinrix]
2176|GSK|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100382|http://clinicaltrials.gov/show/NCT00289731|[C0593953]|[Twinrix]
2177|GSK|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100382|http://clinicaltrials.gov/show/NCT00289731|[C0593953]|[Twinrix]
2178|GSK|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100382|http://clinicaltrials.gov/show/NCT00289731|[C0593953]|[Twinrix]
2179|GSK|Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100386%20(EXT%20Y5)|http://clinicaltrials.gov/show/NCT00197171|[C0593953]|[Twinrix]
2180|GSK|Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100386%20(EXT%20Y5)|http://clinicaltrials.gov/show/NCT00197171|[C0593953]|[Twinrix]
2181|GSK|A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)|http://clinicaltrials.gov/show/NCT00289770|[C0593953]|[Twinrix]
2182|GSK|A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)|http://clinicaltrials.gov/show/NCT00289770|[C0593953]|[Twinrix]
2183|GSK|A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)|http://clinicaltrials.gov/show/NCT00289770|[C0593953]|[Twinrix]
2184|GSK|A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)|http://clinicaltrials.gov/show/NCT00289770|[C0593953]|[Twinrix]
2185|GSK|A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals’ combined hepatitis A - hepatitis B vaccine when administered in healthy adults|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100551 (EXT Y11)|http://clinicaltrials.gov/show/NCT00289770|[C0593953]|[Twinrix]
2186|GSK|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)|http://clinicaltrials.gov/show/NCT00289718|[C0593953]|[Twinrix]
2187|GSK|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)|http://clinicaltrials.gov/show/NCT00289718|[C0593953]|[Twinrix]
2188|GSK|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)|http://clinicaltrials.gov/show/NCT00289718|[C0593953]|[Twinrix]
2190|GSK|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)|http://clinicaltrials.gov/show/NCT00289718|[C0593953]|[Twinrix]
2191|GSK|Challenge dose administration of Twinrix™ or comparator 4 years after primary vaccination.|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111572|http://clinicaltrials.gov/show/NCT00684671|[C0593953]|[Twinrix]
2225|Novartis|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists|Chronic Idiopathic Urticaria (CIU)|Phase 3|http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4883g|https://clinicaltrials.gov/show/NCT01264939|[C0966225]|[omalizumab]
2414|GSK|A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=GLP110125|http://clinicaltrials.gov/show/NCT00518115|[C2607479]|[albiglutide]
2415|GSK|A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114130|http://clinicaltrials.gov/show/NCT01098539|[C2607479]|[albiglutide]
2416|GSK|A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112753|http://clinicaltrials.gov/show/NCT00838903|[C2607479, C0025598]|[albiglutide, metformin]
2417|GSK|A multicenter, randomized, parallel, placebo-controlled, one-year study of the efficacy and safety of bupropion hydrochloride sustained-release tablets versus placebo as an aid to smoking cessation treatment in adult cigarette smokers previously treated with bupropion|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40003|nan|[C0085208]|[bupropion]
2418|GSK|The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40005|nan|[C0085208]|[bupropion]
2419|GSK|A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=CIL103657|http://clinicaltrials.gov/show/NCT00103922|[C0968887]|[Cilomilast]
2420|GSK|An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/180|nan|[C0968887]|[Cilomilast]
2421|GSK|A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/125|nan|[C0968887, C0073992, C0117996]|[Cilomilast, salmeterol, fluticasone propionate]
2422|GSK|A 12-Week, Parallel-Group, Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose Ranging Study toEvaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45mg), AdministeredOrally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus foll ...|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=100925|http://clinicaltrials.gov/show/NCT00111800|[C2699586]|[denagliptin]
2423|GSK|A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111834|http://clinicaltrials.gov/show/NCT00748306|[C4550339]|[Fiboflapon]
2424|GSK|A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112025|http://clinicaltrials.gov/show/NCT00812929|[C4550339]|[Fiboflapon]
2425|GSK|An open-label, randomised, single-dose, multi-cohort, crossover bioavailability study of a solution formulation and three capsule formulations of GSK2190915 in healthy adult subjects followed by a repeat-dose, randomized, parallel group, double-blinded study of one selected capsule formulation and matched placebo in elderly healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112071|http://clinicaltrials.gov/show/NCT02224521|[C4550339]|[Fiboflapon]
2426|GSK|An open label, sequential, single cohort, repeat dose study to investigate the potential interaction of GSK2190915 on the pharmacokinetics of rosuvastatin in healthy adult subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112362|http://clinicaltrials.gov/show/NCT01411111|[C4550339]|[Fiboflapon]
2427|GSK|A randomised, double-blind, placebo-controlled, cross-over study to evaluate the effect of treatment with repeat dose GSK2190915 as an add-on to current therapy on the percentage of neutrophils in induced sputum in asthmatic patients with elevated sputum neutrophils|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115134|http://clinicaltrials.gov/show/NCT01471665|[C4550339]|[Fiboflapon]
2428|GSK|Randomised, open label, two period, crossover study to compare the steroid systemic exposure of Fluticasone Propionate (FP) from FP/Salmeterol (SALM) (500/50) DISKUS and Budesonide (BUD) from BUD/formoterol (FOR).(200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=100807|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2429|GSK|A single-blind, placebo-controlled, two part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682 in healthy volunteers|Multiple Sclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114070|http://clinicaltrials.gov/show/NCT01387217|[C4549166]|[GSK2018682]
2430|GSK|A single-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682 (S1P1 agonist) in healthy volunteers|Multiple Sclerosis, Relapsing-Remitting|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114347|http://clinicaltrials.gov/show/NCT01431937|[C4549166]|[GSK2018682]
2431|GSK|An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115860|http://clinicaltrials.gov/show/NCT01462669|[C0530684]|[ezogabine]
2432|GSK|A two part study to assess the pharmacokinetic performance of three retigabine modified release (MR) formulations after single dose and to assess the pharmacokinetics and tolerability of titration with retigabine MR|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113215|nan|[C0530684]|[ezogabine]
2433|GSK|Open-Label Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Retigabine Following Single and Multiple Dose Administration of Two Different Modified Release Formulations Compared to Single Dose Administration of One Immediate Release Formula|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-MR103|nan|[C0530684]|[ezogabine]
2434|GSK|A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-108|nan|[C0530684]|[ezogabine]
2435|GSK|A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-107|nan|[C0530684]|[ezogabine]
2436|GSK|A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-106|nan|[C0530684]|[ezogabine]
2437|GSK|Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-105|nan|[C0530684]|[ezogabine]
2438|GSK|Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-104|nan|[C0530684]|[ezogabine]
2439|GSK|A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-103|nan|[C0530684]|[ezogabine]
2440|GSK|Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-101SR|nan|[C0530684]|[ezogabine]
2441|GSK|A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy|Seizures|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-214|nan|[C0530684]|[ezogabine]
2442|GSK|A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205)|Seizures|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-212|nan|[C0530684]|[ezogabine]
2443|GSK|A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202)|Seizures|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-208|nan|[C0530684]|[ezogabine]
2444|GSK|A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=712753/007|http://clinicaltrials.gov/show/NCT00499707|[C0289313, C0025598]|[rosiglitazone, metformin]
2445|GSK|A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=712753/002|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
2446|GSK|A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=712753/003|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
2447|GSK|A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET® (8.0mg / 2.0g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=712753/009|http://clinicaltrials.gov/show/NCT00069836|[C0289313, C0025598]|[rosiglitazone, metformin]
2448|GSK|A two part randomized, double-blind, placebo controlled study to investigate the effects of topical doses of SB705498 oncapsaicin, histamine, and cowhage responses in healthy volunteers.|Dermatitis, Atopic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115246|http://clinicaltrials.gov/show/NCT01673529|[C1744311]|[SB 705498]
2449|GSK|Two part study to investigate pharmacokinetics (PK) & pharamcodynamics (PD) of SB-705498 in cough. Part A:open label study in healthy subjects to determine exposure to SB-705498. Part B:double-blind, placebo controlled, cross over study to investigate effect of SB-705498 on capsaicin induced cough and 24 hour cough counts in cough patients|Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114693|http://clinicaltrials.gov/show/NCT01476098|[C1744311]|[SB 705498]
2450|GSK|A randomised, double blind placebo controlled, 2 way cross over study in adults with non-allergic rhinits to evaluate the effect of once daily administration of intranasal SB-705498 12mg for two weeks and the response to a chamber challenge of cold dry air|Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114974|http://clinicaltrials.gov/show/NCT01424514|[C1744311]|[SB 705498]
2451|GSK|A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100mg Tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who meet International Headache Society (IHS) Criteria for Migraine.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40312|nan|[C0075632]|[sumatriptan]
2452|GSK|A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder International Headache Society (IHS) 1.7.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40299|nan|[C0075632]|[sumatriptan]
2453|GSK|A randomized, double-blind, placebo-controlled, single-attack, parallel-group evaluation of the efficacy of sumatriptan 50mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40298|nan|[C0075632]|[sumatriptan]
2454|GSK|A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40286|nan|[C0075632]|[sumatriptan]
2455|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40285|nan|[C0075632]|[sumatriptan]
2456|GSK|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phase of a Menstrually-Associated Migraine Attack|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40282|nan|[C0075632]|[sumatriptan]
2457|GSK|A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113359|http://clinicaltrials.gov/show/NCT01316887|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
2458|GSK|A randomised, placebo-controlled, incomplete block, four period crossover , repeat dose study to evaluate the effect of the inhaled GSK573719/Vilanterol combination and GSK573719 monotherapy on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114635|http://clinicaltrials.gov/show/NCT01521377|[C3700388, C3709474]|[vilanterol and umeclidinium bromide, umeclidinium bromide]
2459|GSK|An open-label, non-randomized, pharmacokinetic and safety study of single dose GSK573719 + GW643444 (VI) combination and repeat doses of GSK573719 in healthy subjects and in subjects with moderate hepatic impairment|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114637|http://clinicaltrials.gov/show/NCT01577680|[C3700388, C3709474]|[vilanterol and umeclidinium bromide, umeclidinium bromide]
2460|GSK|Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss|Tinnitus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKP106254|http://clinicaltrials.gov/show/NCT00394056|[C2607417, C0070122]|[vestipitant, paroxetine]
2461|GSK|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD)|Social Phobia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKP103401|http://clinicaltrials.gov/show/NCT00403962|[C2607417, C0070122]|[vestipitant, paroxetine]
2462|GSK|A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powder (GW642444) and salmeterol, compared with placebo in the treatment of persistent asthma in adults and adolescents uncontrolled on inhaled corticosteroids|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112060|http://clinicaltrials.gov/show/NCT01181895|[C2935023]|[vilanterol]
2463|ViiV|A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir|Infection, Human Immunodeficiency Virus I|Phase 4|https://www.viiv-studyregister.com/study/19689|http://clinicaltrials.gov/show/NCT00373945|[C0663655]|[abacavir]
2523|GSK|Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder|Obsessive-Compulsive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/116|nan|[C0070122]|[paroxetine]
2524|GSK|Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder|Obsessive-Compulsive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/118|nan|[C0070122]|[paroxetine]
2525|GSK|A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/120|nan|[C0070122]|[paroxetine]
2526|GSK|A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder.|Obsessive-Compulsive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/136|nan|[C0070122]|[paroxetine]
2527|GSK|A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder.|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/187|nan|[C0070122]|[paroxetine]
2528|GSK|A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/223|nan|[C0070122]|[paroxetine]
2529|GSK|A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia|Social Phobia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=29060/382|nan|[C0070122]|[paroxetine]
2530|GSK|A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia.|Social Phobia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/454|nan|[C0070122]|[paroxetine]
2531|GSK|A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/494|nan|[C0070122]|[paroxetine]
2532|GSK|A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/495|nan|[C0070122]|[paroxetine]
2533|GSK|A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder|Panic Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/497|nan|[C0070122]|[paroxetine]
2534|GSK|A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia|Social Phobia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/502|nan|[C0070122]|[paroxetine]
2535|GSK|A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Post-traumatic Stress Disorder (PTSD)|Post-Traumatic Stress Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/627|nan|[C0070122]|[paroxetine]
2536|GSK|A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD)|Anxiety Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/637|nan|[C0070122]|[paroxetine]
2537|GSK|A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder|Anxiety Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/641|nan|[C0070122]|[paroxetine]
2538|GSK|A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder|Anxiety Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/642|nan|[C0070122]|[paroxetine]
2539|GSK|A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD)|Post-Traumatic Stress Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/648|nan|[C0070122]|[paroxetine]
2540|GSK|A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Post-traumatic Stress Disorder (PTSD).|Post-Traumatic Stress Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/651|nan|[C0070122]|[paroxetine]
2541|GSK|A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder|Social Phobia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/790|nan|[C0070122]|[paroxetine]
2542|GSK|A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD)|Anxiety Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/791|nan|[C0070122]|[paroxetine]
2543|GSK|An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114417|http://clinicaltrials.gov/show/NCT01328444|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
2544|GSK|An exercise endurance study to evaluate the effects of treatment of Chronic Obstructive Pulmonary Disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study B|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114418|http://clinicaltrials.gov/show/NCT01323660|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
2630|GSK|A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease.|Alzheimer's Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVA102672|http://clinicaltrials.gov/show/NCT00348309|[C0289313]|[rosiglitazone]
2745|Astellas|A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects with Symptoms of Overactive Bladder.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-049|https://clinicaltrials.gov/ct2/show/NCT00688688|[C2983812]|[mirabegron]
2746|Astellas|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive bladder.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-074|https://clinicaltrials.gov/ct2/show/NCT00912964|[C2983812]|[mirabegron]
2747|Astellas|A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-EC-001|https://clinicaltrials.gov/ct2/show/NCT01638000|[C2983812]|[mirabegron]
2748|Astellas|A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-046|https://clinicaltrials.gov/ct2/show/NCT00689104|[C2983812]|[mirabegron]
2749|Astellas|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-047|https://clinicaltrials.gov/ct2/show/NCT00662909|[C2983812]|[mirabegron]
2750|Astellas|A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.|Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-CL-055|https://clinicaltrials.gov/ct2/show/NCT01018511|[C1509436, C0257343]|[solifenacin succinate, tamsulosin]
2751|Astellas|An open-label, long term, multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.|Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-CL-057|https://clinicaltrials.gov/ct2/show/NCT01021332|[C1509436, C0257343]|[solifenacin succinate, tamsulosin]
2757|GSK|Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants.|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101222|nan|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
2758|GSK|Study to assess the lot-to-lot consistency of the production method of GSK Biologicals' DTPw-HBV/ Hib Kft. vaccine and to compare to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course.|Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101223|nan|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
2767|GSK|Evaluation of GSK Biologicals’ Boostrix™ Polio in healthy adults, 10 years after a booster vaccination|Acellular pertussis; Diphtheria; Poliomyelitis; Tetanus|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=113060|http://clinicaltrials.gov/show/NCT01323959|[C5233092, C0305062, C0982332, C0718003]|[Reduced cysteine content, 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', 'Poliovirus Vaccine, Inactivated']
2781|GSK|Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)|http://clinicaltrials.gov/show/NCT00197184|[C0593953]|[Twinrix]
2782|GSK|Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)|http://clinicaltrials.gov/show/NCT00197184|[C0593953]|[Twinrix]
2783|GSK|Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/132 (EXT Y2)|http://clinicaltrials.gov/show/NCT00197184|[C0593953]|[Twinrix]
2784|GSK|An open, multicentric, post-marketing surveillance study of GlaxoSmithKline Biologicals’ combined hepatitis A-hepatitis B vaccine (Twinrix™), injected as a three dose primary vaccination course according to the prescribing information, in healthy children and adults.|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=208127/127|nan|[C0593953]|[Twinrix]
2815|GSK|A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/183|nan|[C0289313]|[rosiglitazone]
2816|GSK|A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=100723|nan|[C0289313]|[rosiglitazone]
2817|GSK|2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/135|nan|[C0289313]|[rosiglitazone]
2818|GSK|A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis).|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/136|nan|[C0289313]|[rosiglitazone]
2819|GSK|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Rosiglitazone on Post Prandial Glycaemia in Type 2 Diabetic Patients.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/140|nan|[C0289313]|[rosiglitazone]
2820|GSK|A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg once daily) in Combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/143|http://clinicaltrials.gov/show/NCT00333723|[C0289313]|[rosiglitazone]
2821|GSK|A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA when added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy when Administered to Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/284|http://clinicaltrials.gov/show/NCT00501020|[C0289313]|[rosiglitazone]
2822|GSK|A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/326|http://clinicaltrials.gov/show/NCT00044460|[C0289313]|[rosiglitazone]
2823|GSK|A Double-Blind Feasibility Study to Estimate and Compare the Effect of Rosiglitazone in Parallel with Glyburide on Cognition in Patients with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/282|nan|[C0289313]|[rosiglitazone]
2824|GSK|A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/375|http://clinicaltrials.gov/show/NCT00197132|[C0289313]|[rosiglitazone]
2825|GSK|A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=797620/001|nan|[C0289313, C0061323]|[rosiglitazone, glimepiride]
2826|GSK|A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=797620/003|nan|[C0289313, C0061323]|[rosiglitazone, glimepiride]
2827|GSK|A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=797620/004|nan|[C0289313, C0061323]|[rosiglitazone, glimepiride]
2828|GSK|A Bioequivalence Study with a Combination Tablet Formulation of Rosiglitazone and Metformin (4mg/1000mg) Compared to the Commercial Tablet Formulation of AVANDAMET (2mg rosiglitazone/500mg metformin) and a Dose Proportionality Study Comparing the Combination Tablet Formulations of Rosiglitazone and Metformin (4mg/1000mg & 2mg/1000mg).|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=712753/001|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
2829|GSK|A study to estimate the pharmacokinetics of six extended release formulations of AVANDAMET (rosiglitazone maleate 4mg / metformin HCl 1000mg), compared to the commercial formulation of AVANDAMET (rosiglitazone maleate 2mg / metformin HCl 500mg, q12h), and concomitant dosing of Glucophage XR (metformin HCl 2 × 500mg) with AVANDIA (rosiglitazone maleate 4mg)|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=712753/012|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
2937|GSK|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=108366|http://clinicaltrials.gov/show/NCT01147692|[C2607479]|[albiglutide]
2938|GSK|A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114856|http://clinicaltrials.gov/show/NCT01357889|[C2607479]|[albiglutide]
2939|GSK|A multi-center, randomised, parallel-group, double-blind, placebo-controlled one year study (with a 7 week Treatment Phase) to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) versus placebo as an aid to smoking cessation in a population of smokers with established, stable cardiovascular disease|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40014|nan|[C0085208]|[bupropion]
2940|GSK|A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 346) and A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 347)|Hypertension|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=105517/346; https://www.gsk-studyregister.com/en/trial-details/?id=105517/347|nan|[C0054836]|[carvedilol]
2941|GSK|A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/181|nan|[C0968887]|[Cilomilast]
2942|GSK|A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/168|nan|[C0968887]|[Cilomilast]
2943|GSK|A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/157|nan|[C0968887]|[Cilomilast]
2944|GSK|A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/156|nan|[C0968887]|[Cilomilast]
2945|GSK|A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/041|nan|[C0968887]|[Cilomilast]
2946|GSK|A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207499/040|nan|[C0968887]|[Cilomilast]
2947|GSK|A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AC2105333|http://clinicaltrials.gov/show/NCT00376714|[C2699560]|[Darotropium Bromide]
2948|GSK|A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=AC2106956|http://clinicaltrials.gov/show/NCT00422604|[C2699560]|[Darotropium Bromide]
2949|GSK|A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=DB1111509|http://clinicaltrials.gov/show/NCT00671216|[C2699560]|[Darotropium Bromide]
2950|GSK|A single-centre, randomised, double-blind placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic and urinary pharmacokinetics of GSK233705 administered twice daily for 14 days in healthy male subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105331|nan|[C2699560]|[Darotropium Bromide]
2951|GSK|A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy Japanese subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112146|http://clinicaltrials.gov/show/NCT00783003|[C2699560, C2935023]|[Darotropium Bromide, vilanterol]
2952|GSK|An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3)|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102761|nan|[C2699586]|[denagliptin]
2953|GSK|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety And Preliminary Efficacy of Neoadjuvant Therapy With GI198745 in Subjects With Localized Prostate Cancer Undergoing Radical Prostatectomy.|Neoplasms, Prostate|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ARIA2003|nan|[C0754659]|[dutasteride]
2954|GSK|A double blind, placebo controlled, single dose, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled reformulated FP (TIBAC) in comparison with the standard formulation FP.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FPR10001|nan|[C0117996]|[fluticasone propionate]
2955|GSK|A randomised, double blind, placebo controlled, cross over study to investigate the duration of action of inhaled doses of Fluticasone Propionate (1000mg) on airway responsiveness to adenosine-5'-monophosphate (AMP) in mild asthmatic patients|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FPR10006|nan|[C0117996]|[fluticasone propionate]
2956|GSK|Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FAS40012|nan|[C0117996]|[fluticasone propionate]
2957|GSK|A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAP10006|nan|[C0117996]|[fluticasone propionate]
2958|GSK|Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAP19052|nan|[C0117996]|[fluticasone propionate]
2959|GSK|Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAP19058|nan|[C0117996]|[fluticasone propionate]
2960|GSK|A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FAS10002|nan|[C0117996]|[fluticasone propionate]
2961|GSK|A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101877|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2962|GSK|Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10017|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2963|GSK|An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FAS40008|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2964|GSK|A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40008|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2965|GSK|A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) 50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4- 11 years with asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40012|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2966|GSK|A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM40062|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2967|GSK|A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC, 100/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40024|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2968|GSK|A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC 250/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who Require Chronic Inhaled Corticosteroid Therapy for the Treatment of Persistent Asthma|Bronchospasm|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAS40025|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
2969|GSK|A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria.|Migraine Disorders and Premenstrual Syndrome|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=S2W20006|nan|[C0540623]|[naratriptan]
2970|GSK|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures|Seizures|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-301|http://clinicaltrials.gov/show/NCT00232596|[C0530684]|[ezogabine]
2971|GSK|Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures|Seizures|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-302|http://clinicaltrials.gov/show/NCT00235755|[C0530684]|[ezogabine]
2972|GSK|A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy|Seizures|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-216|nan|[C0530684]|[ezogabine]
2973|GSK|A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy|Seizures|Phase 2/3|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-205|nan|[C0530684]|[ezogabine]
2974|GSK|Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-123|nan|[C0530684]|[ezogabine]
2975|GSK|Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-117|nan|[C0530684]|[ezogabine]
2976|GSK|Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2)|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=3065A1-115|nan|[C0530684]|[ezogabine]
2977|GSK|An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/109|nan|[C0289313]|[rosiglitazone]
2979|GSK|A Double-Blind Study to Assess the Effect of Rosiglitazone (RSG) on the Pharmacodynamics and Pharmacokinetics of Acenocoumerol in Healthy Male Volunteers|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/225|nan|[C0289313]|[rosiglitazone]
2980|GSK|A Study to Estimate the Effect of Repeat Oral Doses of Rosiglitazone (8 mg) on the Pharmacokinetics of Glimepiride (4 mg) and the Effect of a Single Oral Dose of Glimepiride (4 mg) on the Pharmacokinetics of Rosiglitazone (8 mg) in Healthy Subjects.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/340|nan|[C0289313]|[rosiglitazone]
2981|GSK|A 24-week Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/207|nan|[C0289313]|[rosiglitazone]
2982|GSK|A single dose study to assess the tolerability and food effect of an enterically-coated formulation of the commercial immediate release tablet of rosiglitazone and an enterically-coated modified release tablet formulation of rosiglitazone in healthy volunteers.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/299|nan|[C0289313]|[rosiglitazone]
2983|GSK|A study to evaluate the pharmacokinetics of eight prototype formulations of rosiglitazone 8 mg in healthy volunteers.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/309|nan|[C0289313]|[rosiglitazone]
2984|GSK|A six-month double-blind, randomised, parallel-group study to compare the effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy (less than or equal to 15mg daily) on body fat distribution when administered to subjects with type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/369|nan|[C0289313]|[rosiglitazone]
2985|GSK|A Study to Evaluate the Effect of Food on the Pharmacokinetics of a Modified Release Formulation of Rosiglitazone 8 mg in Healthy Volunteers After Repeat Dosing.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/301|nan|[C0289313]|[rosiglitazone]
2986|GSK|A Bioequivalence Study Comparing Tablets Manufactured with the 8 mg Anhydrate Form IV (ANF4) to the Commercial Anhydrate Form I (ANF1) of Rosiglitazone Maleate.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/300|nan|[C0289313]|[rosiglitazone]
2987|GSK|A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (4 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 4 mg and Metformin 500 mg Commercial Tablets-and a Dose Proportionality Study Comparing the 4 mg/500 mg and 1 mg/500 mg Combination Formulations.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/270|nan|[C0289313, C1620263]|[rosiglitazone, metformin / rosiglitazone]
2988|GSK|A Study to Assess the Effect of Food on the Pharmacokinetics of a Rosiglitazone 4mg and Metformin 500mg Combination Tablet Formulation and a Study Comparing the Pharmacokinetics of Rosiglitazone 4mg and Metformin 500mg Combination Tablet to Concomitant Dosing of Rosiglitazone 4mg and Metformin 500mg Commercial Tablets in the Fed State in Healthy Volunteers|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=49653/271|nan|[C0289313, C1620263]|[rosiglitazone, metformin / rosiglitazone]
2989|GSK|A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Cardiovascular Pharmacodynamic Effects and Pharmacokinetics of Salmeterol vs Placebo Following 15 Days BD Regimen In COPD Subjects|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SCO20001|nan|[C0073992]|[salmeterol]
2990|GSK|A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40320|nan|[C0073992]|[salmeterol]
2991|GSK|A randomised, open-label, parallel group 28-day pilot study to compare the addition of inhaled salmeterol 50mcg b.i.d. (via the DISKHALER inhaler) or tulobuterol patch 2mg once daily nocte in adult asthmatic subjects symptomatic on treatment with inhaled corticosteroids.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40332|nan|[C0073992]|[salmeterol]
2992|GSK|A Randomised, Single-Blind, Parallel-Group, 28-Day, Pilot Study to Compare the Addition of Inhaled Salmeterol 50µg bid (via the DISKHALER™ Inhaler) or Tulobuterol-Patch 2mg qd Nocte in Adult Asthmatic Subjects who are Symptomatic on Inhaled Corticosteroids Alone|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40329|nan|[C0073992]|[salmeterol]
2993|GSK|A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Compare the Systemic Pharmacodynamic Effects and Pharmacokinetics of Salmeterol Delivered by the Non-CFC Propellant (HFA-134a; GR106642X) and the CFCPropellant (Propellant 11/12) Metered Dose Inhalers in Healthy Subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SLGB1006|nan|[C0073992]|[salmeterol]
2994|GSK|A double-blind, randomised, two-period, crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects of 7 days co-administration of salmeterol (50 mcg bid) with ketoconazole (400 mg od).|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106128|nan|[C0073992]|[salmeterol]
2995|GSK|Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT™ Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo Administered Via a Valved-Holding Chamber with Facemask in Subjects with Symptoms of Asthma or Reactive Airways Disease Age 6 to 23 months|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SMS30077|nan|[C0073992]|[salmeterol]
2996|GSK|SMART: A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42mcg Twice Daily|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SLGA5011|nan|[C0073992]|[salmeterol]
2997|GSK|A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SMO30006|nan|[C0073992]|[salmeterol]
2998|GSK|A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg bd Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Children Aged 4-11 Years With Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SMO30007|nan|[C0073992]|[salmeterol]
2999|GSK|A Five-Week, Randomized, Double-Blind, Double-Dummy, Two-Period, Four-Treatment Crossover, Placebo-Controlled, Balanced, Incomplete Block Design, Multi-Center Study of Salmeterol Inhalation Aerosol 25mcg BID, 25mcg TID, 50mcg BID and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 6 to 23 Months|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SMS20011|nan|[C0073992]|[salmeterol]
3000|GSK|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Clinical Trial of 4 Weeks Treatment With SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID, and Placebo Administered via a Valved Holding Chamber With Facemask in Subjects With Asthma Aged 24 to 47 Months|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SMS30076|nan|[C0073992]|[salmeterol]
3001|GSK|A Randomized, Multi-Center, Cross Over Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) via the DISKUS ™ and Salmeterol Xinafoate Inhalation Aerosol (42mcg BID) via the Metered Dose Inhaler on Measures of Device Preference in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40330|nan|[C0073992]|[salmeterol]
3002|GSK|An open, randomised, two-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM10961|nan|[C0075632]|[sumatriptan]
3003|GSK|An open, randomised, four-period crossover study to investigate the bioavailability of a new orally disintegrating (melt) formulation (ODT) of sumatriptan, with and without water compared to the currently marketed sumatriptan 100mg tablet and also to investigate the effect of food on the ODT formulation, in healthy male and female subjects|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM10955|nan|[C0075632]|[sumatriptan]
3004|GSK|An open, randomised, three-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan 100mg tablet compared to the currently marketed sumatriptan 100mg tablet administered immediately after food and the fast disintegrating tablet administered in the fasted state to healthy male and female subjects|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM10954|nan|[C0075632]|[sumatriptan]
3005|GSK|An open, randomised, four-period crossover study to demonstrate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg IMITREX† /IMIGRAN† tablets), in healthy male and female volunteers|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM10950|nan|[C0075632]|[sumatriptan]
3006|GSK|An open, randomised, single-dose, three-way crossover, pilot study investigating the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50mg tablets versus the currently marketed sumatriptan 50mg tablets in healthy volunteers|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM10948|nan|[C0075632]|[sumatriptan]
3007|GSK|An open-label evaluation of patient satisfaction with IMITREX (sumatriptan succinate) tablets, 100mg, administered at the first sign of pain for up to three migraines in patients who are not satisfied with their current triptan therapy.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40301|nan|[C0075632]|[sumatriptan]
3008|GSK|Identification of Migraine Headache Among Self-Described and/or Physician Diagnosed Sinus Headache Sufferers and Treatment with IMITREX† 50mg Tablets|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40294|nan|[C0075632]|[sumatriptan]
3009|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study of Sumatriptan 6 mg Injection In the Treatment of Moderate-to-Severe Migraine Present Upon Awakening.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SUM40287|nan|[C0075632]|[sumatriptan]
3010|GSK|A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack.|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SUM30046|nan|[C0075632]|[sumatriptan]
3011|GSK|A Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate Two Dose Levels (5mg And 20mg) Of Sumatriptan Nasal Spray In The Acute Treatment Of A Single Migraine Attack In Adolescent Migraineurs (12-17 Years Of Age)|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SUM30045|nan|[C0075632]|[sumatriptan]
3012|GSK|A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study To Investigate The Efficacy And Tolerability Of 100mg Sumatriptan Administered As A Film-Coated, Fast Disintegrating Tablet|Migraine Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SUM20033|nan|[C0075632]|[sumatriptan]
3013|GSK|A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects|Influenza A Virus, H1N1 Subtype|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113625|http://clinicaltrials.gov/show/NCT00989404|[C0216660]|[zanamivir]
3084|GSK|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100556 (Y11)|http://clinicaltrials.gov/show/NCT00289718|[C0593953]|[Twinrix]
3085|ViiV|A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir once daily and GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naïve and Experienced, Pediatric Subjects 2 to 18 Years Old.|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19690|http://clinicaltrials.gov/show/NCT00040664|[C1176315]|[fosamprenavir]
3086|ViiV|A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to &lt;2 years.|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19716|http://clinicaltrials.gov/show/NCT00071760|[C1176315]|[fosamprenavir]
3087|ViiV|A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to &lt;6 years old.|Infection, Human Immunodeficiency Virus I|Phase 2|https://www.viiv-studyregister.com/study/19717|http://clinicaltrials.gov/show/NCT00089583|[C1176315]|[fosamprenavir]
3123|GSK|A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long-term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112754|http://clinicaltrials.gov/show/NCT00838916|[C2607479]|[albiglutide]
3124|GSK|A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and with Metformin plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112757|http://clinicaltrials.gov/show/NCT00839527|[C2607479]|[albiglutide]
3125|GSK|A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=108486|http://clinicaltrials.gov/show/NCT00976391|[C2607479]|[albiglutide]
3126|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112755|http://clinicaltrials.gov/show/NCT00849056|[C2607479]|[albiglutide]
3127|GSK|A single-site, randomized, double-blind, placebo-controlled, parallel-group, stepped glucose clamp study to assess the effects of albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=108372|http://clinicaltrials.gov/show/NCT01475734|[C2607479]|[albiglutide]
3128|GSK|A multi-centre, randomised, double-blind, double dummy study comparing the efficacy and safety of chlorproguanil-dapsone-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in children and adolescents in Africa.|Malaria, Falciparum|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=CDA 714703/005|http://clinicaltrials.gov/show/NCT00344006|[C0052432, C0055470, C0010980]|[artesunate, chlorproguanil, dapsone]
3129|GSK|A multi-centre, randomised, double-blind study to compare the efficacy and safety of chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone in the treatment of acute uncomplicated Plasmodium falciparum malaria in children, adolescents and adults in Africa.|Malaria, Falciparum|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=CDA 714703/006|http://clinicaltrials.gov/show/NCT00371735|[C0052432, C0055470, C0010980]|[artesunate, chlorproguanil, dapsone]
3130|GSK|An open, randomised, crossover study to assess the pharmacokinetics and tolerability of single doses of LAPDAP™, artesunate, and LAPDAP plus artesunate|Malaria|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103078|nan|[C0052432, C0055470, C0010980]|[artesunate, chlorproguanil, dapsone]
3131|GSK|An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKV105091|http://clinicaltrials.gov/show/NCT00405080|[C2347566]|[casopitant]
3132|GSK|An open-label, randomized (with respect to different doses of casopitant), two-period parallel group study to evaluate the potential pharmacokinetic interaction of co-administered casopitant and digoxin in healthy subjects|Nausea and Vomiting, Chemotherapy-Induced|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105095|nan|[C2347566]|[casopitant]
3133|GSK|A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AC2103473|http://clinicaltrials.gov/show/NCT00279019|[C2699560]|[Darotropium Bromide]
3134|GSK|A randomised, double blind, placebo-controlled, double dummy, five-way cross over dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 (20-500ug via DPI), and , tiotropium bromide (18ug via DPI) in healthy male subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103471|nan|[C2699560]|[Darotropium Bromide]
3135|GSK|Multicenter, double-blind, randomized, parallel-group study, comparing 0.5 mg and 3.5 mg dutasteride daily for 4 months prior to radical prostatectomy versus radical prostatectomy alone in men with biopsy-proven and clinically localized prostate cancer|Neoplasms, Prostate|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40010|nan|[C0754659]|[dutasteride]
3136|GSK|A single centre, randomised, double-blind, placebo-controlled,four-way cross over study to assess the safety, tolerability,pharmacokinetics and pharmacodynamics of single doses ofGSK2190915 in healthy Japanese subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112359|http://clinicaltrials.gov/show/NCT00955383|[C4550339]|[Fiboflapon]
3138|GSK|A single dose, crossover study in healthy female subjects to assess the regional absorption and bioavailability of 100 mg GSK2190915A|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114604|http://clinicaltrials.gov/show/NCT01318980|[C4550339]|[Fiboflapon]
3139|GSK|A 12 week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with Tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115247|http://clinicaltrials.gov/show/NCT01395888|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3140|GSK|A randomized, double blind, placebo-controlled three-way crossover study in mild asthmatics to evaluate the effect of smoking status on the attenuation by inhaled corticosteroids of the allergen-induced asthmatic response.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114748|http://clinicaltrials.gov/show/NCT01400906|[C0117996]|[fluticasone propionate]
3141|GSK|Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=112989|http://clinicaltrials.gov/show/NCT00984659|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3142|GSK|A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=113874|http://clinicaltrials.gov/show/NCT01110200|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3145|GSK|A multi-enter, randomized, double-blind, placebo-controlled, four-way incomplete block crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20 mcg) of GSK159797|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2E106359|http://clinicaltrials.gov/show/NCT00358488|[C2698231]|[Milveterol]
3146|GSK|A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia.|Social Phobia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/676|nan|[C0070122]|[paroxetine]
3147|GSK|A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder|Premenstrual Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/689|nan|[C0070122]|[paroxetine]
3148|GSK|A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder|Obsessive-Compulsive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/704|nan|[C0070122]|[paroxetine]
3149|GSK|A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression|Obsessive-Compulsive Disorder and Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/715|nan|[C0070122]|[paroxetine]
3150|GSK|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder|Social Phobia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=TMT106386|http://clinicaltrials.gov/show/NCT00470483|[C0070122]|[paroxetine]
3151|GSK|A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD)|Obsessive-Compulsive Disorder and Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/716|nan|[C0070122]|[paroxetine]
3152|GSK|A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder|Premenstrual Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/677|nan|[C0070122]|[paroxetine]
3153|GSK|A double-blind, placebo-controlled, 3-arm fixed dose study of paroxetine CR continuous treatment (12.5mg and 25mg) for Premenstrual Dysphoric Disorder.|Premenstrual Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/688|nan|[C0070122]|[paroxetine]
3154|GSK|A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689|Premenstrual Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/711|nan|[C0070122]|[paroxetine]
3155|GSK|A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder|Premenstrual Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/717|nan|[C0070122]|[paroxetine]
3156|GSK|An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=PCR111656|http://clinicaltrials.gov/show/NCT00749359|[C0070122]|[paroxetine]
3157|GSK|An open label, randomised, repeat dose study to assess the pharmacokinetic performance of five ezogabine/retigabine modified release (MR) formulations at steady state compared to the immediate release (IR) formulation.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114552|http://clinicaltrials.gov/show/NCT01332513|[C0530684]|[ezogabine]
3158|GSK|A 12-Week, Randomized, Double-blind Study to Evaluate the Effects of Rosiglitazone 4 mg BD and Rosiglitazone 4 mg QD on Lipids in Type 2 Diabetes Mellitus Subjects Taking Statins|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=49653/311|nan|[C0289313]|[rosiglitazone]
3159|GSK|A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=797620/002|nan|[C0289313, C0061323]|[rosiglitazone, glimepiride]
3160|GSK|A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of a GSK New Chemical Entity (NCE), paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subj ...|Social Phobia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKD10020|nan|[C2607417]|[vestipitant]
3161|GSK|An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKD20006|http://clinicaltrials.gov/show/NCT00048204|[C2607417]|[vestipitant]
3162|GSK|A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia.|Depressive Disorder and Anxiety Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NKP102280|http://clinicaltrials.gov/show/NCT00343707|[C2607417, C0070122]|[vestipitant, paroxetine]
3163|GSK|An open label repeat dose study to investigate the effect of New Compound (X mg) and paroxetine (10 mg) given in combination for 15 days on the pharmacokinetics of Midazolam and Dextromethorphan in healthy male and female volunteers|Depressive Disorder and Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=100716|nan|[C2607417, C0070122]|[vestipitant, paroxetine]
3164|GSK|A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 (5, 7.5, 15 or 25 mg) and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers.|Depressive Disorder and Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=100690|nan|[C2607417, C0070122]|[vestipitant, paroxetine]
3165|GSK|A Study to Investigate the Effect of Intranasal GR121167X on Infection Rates in Healthy Male Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) virus|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1001|nan|[C0216660]|[zanamivir]
3166|GSK|A Study to Investigate the Effect of Intranasal GG167 Initiated at Various Intervals Post Inoculation on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1002|nan|[C0216660]|[zanamivir]
3167|GSK|A Study to Investigate the Effect of Intranasal GG167 at Various Dosing Frequencies on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1003|nan|[C0216660]|[zanamivir]
3168|GSK|A Study to Investigate the Effect of Intranasal GG167 as Nasal Drops and Nasal Spray on Infection in Healthy Volunteers Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1004|nan|[C0216660]|[zanamivir]
3169|GSK|A Study to Investigate the Effect of Intranasal GG167 on Infection in Healthy Volunteers Experimentally Inoculated with Influenza B/YAMAGATA/16/88 Virus|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NAIA1005|nan|[C0216660]|[zanamivir]
3215|Astellas|A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0004|https://clinicaltrials.gov/ct2/show/NCT01071850|[C3492889]|[ipragliflozin]
3216|Astellas|Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Diabetes Mellitus, Type 2|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0005|https://clinicaltrials.gov/ct2/show/NCT01117584|[C3492889]|[ipragliflozin]
3217|Astellas|Randomized, Open-label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Infections in High Risk Liver Transplant Recipients.|Invasive Fungal Infections|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=9463-EC-0001|https://clinicaltrials.gov/ct2/show/NCT01058174|[C1120386]|[micafungin]
3218|Astellas|A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson|Myocardial Perfusion Imaging|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-3002|https://clinicaltrials.gov/ct2/show/NCT00826280|[C1698215]|[regadenoson]
3219|Astellas|A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects|Transplantation, Kidney|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1210|https://clinicaltrials.gov/ct2/show/NCT00717470|[C0085149]|[tacrolimus]
3220|Astellas|A multicenter, three arm, randomized, open label clinical study to compare renal function in liver transplant recipients receiving an immunosuppressive regimen of Advagraf (immediately or delayed post-transplant) and MMF with or without a Monoclonal Anti-IL2R antibody (Basiliximab)|Transplantation, Liver|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1106|https://clinicaltrials.gov/ct2/show/NCT01011205|[C0085149]|[tacrolimus]
3222|GSK|An open, randomised, multi-centre dose-ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate.|Malaria|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=714703/003|https://clinicaltrials.gov/ct/show/NCT00519467|[C0052432, C0055470, C0010980]|[artesunate, chlorproguanil, dapsone]
3249|GSK|Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B|Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=213501/018|nan|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
3250|GSK|Study to assess immunogenicity and reactogenicity of GSK Bio’s quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants|Diphtheria; Tetanus; Whole Cell Pertussis; Hepatitis B; Haemophilus influenzae type b|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=213501/019|nan|[C0545299, C0305062, C0717973, C0062527, C0062086]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'pertussis, whole cell', hepatitis B surface antigen vaccine, Haemophilus influenzae type b polysaccharide vaccine]
3261|GSK|A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112356|http://clinicaltrials.gov/show/NCT00812773|[C4550339]|[Fiboflapon]
3262|GSK|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114387|http://clinicaltrials.gov/show/NCT01248975|[C4550339]|[Fiboflapon]
3263|GSK|Absolute Bioavailability of FP, BDP, and Budesonide following single inhaled 400mcg dose and assay limits of 50pg/mL.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FMS10031|nan|[C0117996]|[fluticasone propionate]
3264|GSK|A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ...|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SAS30024|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3265|GSK|A randomised, double blind, placebo controlled, three-way cross-over study in asymptomatic patients with seasonal allergic rhinitis to compare the effect of 7 days treatment with intranasal salmeterol/fluticasone propionate combination ( 100mcg/200mcg) with 7 days treatment of fluticasone propionate (200mcg) or placebo, on nasal clinical symptoms and nasal blockage following intranasal allergen challenge.|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SNA10001|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3266|GSK|A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SAS10020|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3267|GSK|An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors|Solid Tumours|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MET111516|http://clinicaltrials.gov/show/NCT00742261|[C2973987]|[Foretinib]
3268|GSK|A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma|Carcinoma, Renal Cell|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MET111644|http://clinicaltrials.gov/show/NCT00726323|[C2973987]|[Foretinib]
3280|GSK|A randomised, double blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of single inhaled doses of a new chemical entity in healthy male subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2A10001|nan|[C3530051]|[GW597901]
3281|GSK|A multi-centre, randomised, double-blind, placebo controlled, crossover study to examine the efficacy, safety, tolerability and systemic pharmacokinetics of single inhaled dose of a new chemical entity in asthmatic subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2A10002|nan|[C3530051]|[GW597901]
3291|GSK|Comparison of the immunogenicity and safety in healthy monozygotic and dizygotic twins, which have been grown up in the same environment, after having receipt three vaccinations (Mths 0-1-6) with the hepatitis A and B combination vaccine TWINRIX™ ADULT|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=208127/098|nan|[C0593953]|[Twinrix]
3292|GSK|A phase III, open, randomized, multicenter, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bios’ combined hepatitis A/hepatitis B vac admin according to a 0-6 mth schedule by intramuscular injection versus TWINRIX™ JUNIOR admin in healthy children|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/120|http://clinicaltrials.gov/show/NCT00197184|[C0593953]|[Twinrix]
3294|GSK|A phase III open study to assess the anamnestic response to a single injection of Twinrix vaccine, given approximately 44 months after primary vaccination with combined hepatitis A/ hepatitis B vac, in healthy subjects who have a previously documented seroprotective anti-HBs antibody response|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/123|nan|[C0593953]|[Twinrix]
3296|GSK|A phase II, open, randomized, multicentric study to evaluate the immunogenicity, reactogenicity and safety of an experimental vaccine to that of Twinrix™ Adult admin following an accelerated schedule (0-7-21 days + 12 mths) in healthy adults aged more than 16 years.|Hepatitis A; Hepatitis B|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=208127/126|nan|[C0593953]|[Twinrix]
3298|GSK|A phase IV open study to assess the persistence of anti-HBs and anti-HAV antibodies in older adults approximately 2 years after a primary 3-dose vaccination course with GlaxoSmithKline Biologicals’ combined hepatitis A/hepatitis B vaccine Twinrix( (720/20).|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=208127/130|nan|[C0593953]|[Twinrix]
3339|GSK|A randomised, double-blind, placebo-controlled, dose ascending crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled GSK159797 delivered by dry powder inhaler in mild to moderate asthmatic subjects|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2E101312|http://clinicaltrials.gov/show/NCT00354666|[C2698231]|[Milveterol]
3340|GSK|A randomised, double blind, placebo controlled, parallel group study to examine the safety, tolerability, and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 and COA|Pulmonary Disease, Chronic Obstructive|Phase 1|nan|nan|[C2698231]|[Milveterol]
3341|GSK|A randomised, double blind, placebo controlled, parallel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=100527|nan|[C2698231]|[Milveterol]
3342|GSK|An open labeled, single sequence study to investigate the safety and pharmacokinetics of oral pimozide when co-administered with repeat dosing oral paroxetine 60 mg od in healthy volunteers.|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=29060/877|nan|[C0070122]|[paroxetine]
3343|GSK|A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder|Post-Traumatic Stress Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/650|nan|[C0070122]|[paroxetine]
3344|GSK|A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=29060/653|nan|[C0070122]|[paroxetine]
3353|GSK|A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases|Neoplasms, Colorectal|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113221|http://clinicaltrials.gov/show/NCT00920803|[C2002402]|[SRT 501]
3355|GSK|An open-label, randomised, two-period, crossover study to assess the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered two hours after a single IMITREX 100 mg tablet relative to two 6 mg STATdose injections administered one hour apart in healthy volunteers.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SUM20040|nan|[C0075632]|[sumatriptan]
3356|GSK|A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE)|Sleep Initiation and Maintenance Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NKG10006|nan|[C2607417]|[vestipitant]
3357|GSK|An Open Label, Single-Dose, Five-Way Crossover Study Examining Relative Oral Bioavailabilty of Zanamivir With Bioenhancing Excipients Following Direct Release Into Mid-Small Intestine Using Gamma Scintigraphy and the InteliSite Companion Capsule in Healthy Subjects.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107485|nan|[C0216660]|[zanamivir]
3384|GSK|U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects with Acne|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114551|http://clinicaltrials.gov/show/NCT01706263|[C0005088, C0036079]|[benzoyl peroxide, salicylic acid]
3385|GSK|Phase 1 study of skin irritation|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114731|nan|[C0065767]|[calcipotriene]
3386|GSK|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).|Hypertrophy, Left Ventricular|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=COR100216|http://clinicaltrials.gov/show/NCT00108082|[C0054836]|[carvedilol]
3387|GSK|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients|Hypertension|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=COR103561|http://clinicaltrials.gov/show/NCT00273052|[C0054836]|[carvedilol]
3388|GSK|A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria|Heart failure, Congestive and Microalbuminuria|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=COR103560|http://clinicaltrials.gov/show/NCT00123903|[C0054836]|[carvedilol]
3390|GSK|A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115677|http://clinicaltrials.gov/show/NCT01751074|[C2348075]|[darapladib]
3391|GSK|A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of the Lp-PLA2 inhibitor SB-480848 (40, 80mg od) on carotid plaque composition in patients with carotid artery disease and planned carotid endarterectomy, stratified for statin use and gender, after 14+/-4 days treatment|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=480848/010|http://clinicaltrials.gov/show/NCT01916720|[C2348075]|[darapladib]
3392|GSK|A Study to Evaluate the Effect of Steady-State New Chemical Entity (NCE) on the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Warfarin in Healthy Subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/013|nan|[C2348075]|[darapladib]
3393|GSK|A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2, eff|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=LPL104884|http://clinicaltrials.gov/show/NCT00269048|[C2348075]|[darapladib]
3394|GSK|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects with Moderate Hepatic Impairment|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/028|http://clinicaltrials.gov/show/NCT01154114|[C2348075]|[darapladib]
3395|GSK|A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement|Retinopathy, Diabetic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115403|http://clinicaltrials.gov/show/NCT01506895|[C2348075]|[darapladib]
3396|GSK|A Study to Evaluate the Effect of Repeat Oral Doses of SB-480848 on Platelet Function as Compared to Placebo|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101597|nan|[C2348075]|[darapladib]
3397|GSK|A Study to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of SB-480848|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105550|nan|[C2348075]|[darapladib]
3398|GSK|Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107038|nan|[C2348075]|[darapladib]
3399|GSK|A Dose Rising Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Doses of the Enteric-Coated Free Base Formulation of SB-480848 in Healthy Adult Subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107988|nan|[C2348075]|[darapladib]
3400|GSK|A Study to Assess the ADMEand Absolute Bioavailability of SB-480848 in healthy subjects (3C)|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/015|nan|[C2348075]|[darapladib]
3401|GSK|A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SB 480848/035|http://clinicaltrials.gov/show/NCT00411073|[C2348075]|[darapladib]
3402|GSK|A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LPL110077|http://clinicaltrials.gov/show/NCT00551317|[C2348075]|[darapladib]
3403|GSK|A randomised, double-blind, placebo-controlled, parallel group, repeat dose study to assess the effect of SB-480848 on overall asthma control in adult subjects with persistent asthma controlled on stable, low-dose, inhaled corticosteroids|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LPL107629|http://clinicaltrials.gov/show/NCT00368576|[C2348075]|[darapladib]
3404|GSK|A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and its Metabolites in Healthy Volunteers.|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LPL112498|http://clinicaltrials.gov/show/NCT00743860|[C2348075]|[darapladib]
3405|GSK|An international, multicenter, randomized, placebo controlled, parallel-group, 1 year treatment, integrated biomarkers and imaging study in subjects with angiographically documented coronary artery disease (CHD) to examine the effects of the novel lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor SB-480848 on intermediate cardiovascular endpoints, patient safety and tolerability|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SB-480848/026|http://clinicaltrials.gov/show/NCT00268996|[C2348075]|[darapladib]
3406|GSK|Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride|Hypogonadism, Male|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106218|nan|[C0754659]|[dutasteride]
3407|GSK|An open label, single dose, randomized, three period crossover study to investigate the relative bioavailability of 0.5 mg of dutasteride from soft gelatin capsules (reference) vs. soft gelatin capsules containing two investigational formulations in healthy male volunteers.|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103880|nan|[C0754659]|[dutasteride]
3408|GSK|An open label, single dose, randomised, three period crossover study to investigate the relative bioavailability of dutasteride softgel vs. dutasteride tablet and dutasteride softgel vs. dutasteride capsule in healthy male volunteers|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ARI19033|nan|[C0754659]|[dutasteride]
3409|GSK|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study Investigating the Effects of Either 4 or 6 Weeks Dutasteride 0.5mg Daily on Peri-Operative Bleeding Following Transurethral Resection of the Prostate (TURP) in Subjects with Benign Prostatic Hyperplasia (BPH).|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI40007|nan|[C0754659]|[dutasteride]
3410|GSK|A randomised, double-blind, placebo-controlled, 5-way cross incomplete block design study to investigate the relative potency of single inhaled doses of a NCE and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10007|nan|[C1948374]|[fluticasone furoate]
3411|GSK|A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115283|http://clinicaltrials.gov/show/NCT01436071|[C1948374]|[fluticasone furoate]
3412|GSK|A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115285|http://clinicaltrials.gov/show/NCT01436110|[C1948374]|[fluticasone furoate]
3413|GSK|A randomised, double-blind, placebo-controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability and PK of once daily inhaled GW685698 with the excipient COA administered via DISKUS in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10009|nan|[C1948374]|[fluticasone furoate]
3414|GSK|A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of a new chemical entity (NCE) and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103096|nan|[C1948374]|[fluticasone furoate]
3415|GSK|A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis|Rhinitis, Allergic, Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=FFU109045|http://clinicaltrials.gov/show/NCT00435461|[C1948374]|[fluticasone furoate]
3416|GSK|A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10003|nan|[C1948374]|[fluticasone furoate]
3417|GSK|A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10026|nan|[C1948374]|[fluticasone furoate]
3418|GSK|A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=FFA20001|http://clinicaltrials.gov/show/NCT01499446|[C1948374]|[fluticasone furoate]
3419|GSK|An open label, part-randomised, four-way crossover, single and repeat dose study to determine the dose proportionality and absolute bioavailability of fluticasone furoate (FF) when administered as FF inhalation powder from the novel dry powder inhaler in healthy subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115441|http://clinicaltrials.gov/show/NCT01669070|[C1948374]|[fluticasone furoate]
3420|GSK|A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10001|nan|[C1948374]|[fluticasone furoate]
3421|GSK|A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability and systemic pharmacokinetics and pharmacodynamics of repeat doses (500, 1000 and 2000mg) of GW685698X administered once daily for fourteen da|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10002|nan|[C1948374]|[fluticasone furoate]
3422|GSK|A randomised, single dose, open label, 3-way cross-over study to assess the systemic pharmacokinetics of GW685698X (1000mg) administered via Diskhaler with or without charcoal and an intravenous dose (250mg) in healthy male subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=FFA10008|nan|[C1948374]|[fluticasone furoate]
3423|GSK|Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and FluticasonePropionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=FFU108556|http://clinicaltrials.gov/show/NCT00398476|[C1948374]|[fluticasone furoate]
3424|GSK|A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared to fluticasone propionate delivered twice daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113714|http://clinicaltrials.gov/show/NCT01498653|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3425|GSK|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112352|http://clinicaltrials.gov/show/NCT01323621|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3426|GSK|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113109|http://clinicaltrials.gov/show/NCT01323634|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3427|GSK|A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily via a Dry Powder Inhaler Compared with Placebo in Subjects of Asian Ancestry with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113684|http://clinicaltrials.gov/show/NCT01376245|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3428|GSK|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116974|http://clinicaltrials.gov/show/NCT01706328|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3429|GSK|An open-label, randomised, replicate, six-way crossover, single dose study to determine the bioequivalence of fluticasone furoate (FF) inhalation powder (single strip configuration) compared with FF inhalation powder (two strip configuration) and compared with FF / vilanterol (VI) inhalation powder administered via the novel dry powder inhaler.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115440|http://clinicaltrials.gov/show/NCT01485445|[C1948374, C3700389]|[fluticasone furoate, vilanterol and fluticasone furoate]
3430|GSK|A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS)|Secondary prevention of Thromboembolic events; Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=EFC3557|nan|[C1099664]|[fondaparinux sodium]
3431|GSK|A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS)|Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=EFC4582|nan|[C1099664]|[fondaparinux sodium]
3432|GSK|A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer|Neoplasms, Gastrointestinal Tract|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MET111643|http://clinicaltrials.gov/show/NCT00725712|[C2973987]|[Foretinib]
3433|GSK|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors|Solid Tumours|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MET111647|http://clinicaltrials.gov/show/NCT00742131|[C2973987]|[Foretinib]
3434|GSK|A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck|Neoplasms, Head and Neck|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MET111646|http://clinicaltrials.gov/show/NCT00725764|[C2973987]|[Foretinib]
3437|GSK|A randomized, double-blind, placebo-controlled, parallel group study to compare GW766944 (an oral CCR3 receptor antagonist) versus placebo in patients with asthma and sputum eosinophilia.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114312|http://clinicaltrials.gov/show/NCT01160224|[C3886130]|[GW766994]
3439|GSK|A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis|Dermatitis, Atopic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113434|http://clinicaltrials.gov/show/NCT01299610|[C3659427]|[GW870086X]
3440|GSK|A randomised, double-blind (for GW870086X), placebo-controlled study of topical GW870086X formulation to explore the potential for skin thinning in healthy adult volunteers|Dermatitis, Atopic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113435|http://clinicaltrials.gov/show/NCT01381445|[C3659427]|[GW870086X]
3441|GSK|A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis|Osteoporosis|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=BON103593|http://clinicaltrials.gov/show/NCT02948881|[C0379200]|[ibandronic acid]
3442|GSK|A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS|Dermatitis, Seborrheic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114568|http://clinicaltrials.gov/show/NCT00703846|[C0022625]|[ketoconazole]
3443|GSK|A Multicenter, Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40117|nan|[C0064636]|[lamotrigine]
3444|GSK|An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=LAM40124|nan|[C0064636]|[lamotrigine]
3445|GSK|Protocol SB-275833/030 – Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500mg in Adults, or 12.5mg/kg (250mg/5ml) in Children, Twice Daily…|Skin Infections, Bacterial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=275833/030|nan|[C1703334]|[retapamulin]
3446|GSK|A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily|Skin Infections, Bacterial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=275833/032|nan|[C1703334]|[retapamulin]
3447|GSK|A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment versus Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adults and Paediatric Subjects with Impetigo.|Impetigo|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TOC103469|http://clinicaltrials.gov/show/NCT00133848|[C1703334]|[retapamulin]
3448|GSK|See Detailed Description|Skin Infections, Bacterial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TOC100224|http://clinicaltrials.gov/show/NCT00133874|[C1703334]|[retapamulin]
3450|GSK|A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS)|Restless Legs Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ROX104805|http://clinicaltrials.gov/show/NCT00256854|[C0244821]|[ropinirole]
3451|GSK|An Open-Label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101468/248|http://clinicaltrials.gov/show/NCT00632736|[C0244821]|[ropinirole]
3452|GSK|A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Sulphonylurea therapy, When Administered to Patients with Type 2 Diabetes Mellitus.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/015|nan|[C0289313]|[rosiglitazone]
3453|GSK|A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/020|nan|[C0289313]|[rosiglitazone]
3454|GSK|A 26-week Randomized, Double-Blind, Double-Dummy, Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maximal Dose (20 mg/day) of Glyburide.|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/079|nan|[C0289313]|[rosiglitazone]
3455|GSK|A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on…|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/096|nan|[C0289313]|[rosiglitazone]
3456|GSK|A 26-Week Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of BRL 49653C when Administered Twice Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on Insulin Monotherapy|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/082|nan|[C0289313]|[rosiglitazone]
3457|GSK|A 26-week Randomised, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Type 2 Diabetes who are Inadequately Controlled on Insulin Monotherapy|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=49653/095|nan|[C0289313]|[rosiglitazone]
3458|GSK|A study to assess the effect of food and time of dosing on the pharmacokinetics of Avandamet™ (rosiglitazone maleate 8 mg/metformin HCl 1000 mg administered as 2 ' 4/500) Glucophage XR 1000 mg (given as metformin HCl 2 ' 500 mg) and Avandia™ (rosiglitazone maleate 8 mg) in healthy adult subjects.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=712753/011|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
3459|GSK|A 28-Week, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Formulation X in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100344|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
3460|GSK|A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment.|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AVT105913|http://clinicaltrials.gov/show/NCT00386100|[C0289313, C0025598]|[rosiglitazone, metformin]
3461|GSK|An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=712753/004|http://clinicaltrials.gov/show/NCT00067951|[C0289313, C0025598]|[rosiglitazone, metformin]
3462|GSK|A study to assess the steady state pharmacokinetics of repeat oral doses of AVANDAMET XR (combination formulation of rosiglitazone 8mg/metformin 1000mg) and AVANDAMET IR (rosiglitazone 4mg/metformin 500mg) in healthy subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=712753/014|nan|[C0289313, C0025598]|[rosiglitazone, metformin]
3463|GSK|A single centre, randomised, double-blind, placebo-controlled, crossover, pilot study to determine the efficacy and safety of 400 µg and 200 µg doses of Ventolin ™ salbutamol inhaler versus placebo for the treatment of smoking related cough.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SBM20002|nan|[C0001927]|[albuterol]
3464|GSK|A single centre, randomised, double blind, double dummy, cross-over study to measure the topical and systemic effects of Salbutamol delivered by the Turbuhaler inhaler compared with the Diskus dry powder inhaler at high and low flow rates in adult patients with reversible obstructive airways disease.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SBM40003|nan|[C0001927]|[albuterol]
3465|GSK|A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114956|http://clinicaltrials.gov/show/NCT01691482|[C0001927]|[albuterol]
3466|GSK|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40314|nan|[C0073992]|[salmeterol]
3467|GSK|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40315|nan|[C0073992]|[salmeterol]
3468|GSK|A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol in Subjects With Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40321|nan|[C0073992]|[salmeterol]
3469|GSK|A randomized, double-blind, placebo-controlled study in healthy volunteers to examine the safety, tolerability and pharmacokinetics of a) single, ascending and b) twice-daily repeat doses of intranasal SB-705498|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111610|http://clinicaltrials.gov/show/NCT00907933|[C1744311]|[SB 705498]
3470|GSK|A randomised, double-blind, placebo-controlled study to assess the effect of oral, single dose SB-705498 in a validated intranasal capsaicin challenge model in healthy volunteers|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111611|http://clinicaltrials.gov/show/NCT00731250|[C1744311]|[SB 705498]
3471|GSK|A randomized, double blind, placebo controlled study to assessthe effect of intranasal single dose SB-705498 on the response tointranasal capsaicin challenge in non-allergic rhinitis patients|Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111925|http://clinicaltrials.gov/show/NCT01439308|[C1744311]|[SB 705498]
3472|GSK|An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatripta ...|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102146|nan|[C0075632]|[sumatriptan]
3473|GSK|An open label, single dose, randomised, parallel group pharmacokinetic study to evaluate a combination product containing naproxen sodium and sumatriptan in adolescent subjects with migraine and healthy adult subjects administered at three doses.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=108504|http://clinicaltrials.gov/show/NCT00989625|[C0075632]|[sumatriptan]
3474|GSK|A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET)|Migraine, Without Aura|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TXA107563|http://clinicaltrials.gov/show/NCT00387881|[C0075632, C0027396]|[sumatriptan, naproxen]
3475|GSK|Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of MT 400 Tablets or Naproxen Sodium Tablets on Chromosomal Aberrations (CA) in Peripheral Blood Lymphocytes|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-108|http://clinicaltrials.gov/show/NCT00596245|[C0075632, C0027396]|[sumatriptan, naproxen]
3476|GSK|A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-101 (112490)|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3477|GSK|A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-102 (112491)|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3478|GSK|A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-103 (112492)|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3479|GSK|An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-104 (112493)|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3480|GSK|A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers.|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MT400-105 (112494)|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3481|GSK|TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=107979|http://clinicaltrials.gov/show/NCT00843024|[C0075632, C0027396]|[sumatriptan, naproxen]
3482|GSK|Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TXA107977|http://clinicaltrials.gov/show/NCT00488514|[C0075632, C0027396]|[sumatriptan, naproxen]
3483|GSK|An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System® and a TREXIMA tablet followed by IMI|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=103629|http://clinicaltrials.gov/show/NCT00875784|[C0075632, C0027396]|[sumatriptan, naproxen]
3484|GSK|A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX106571|http://clinicaltrials.gov/show/NCT00383162|[C0075632, C0027396]|[sumatriptan, naproxen]
3485|GSK|A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX106573|http://clinicaltrials.gov/show/NCT00382993|[C0075632, C0027396]|[sumatriptan, naproxen]
3486|GSK|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)*, Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX103632|http://clinicaltrials.gov/show/NCT00240630|[C0075632, C0027396]|[sumatriptan, naproxen]
3487|GSK|A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet)|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX103635|http://clinicaltrials.gov/show/NCT00240617|[C0075632, C0027396]|[sumatriptan, naproxen]
3488|GSK|An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX105848|http://clinicaltrials.gov/show/NCT00385008|[C0075632, C0027396]|[sumatriptan, naproxen]
3489|GSK|A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX105850|http://clinicaltrials.gov/show/NCT00329459|[C0075632, C0027396]|[sumatriptan, naproxen]
3490|GSK|See Detailed Description|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=TRX105852|http://clinicaltrials.gov/show/NCT00329355|[C0075632, C0027396]|[sumatriptan, naproxen]
3491|GSK|A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101998|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3492|GSK|A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=101999|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3493|GSK|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™* in the Acute Treatment of Migraine Headaches|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112495|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3494|GSK|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™*in the Acute Treatment of Migraine Headaches|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112496|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3495|GSK|An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months.|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112497|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3496|GSK|An open-label, randomized, single-dose, 2-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA™(sumatriptan 85mg and naproxen sodium 500mg)*, Tablet compared with an IMITREX® (sumatriptan) 100mg Tablet|Migraine Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106396|nan|[C0075632, C0027396]|[sumatriptan, naproxen]
3497|GSK|Phase II Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for subjects with Untreated Low-Grade Non Hodgkin's Lymphoma.|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104514|http://clinicaltrials.gov/show/NCT01663714|[C0879399]|[tositumomab]
3498|GSK|A phase I, dose-escalation, open label, multicenter study of Iodine-131 anti-B1 antibody for intermediate- and high-risk B-cell chronic lymphocytic leukemiaNote: Extensive searching has revealed that no clinical study report is available for this study.|Leukaemia, Lymphocytic, Chronic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CP-98-018|nan|[C0879399]|[tositumomab]
3499|GSK|Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients with Previously Treated Non Hodgkin’s Lymphoma With More Than 25% Bone Marrow Involvement|Lymphoma, Non-Hodgkin|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104512|http://clinicaltrials.gov/show/NCT00992758|[C0879399]|[tositumomab]
3500|GSK|Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104731|http://clinicaltrials.gov/show/NCT01224821|[C0879399]|[tositumomab]
3501|GSK|Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=393229/023|http://clinicaltrials.gov/show/NCT00933335|[C0879399]|[tositumomab]
3502|GSK|Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=393229/010|http://clinicaltrials.gov/show/NCT00938041|[C0879399]|[tositumomab]
3503|GSK|A single-blind, non-randomized pharmacokinetic and safety study of single dose of GSK573719 and GSK573719 + GW642444 combination in healthy subjects and in subjects with severe renal impairment|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114636|http://clinicaltrials.gov/show/NCT01571999|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3510|Astellas|A Randomized, Double-blind, Parallel, Placebo-controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy|Urinary Incontinence|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=905-UC-050|https://clinicaltrials.gov/ct2/show/NCT01371994|[C1509436]|[solifenacin succinate]
3516|GSK|An open-label, randomized, single dose, three-way crossover study to determine the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine (5mg) and losartan (100mg) in healthy adult male and female Subjects under fasting conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116797|http://clinicaltrials.gov/show/NCT01648231|[C0051696, C0126174]|[amlodipine, losartan]
3517|GSK|An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115576|http://clinicaltrials.gov/show/NCT01446237|[C0005088, C0036079]|[benzoyl peroxide, salicylic acid]
3518|GSK|A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114739|nan|[C0065767]|[calcipotriene]
3519|GSK|A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Phototoxic Potential of Topically Applied EF Calcipotriene Foam, 0.005% in Healthy Volunteers|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114740|nan|[C0065767]|[calcipotriene]
3520|GSK|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , versus Vehicle Foam in Subjects with Plaque-type Psoriasis|Psoriasis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114742|http://clinicaltrials.gov/show/NCT00689481|[C0065767]|[calcipotriene]
3521|GSK|A study to determine the bioequivalence of reformulated 125mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 125mg/5mL suspension at a dose of 250mg.|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CAE10004|nan|[C0055015]|[cefuroxime axetil]
3522|GSK|A study to determine the bioequivalence of reformulated 250mg/5mL cefuroxime axetil oral suspension (CAOS) to standard marketed 250mg/5mL suspension.|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CAE10005|nan|[C0055015]|[cefuroxime axetil]
3523|GSK|A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety -|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=LPL110118|http://clinicaltrials.gov/show/NCT00734032|[C2348075]|[darapladib]
3524|GSK|A 28 day, double blind, placebo-controlled, parallel-group dose-ranging phase IIA to examine the safety, tolerability and effects of SB-480848 on LP-PLA2 activity in dyslipidemic patients|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=480848/005|nan|[C2348075]|[darapladib]
3525|GSK|The Effect of SB-480848 on the Pharmacokinietics of Digoxin in healthy subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/014|nan|[C2348075]|[darapladib]
3526|GSK|A Dose Ranging Study to Evaluate the Pharmacokinetics of an SB480848 Freebase Enteric Coated Formulation|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101582|nan|[C2348075]|[darapladib]
3527|GSK|A Study to Assess the Effects of Food and Repeat Dosing of Esomeprazole on the Pharmacokinetics of a Single Dose of Freebase Enteric Coated SB480848|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101560|nan|[C2348075]|[darapladib]
3528|GSK|A Study to Assess the Effect of Steady-state Omeprazole on the Pharmacokinetics of single dose SB480848 in Healthy Adult Subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/019|nan|[C2348075]|[darapladib]
3529|GSK|A Study to Evaluate the Single Dose Pharmacokinetics of Enteric Coated Freebase Formulations of SB480848 in Healthy Adults|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/904|nan|[C2348075]|[darapladib]
3530|GSK|A Repeat Dose, Dose Ranging Study to Evaluate the Safety and Pharmacokinetics of a Freebase Enteric Coated Formulation of SB480848|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/903|nan|[C2348075]|[darapladib]
3531|GSK|A randomized, repeat-dose, dose ranging study to evaluate the safety and pharmacokinetics of the SB480848 Enteric Coated Formulation|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=480848/012|nan|[C2348075]|[darapladib]
3532|GSK|An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LPL111814|http://clinicaltrials.gov/show/NCT00704431|[C2348075]|[darapladib]
3533|GSK|Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects-|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=LPL110736|http://clinicaltrials.gov/show/NCT00622830|[C2348075]|[darapladib]
3534|GSK|Assessment of the Anti-Inflammatory activity, efficacy and safety of Intravenous SB-681323 in subjects at risk for development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).|Lung Injury, Acute|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111592|http://clinicaltrials.gov/show/NCT00996840|[C3272846]|[dilmapimod]
3535|GSK|See Detailed Description|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO40036|http://clinicaltrials.gov/show/NCT00361959|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3536|GSK|A single dose bioequivalence study comparing a new formulation of fondaparinux sodium at 12.5 mg/mL and the reference formulation at 10 mg/mL, in healthy male subjects. Open, randomized, crossover and single center study|Healthy Subjects|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=BDR4979|nan|[C1099664]|[fondaparinux sodium]
3537|GSK|An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116806|http://clinicaltrials.gov/show/NCT01725672|[C0061323, C0025598]|[glimepiride, metformin]
3538|GSK|A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic rhinitis|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110159|http://clinicaltrials.gov/show/NCT00824356|[C3177195]|[GSK 1004723]
3539|GSK|See Detailed Description|Rhinitis, Allergic, Seasonal|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HHI110157|http://clinicaltrials.gov/show/NCT00694993|[C3177195]|[GSK 1004723]
3540|GSK|A randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112864|http://clinicaltrials.gov/show/NCT00972504|[C3177195, C3177194]|[GSK 1004723, GSK 835726]
3541|GSK|An adaptive PET study in healthy volunteers using [11C]GSK931145 to establish the relationship of Glycine Transporter 1 occupancy by GSK1018921 to plasma concentrations over time.|Schizophrenia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=109731|http://clinicaltrials.gov/show/NCT00945503|[C3253188, C3253619]|[GSK 1018921, 11C-GSK931145]
3542|GSK|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma|Solid Tumours|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=PIK111051|http://clinicaltrials.gov/show/NCT00695448|[C2703119]|[GSK1059615]
3543|GSK|A single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1070806 in healthy and obese subjects.|Inflammatory Bowel Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110040|http://clinicaltrials.gov/show/NCT01035645|[C4278474]|[GSK1070806]
3544|GSK|A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin|Dyslipidaemias|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111596|http://clinicaltrials.gov/show/NCT00783549|[C3852542]|[GSK1292263]
3545|GSK|A study in type 2 diabetic subjects of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111598|http://clinicaltrials.gov/show/NCT01119846|[C3852542]|[GSK1292263]
3546|GSK|A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113132|http://clinicaltrials.gov/show/NCT01128621|[C3852542]|[GSK1292263]
3547|GSK|A study to investigate the interaction of GSK1292263 with rosuvastatin and simvastatin in healthy subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113506|http://clinicaltrials.gov/show/NCT01101568|[C3852542]|[GSK1292263]
3548|GSK|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111341|http://clinicaltrials.gov/show/NCT00828867|[C3711860]|[GSK1322322]
3549|GSK|A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112034|http://clinicaltrials.gov/show/NCT00924911|[C3711860]|[GSK1322322]
3550|GSK|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112668|http://clinicaltrials.gov/show/NCT00896558|[C3711860]|[GSK1322322]
3551|GSK|A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113376|http://clinicaltrials.gov/show/NCT01610388|[C3711860]|[GSK1322322]
3552|GSK|An Open Label, Non-Randomized, Single dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112167|http://clinicaltrials.gov/show/NCT01663389|[C3711860]|[GSK1322322]
3553|GSK|A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection|Skin Infections, Bacterial|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113414|http://clinicaltrials.gov/show/NCT01209078|[C3711860]|[GSK1322322]
3554|GSK|A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116595|http://clinicaltrials.gov/show/NCT01648179|[C3711860]|[GSK1322322]
3556|GSK|An open label positron emission tomography study in healthy male subjects to investigate brain DAT and SERT occupancy, pharmacokinetics and safety of single oral doses ofGSK1360707, using 11C- PE2I and 11C-DASB as PET ligands|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112773|http://clinicaltrials.gov/show/NCT01153802|[C3713902]|[GSK1360707]
3557|GSK|A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to make a preliminary assessment of the effect of food.|Pain, Inflammatory|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111383|http://clinicaltrials.gov/show/NCT00849134|[C4079824]|[GSK1482160]
3558|GSK|A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects|Obesity|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111314|http://clinicaltrials.gov/show/NCT00857883|[C3253174]|[GSK-1521498]
3559|GSK|An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone.|Obesity|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111848|http://clinicaltrials.gov/show/NCT00976066|[C3253174]|[GSK-1521498]
3560|GSK|A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects.|Obesity|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111849|http://clinicaltrials.gov/show/NCT00976105|[C3253174]|[GSK-1521498]
3561|GSK|A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects with Over-Eating Behaviours.|Obesity|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111850|http://clinicaltrials.gov/show/NCT01195792|[C3253174]|[GSK-1521498]
3562|GSK|A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects|Alcoholism|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115256|http://clinicaltrials.gov/show/NCT01366573|[C3253174]|[GSK-1521498]
3563|GSK|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=109035|http://clinicaltrials.gov/show/NCT00896363|[C3852548]|[GSK163090]
3570|GSK|A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114403|http://clinicaltrials.gov/show/NCT01545570|[C4045451]|[GSK2374697]
3571|GSK|A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease.|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110651|http://clinicaltrials.gov/show/NCT01009255|[C3712181]|[GSK239512]
3572|GSK|A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist|Alzheimer's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=H3B109689|http://clinicaltrials.gov/show/NCT00675090|[C3712181]|[GSK239512]
3573|GSK|A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia|Schizophrenia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113147|http://clinicaltrials.gov/show/NCT01009060|[C3712181]|[GSK239512]
3575|GSK|A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects|Hepatitis C|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115040|http://clinicaltrials.gov/show/NCT01332552|[C3849072]|[GSK2485852]
3576|GSK|A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke|Ischaemic Attack, Transient|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111539|http://clinicaltrials.gov/show/NCT00833989|[C4726669]|[refanezumab]
3577|GSK|A single-blind, single dose, placebo controlled, parallel group, first time in human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of ascending IV doses of GSK249320 in healthy volunteers|Cerebrovascular Accident|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MAG103114|http://clinicaltrials.gov/show/NCT00622609|[C4726669]|[refanezumab]
3578|GSK|A randomized, single blind, placebo-controlled, three period crossover, dose selection study to evaluate the effect of GSK256073, an HM74A receptor agonist, on glucose and NEFA 24 hour profile in type 2 diabetic patients.|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114187|http://clinicaltrials.gov/show/NCT01147861|[C4079835]|[GSK256073]
3580|GSK|A randomized, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous infusions GSK315234A in patients with active rheumatoid arthritis (RA)|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104972|http://clinicaltrials.gov/show/NCT00674635|[C3851694]|[GSK315234]
3581|GSK|A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects with Advanced Solid Tumor or Non-Hodgkins Lymphoma|Lymphoma, Non-Hodgkin|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=PLK107427|http://clinicaltrials.gov/show/NCT00536835|[C2347618]|[GSK 461364]
3582|GSK|A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects.|Substance Dependence|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=109710|http://clinicaltrials.gov/show/NCT01039454|[C3886165]|[GSK598809]
3583|GSK|A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward|Substance Dependence|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=DAN106593|http://clinicaltrials.gov/show/NCT00605241|[C3886165]|[GSK598809]
3586|GSK|A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=106870|http://clinicaltrials.gov/show/NCT00843193|[C3658590]|[GSK679586]
3588|GSK|A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110163|http://clinicaltrials.gov/show/NCT00851344|[C3177194]|[GSK 835726]
3589|GSK|See Detailed Description|Rhinitis, Allergic, Seasonal|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=HH3110161|http://clinicaltrials.gov/show/NCT00605852|[C3177194]|[GSK 835726]
3591|GSK|A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects|Bipolar Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107434|nan|[C0064636]|[lamotrigine]
3592|GSK|A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects.|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=RA4104917|http://clinicaltrials.gov/show/NCT00379990|[C0914699]|[GW 274150]
3593|GSK|A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge.|Rhinitis, Allergic, Perennial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AA210012|nan|[C2742038]|[GW 328267]
3594|GSK|A single-centre, escalating dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a slow intravenous infusion of GW328267X in healthy volunteers|Lung Injury, Acute|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115387|http://clinicaltrials.gov/show/NCT01640990|[C2742038]|[GW 328267]
3595|GSK|A randomised, double-blind, placebo-controlled, cross-over study to investigate the effects of pre-treatment with repeat inhaled doses of a new chemical entity on the allergen-induced late phase asthmatic response in mild asthmatic subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AA210005|nan|[C2742038]|[GW 328267]
3596|GSK|A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AA210013|nan|[C2742038]|[GW 328267]
3597|GSK|A randomised, double-blind, placebo-controlled, 3-way cross-over study to investigate the effects of pre-treatment with single inhaled doses of an NCE and fluticasone propionate on the allergen induced late phase asthmatic response in mild asthmatic subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=A4A10003|nan|[C4079641]|[GW559090]
3598|GSK|An 8-day, randomised, placebo-controlled, three-way crossover trial of repeat doses of a new chemical entity (NCE), fluticasone propionate and placebo administered intranasally, blinded for fluticasone propionate versus placebo, in an environmental exposition unit, the Vienna Challenge Chamber (VCC) in subjects with seasonal allergic rhinitis (SAR)|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=A4A10008|nan|[C4079641]|[GW559090]
3603|GSK|A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112851|http://clinicaltrials.gov/show/NCT00945932|[C3659427]|[GW870086X]
3604|GSK|A randomised, double-blind, placebo-controlled, dose ascending,3-way crossover study to assess the pharmacokinetics, safety andtolerability of repeat inhaled doses of nebulised GW870086X inhealthy adult male volunteers.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113209|http://clinicaltrials.gov/show/NCT01160003|[C3659427]|[GW870086X]
3605|GSK|A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persistent Asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114749|http://clinicaltrials.gov/show/NCT01245426|[C3659427]|[GW870086X]
3606|GSK|An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate|Osteoporosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=743830/002|nan|[C0379200]|[ibandronic acid]
3607|GSK|An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate|Osteoporosis, Postmenopausal|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=743830/003|nan|[C0379200]|[ibandronic acid]
3608|GSK|A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy (currently untreated)|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115376|http://clinicaltrials.gov/show/NCT01431963|[C0064636]|[lamotrigine]
3609|GSK|A randomised, double-blind, placebo-controlled parallel group study to examine the safety, tolerability, and pharmacokinetics of repeat inhaled doses of GSK159797 in healthy subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=101682|nan|[C2698231]|[Milveterol]
3610|GSK|A Single Dose Study to Evaluate the Dose Proportionality of the Tablet Formulation of Nabumetone Q and the Relative Bioavailability of Nabumetone Q Compared to RELAFEN in Healthy Subjects|Osteoarthritis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=14777/268|nan|[C0068334]|[nabumetone]
3611|GSK|An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=S2W40027|nan|[C0540623]|[naratriptan]
3612|GSK|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine.|Migraine Disorders|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=S2W40024|nan|[C0540623]|[naratriptan]
3613|GSK|An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects|Hypertriglyceridemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111818|http://clinicaltrials.gov/show/NCT00903409|[C1532673]|['omega-3 acid ethyl esters (USP)']
3614|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation|Fibrillation, Atrial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=OM8 Afib|http://clinicaltrials.gov/show/NCT00402363|[C1532673]|['omega-3 acid ethyl esters (USP)']
3615|GSK|An open-label single dose randomized, parallel group study followed by single-blind repeat dosing, to compare the relative bioavailability of GSK2212836|Cardiovascular Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113412|http://clinicaltrials.gov/show/NCT00996268|[C1532673]|['omega-3 acid ethyl esters (USP)']
3616|GSK|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects|Hypertriglyceridemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=OM6%20program%20(Reliant)|http://clinicaltrials.gov/show/NCT00246701|[C1532673]|['omega-3 acid ethyl esters (USP)']
3617|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Assess the Efficacy and Safety of Adjunctive Lovaza® Therapy in Hypertriglyceridemic Subjects Treated with Antara®|Hypertriglyceridemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=OM5%20program%20(Reliant)|http://clinicaltrials.gov/show/NCT00246636|[C1532673]|['omega-3 acid ethyl esters (USP)']
3618|GSK|A Pharmacokinetic Interaction Study Evaluating the Effect of Lovaza® on Plasma Pharmacokinetics of Zocor® in Healthy Adult Volunteers Under Fasting Conditions|Dyslipidaemias|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111862|nan|[C1532673]|['omega-3 acid ethyl esters (USP)']
3619|GSK|A Pharmacokinetic Interaction Study Evaluating the Effect of Reliant Pharmaceuticals Inc. (Lovaza®) Omega-3-Acid Ethyl Esters Capsules on the Plasma Pharmacokinetics of Parke Davis (Lipitor®) Atorvastatin Tablets in Healthy Adult Volunteers Under Fasting Conditions|Dyslipidaemias|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111863|nan|[C1532673]|['omega-3 acid ethyl esters (USP)']
3620|GSK|A Pharmacokinetic Interaction Study Evaluating the Effect of Omega-3-Acid Ethyl Esters Capsules (Omacor®; Reliant Pharmaceuticals Inc.) on the Plasma Pharmacokinetics of Rosuvastatin Tablets (Crestor®; AstraZeneca) in Healthy Adult Volunteers under Fasting Conditions.|Dyslipidaemias|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111864|nan|[C1532673]|['omega-3 acid ethyl esters (USP)']
3621|GSK|A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (propafenone hydrochloride) Manufactured at Two Different Sites|Arrhythmia, Cardiac|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116371|http://clinicaltrials.gov/show/NCT01956487|[C0033429]|[propafenone]
3622|GSK|An open-label, five-way, partially randomized crossover study to evaluate the regional gastrointestinal absorption of retigabine in healthy volunteers|Seizures|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113214|nan|[C0530684]|[ezogabine]
3623|GSK|A single-centre open label study to investigate the effect of repeat doses of SB-649868 on the pharmacokinetics of Simvastatin and Atorvastatin in healthy male volunteers.|Sleep Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=109652|http://clinicaltrials.gov/show/NCT01299597|[C3180886]|[SB-649868]
3626|GSK|RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II study to determine the safety and efficacy of Coulter Clone® 131Iodine-B1 radioimmunotherapy of advanced non-Hodgkin’s Lymphoma|Lymphoma, Non-Hodgkin|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104728|http://clinicaltrials.gov/show/NCT01536561|[C0879399]|[tositumomab]
3627|GSK|Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104505|http://clinicaltrials.gov/show/NCT00950755|[C0879399]|[tositumomab]
3628|GSK|Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104504|http://clinicaltrials.gov/show/NCT00989664|[C0879399]|[tositumomab]
3629|GSK|Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104507|http://clinicaltrials.gov/show/NCT00996593|[C0879399]|[tositumomab]
3630|GSK|Phase II a randomized study of iodine-131 Anti-b1 Antibody versus anti-b1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL)|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104515|http://clinicaltrials.gov/show/NCT01573000|[C0879399]|[tositumomab]
3631|GSK|Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=BEX104545|http://clinicaltrials.gov/show/NCT00268203|[C0879399]|[tositumomab]
3634|Eisai|Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology|Thyroid Cancer|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT00784303|[C2986924]|[lenvatinib]
3635|Eisai|A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer|Thyroid Cancer|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT01728623|[C2986924]|[lenvatinib]
3636|Eisai|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer|Thyroid Cancer|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01321554|[C2986924]|[lenvatinib]
3637|GSK|An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116799|http://clinicaltrials.gov/show/NCT01797926|[C0051696, C0126174]|[amlodipine, losartan]
3638|GSK|U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects with Acne|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114553|http://clinicaltrials.gov/show/NCT02524665|[C0005088, C0036079]|[benzoyl peroxide, salicylic acid]
3649|GSK|LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)|Atherosclerosis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100601|http://clinicaltrials.gov/show/NCT00799903|[C2348075]|[darapladib]
3650|GSK|A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).|acute coronary syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=480848/033|http://clinicaltrials.gov/show/NCT01000727|[C2348075]|[darapladib]
3651|GSK|An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115678|http://clinicaltrials.gov/show/NCT01873339|[C2348075]|[darapladib]
3652|GSK|A Study to Evaluate the Effect of a High Fiber and a High Fat Meal on the Pharmacokinetics of LANOXIN† (digoxin) Elixir Pediatric in Healthy Adults|Heart failure, Congestive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=120008/901|nan|[C0012265]|[digoxin]
3653|GSK|An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512|Multiple Sclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117016|http://clinicaltrials.gov/show/NCT01802931|[C3712181]|[GSK239512]
3655|GSK|An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100565|nan|[C0593953]|[Twinrix]
3663|GSK|An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure|Hepatitis B|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=NUC10901|nan|[C0209738]|[lamivudine]
3664|GSK|A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus|Hepatitis B|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NUC20905|nan|[C0209738]|[lamivudine]
3665|GSK|A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV.|Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUC30914|nan|[C0209738]|[lamivudine]
3666|GSK|A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment|Hepatitis B, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3026|nan|[C0209738]|[lamivudine]
3667|GSK|A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up)|Hepatitis B, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3018|nan|[C0209738]|[lamivudine]
3668|GSK|An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies|Hepatitis B, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUC30926|nan|[C0209738]|[lamivudine]
3671|GSK|A multicenter, trial comparing the efficacy and safety of Umeclidinium/Vilanterol 62.5/25 mcg once daily with Tiotropium 18 mcg once daily over 24 weeks in subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117115|http://clinicaltrials.gov/show/NCT01777334|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3672|GSK|A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115380|http://clinicaltrials.gov/show/NCT01899638|[C3709474, C2935023, C3700388]|[umeclidinium bromide, vilanterol, vilanterol and umeclidinium bromide]
3675|GSK|Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects|Crohn's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116416|http://clinicaltrials.gov/show/NCT01827631|[C3713948]|[Vercirnon]
3690|Eisai|An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors|Solid Tumors|Phase 1|nan|https://clinicaltrials.gov/ct2/show/NCT00280397|[C2986924]|[lenvatinib]
3691|Eisai|A Phase 1 Study of E7080 in Subjects With Solid Tumor|Cancer|Phase 1|nan|https://clinicaltrials.gov/ct2/show/NCT01268293|[C2986924]|[lenvatinib]
3701|GSK|Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus-A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=GLP107865|http://clinicaltrials.gov/show/NCT00530309|[C2607479]|[albiglutide]
3702|GSK|A Dose Finding Study of GSK716155 versus Placebo in the Treatment of Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110932|http://clinicaltrials.gov/show/NCT01098461|[C2607479]|[albiglutide]
3703|GSK|A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid after Topical Administration of GSK2585823 in Japanese Subjects with Acne Vulgaris|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115959|http://clinicaltrials.gov/show/NCT01527123|[C0005088, C0008947]|[benzoyl peroxide, clindamycin]
3704|GSK|Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl peroxide 3% gel) with Healthy Japanese Male and Female Subjects|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114849|http://clinicaltrials.gov/show/NCT01428466|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
3705|GSK|Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113351|http://clinicaltrials.gov/show/NCT01138007|[C0085208]|[bupropion]
3706|GSK|A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure  - An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study)|Heart failure, Congestive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=CRV110734|http://clinicaltrials.gov/show/NCT00742508|[C0054836]|[carvedilol]
3711|GSK|Study FFR116364, a double-blind, placebo-controlled study of GW685698X in paediatric subjects with perennial allergic rhinitis|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116364|http://clinicaltrials.gov/show/NCT01630135|[C1948374]|[fluticasone furoate]
3712|GSK|Study FFR116365, an open-label study of GW685698X in paediatric subjects with perennial allergic rhinitis|Rhinitis, Allergic, Perennial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116365|http://clinicaltrials.gov/show/NCT01622231|[C1948374]|[fluticasone furoate]
3713|GSK|A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|nan|https://www.gsk-studyregister.com/en/trial-details/?id=114169|http://clinicaltrials.gov/show/NCT01254032|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3714|GSK|CAT LOC Meta-analysis Study|Pulmonary Disease, Chronic Obstructive|nan|https://www.gsk-studyregister.com/en/trial-details/?id=115264|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3715|GSK|A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics and drug interaction of GSK1034702 after repeat doses in healthy subjects|Cognitive Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110792|http://clinicaltrials.gov/show/NCT00950586|[C3253012]|[GSK 1034702]
3716|GSK|A double blind, randomized, placebo controlled, cross-over study to Examine the pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in nicotine abstained otherwise healthy smokers|Mental Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113746|http://clinicaltrials.gov/show/NCT01371799|[C3253012]|[GSK 1034702]
3717|GSK|An open label positron emission tomography (PET) study to investigate brain penetration by [11C] GSK1034702 in healthy subjects|Cognitive Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110771|http://clinicaltrials.gov/show/NCT00937846|[C3253012]|[GSK 1034702]
3718|GSK|Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study|Depressive Disorder and Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105012|http://clinicaltrials.gov/show/NCT01424384|[C3714228]|[GSK424887]
3719|GSK|A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of NCE (25 μg and 50 μg) and escalating cumulative doses of salbutamol (up to 1200 μg) administered alone and in combination to healthy male smokers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AA210010|nan|[C2742038]|[GW 328267]
3721|GSK|A phase II, open, randomised, multicentric study to compare the immunogenicity, reactogenicity and safety of experimental vaccines to that of Twinrix (administered following a 3 dose schedule (0, 1, 6 months) in healthy adults aged 18-40 years.|Hepatitis A; Hepatitis B|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=208127/ 114|nan|[C0593953]|[Twinrix]
3722|GSK|A double-blind study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ high-dose combined hepatitis A/B vaccine containing 1440 EL.U of hepatitis A antigen/40 mcg of hepatitis B surface antigen to that of Twinrix™, both administered following a 0-6 month schedule in healthy adolescents|Hepatitis A; Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208127/100 and 208127/101 (Ext-HAB-075)|nan|[C0593953]|[Twinrix]
3730|GSK|A placebo-controlled pharmacokinetic and safety study of twice daily SRT501 in type 2 diabetic human male subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SRT-501-006|nan|[C0073096]|[resveratrol]
3731|GSK|A randomised, double-blind, triple-dummy, placebo-controlled, five-way crossover study to investigate the bronchoprotective effects against methacholine challenge and the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 µg) and salbutamol (200 µg) over a 24-hour period in at ...|Constriction, Bronchial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=RES11070|nan|[C0073992]|[salmeterol]
3732|GSK|A randomised, double-blind, triple-dummy, placebo-controlled, five-way cross-over study to investigate the bronchodilatory effects of single doses of salmeterol (25, 50 and 200 mg) and salbutamol (200 mg) over a 24-h period in healthy subjects.|Constriction, Bronchial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=RES10988|nan|[C0073992]|[salmeterol]
3733|GSK|A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents|Migraine Disorders|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111035|http://clinicaltrials.gov/show/NCT00963937|[C0075632]|[sumatriptan]
3734|GSK|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115362|http://clinicaltrials.gov/show/NCT01376388|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3735|GSK|A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell transplantation patients|Herpes Simplex|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116100|http://clinicaltrials.gov/show/NCT01602562|[C0249458]|[valacyclovir]
3767|Astellas|A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors|Non-small cell lung cancer|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=OSI-774-302|https://clinicaltrials.gov/ct2/show/NCT00373425|[C1135135]|[erlotinib]
3776|GSK|Study ATG115317, a comparison of atorvastatin and glimepiride fixed dose combination and atorvastatin and glimepiride loose combination in the treatment of patients with Type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115317|http://clinicaltrials.gov/show/NCT01495013|[C0286651, C0061323]|[atorvastatin, glimepiride]
3777|GSK|A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Potential of Topically Applied EF Calcipotriene Foam, 0.005% to Induce Contact Sensitization in Healthy Volunteers Upon Exposure to Repeated Skin Patch Applications|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114738|nan|[C0065767]|[calcipotriene]
3778|GSK|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115676|http://clinicaltrials.gov/show/NCT01711723|[C2348075]|[darapladib]
3779|GSK|A Study of the Efficacy and Safety of Multiple Doses of Dutasteride versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia|Alopecia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114263|http://clinicaltrials.gov/show/NCT01231607|[C0754659]|[dutasteride]
3780|GSK|A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116863|http://clinicaltrials.gov/show/NCT01686633|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3781|GSK|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115805|http://clinicaltrials.gov/show/NCT01627327|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3782|GSK|A randomized, double-blind, placebo-controlled, four-way crossover study to evaluate and compare the pharmacodynamics and pharmacokinetics of fluticasone furoate /vilanterol in different dose combination (50/25mcg, 100/25mcg and 200/25mcg) after single and repeat dose administration from a novel dry powder device in healthy Chinese subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115199|http://clinicaltrials.gov/show/NCT01711463|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3783|GSK|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114156|http://clinicaltrials.gov/show/NCT01192191|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
3784|GSK|A single centre, randomised, double-blind, double dummy, parallel group 3-week study to compare the effect of the salmeterol/fluticasone propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance ra ...|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SCO30008|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3785|GSK|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors|Solid Tumours|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MET111648|http://clinicaltrials.gov/show/NCT00743067|[C2973987]|[Foretinib]
3786|GSK|A Single-Blind, Randomised, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK1360707|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111914|nan|[C3713902]|[GSK1360707]
3789|GSK|A multicenter, two part, randomized, parallel group, placebo and sitagliptin controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114728|http://clinicaltrials.gov/show/NCT01376323|[C4079835]|[GSK256073]
3790|GSK|The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age|Bipolar Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCA102833|http://clinicaltrials.gov/show/NCT00723450|[C0064636]|[lamotrigine]
3791|GSK|A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115705|http://clinicaltrials.gov/show/NCT01471327|[C0969324]|[mepolizumab]
3792|GSK|A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112997|http://clinicaltrials.gov/show/NCT01000506|[C0969324]|[mepolizumab]
3793|GSK|MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115588|http://clinicaltrials.gov/show/NCT01691521|[C0969324]|[mepolizumab]
3794|GSK|MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115575|http://clinicaltrials.gov/show/NCT01691508|[C0969324]|[mepolizumab]
3795|GSK|A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevated blood eosinophil levels|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114092|http://clinicaltrials.gov/show/NCT01366521|[C0969324]|[mepolizumab]
3796|GSK|A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AVS101946|http://clinicaltrials.gov/show/NCT00256867|[C0289313, C0074554]|[rosiglitazone, simvastatin]
3797|GSK|An Open-Label, Randomized, Four-Period Crossover Study in Healthy Subjects to Demonstrate the Bioequivalence of a Fixed Dose Combination Tablet Formulation of Rosiglitazone and Simvastatin (8mg/80mg) to Concomitant Dosing of Rosiglitazone 8mg and Simvastatin 80mg Commercial Tablets and to Assess ...|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=102130|nan|[C0289313, C0074554]|[rosiglitazone, simvastatin]
3798|GSK|Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin’s Lymphoma|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104517|http://clinicaltrials.gov/show/NCT00996996|[C0879399]|[tositumomab]
3799|GSK|A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma|Lymphoma, Non-Hodgkin|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=393229/028|http://clinicaltrials.gov/show/NCT00268983|[C0879399]|[tositumomab]
3800|GSK|A 24-week randomised, double-blind and placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder compared with placebo Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114634|http://clinicaltrials.gov/show/NCT01636713|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3801|GSK|DB2114930: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114930|http://clinicaltrials.gov/show/NCT01817764|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3802|GSK|DB2114951: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114951|http://clinicaltrials.gov/show/NCT01879410|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
3884|GSK|"Cultural adaptation and validation of ""COPD Assessment Test"" (CAT) into Spanish"|Pulmonary Disease, Chronic Obstructive|nan|nan|nan|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
3885|GSK|A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection|Hepatitis C, Chronic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115879|http://clinicaltrials.gov/show/NCT01648140|[C4045304]|[GSK2336805]
3886|GSK|An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma|Cancer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=AKT106757|http://clinicaltrials.gov/show/NCT00493818|[C2347443]|[GSK690693]
3888|GSK|A single-blind, randomised, placebo-controlled, parallel group study to investigate safety, tolerability, pharmacokinetics and the effects on cardiac function of repeat oral doses of SB-649868 in adult and elderly healthy volunteers|Sleep Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112861|http://clinicaltrials.gov/show/NCT01030939|[C3180886]|[SB-649868]
3889|GSK|A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma|Lymphoma, Follicular|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=393229/027|http://clinicaltrials.gov/show/NCT00315731|[C0879399]|[tositumomab]
3896|Astellas|Long-term Study of YM178: Long-term study of YM178 in subjects with overactive bladder.|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-051|https://clinicaltrials.gov/ct2/show/NCT00840645|[C2983812]|[mirabegron]
3920|GSK|An Evaluation of the Bioequivalence of five 0.1 mg GI198745/dutasteride Soft Gelatin Capsules Compared to one 0.5 mg GI198745/dutasteride Gelatin Capsules in Healthy Male Volunteers|Alopecia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117342|http://clinicaltrials.gov/show/NCT01929330|[C0754659]|[dutasteride]
3921|GSK|Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis.|Multiple Sclerosis, Relapsing-Remitting|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116477|http://clinicaltrials.gov/show/NCT01772199|[C3712181]|[GSK239512]
3923|GSK|A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment.|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116086|http://clinicaltrials.gov/show/NCT01817777|[C0025598]|[metformin]
3936|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112756|http://clinicaltrials.gov/show/NCT00849017|[C2607479]|[albiglutide]
3937|GSK|A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: Follow-up phase.|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4013|nan|[C0085208]|[bupropion]
3938|GSK|A multicenter evaluation of the effects of Zyban (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: treatment phase.ZYBAN is a registered trademark of the GlaxoSmithKline group of companies.|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4013|nan|[C0085208]|[bupropion]
3939|GSK|A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis|Psoriasis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116679|http://clinicaltrials.gov/show/NCT01782664|[C4726763]|[Solcitinib]
3940|GSK|A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ILI105618|http://clinicaltrials.gov/show/NCT00500058|[C1527127]|[Recombinant Interleukin-18]
3941|GSK|A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer|Neoplasms, Ovarian|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ILI108621|http://clinicaltrials.gov/show/NCT00659178|[C1527127]|[Recombinant Interleukin-18]
3942|GSK|Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset). A multicentre, double-blind, placebo-controlled, parallel group study.|Lennox-Gastaut Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105-123|nan|[C0064636]|[lamotrigine]
3943|GSK|A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients|Epilepsy, Partial|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=105-040|nan|[C0064636]|[lamotrigine]
3944|GSK|Oral bioavailability study comparing OXEMET™ 1000 mg coated tablets containing metformin hydrochloride with 1000 mg of the reference product (GLAFORNIL™) administered as two 500 mg tablets, through a randomized, single-dose, open label, balanced, 2-way crossover study in healthy volunteers under fasting conditions.OXEMET (TM) is a trademark of the GlaxoSmithKline group of companies. GLAFORNIL(TM) is a trademark of Merck.|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=117219|http://clinicaltrials.gov/show/NCT01842620|[C0025598]|[metformin]
3945|GSK|A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days.|Analgesia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=USA30226|nan|[C0246631]|[remifentanil]
3947|GSK|PHASE II MULTICENTER STUDY OF IODINE-131 ANTI-B1 ANTIBODY CONSOLIDATION FOR PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA FOLLOWING FIRST-LINE CHOP|Lymphoma, Non-Hodgkin|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=393229/007|http://clinicaltrials.gov/show/NCT01868035|[C0879399]|[tositumomab]
3948|GSK|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116133|http://clinicaltrials.gov/show/NCT01716520|[C3709474]|[umeclidinium bromide]
3949|GSK|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115361|http://clinicaltrials.gov/show/NCT01702363|[C3709474]|[umeclidinium bromide]
3950|GSK|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116132|http://clinicaltrials.gov/show/NCT02014480|[C3709474]|[umeclidinium bromide]
3951|GSK|A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 1|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200109|http://clinicaltrials.gov/show/NCT01957163|[C3709474]|[umeclidinium bromide]
3952|GSK|A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 2|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200110|http://clinicaltrials.gov/show/NCT02119286|[C3709474]|[umeclidinium bromide]
3953|Novartis|A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Psoriasis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4823|https://clinicaltrials.gov/show/NCT00941031|[C3179547]|[secukinumab]
3955|Novartis|A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Psoriasis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5383|https://clinicaltrials.gov/show/NCT01071252|[C3179547]|[secukinumab]
3956|Novartis|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11643|https://clinicaltrials.gov/show/NCT01365455|[C3179547]|[secukinumab]
3957|Novartis|A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13605|https://clinicaltrials.gov/show/NCT01358578|[C3179547]|[secukinumab]
3962|GSK|A study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single and repeat inhaled doses of GSK961081 in healthy subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=104865|http://clinicaltrials.gov/show/NCT00887406|[C4519138]|[batefenterol]
3963|GSK|A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MAB104958|http://clinicaltrials.gov/show/NCT00478738|[C4519138]|[batefenterol]
3964|GSK|A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt).|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MAB108115|http://clinicaltrials.gov/show/NCT00550225|[C4519138]|[batefenterol]
3965|GSK|A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MAB110123|http://clinicaltrials.gov/show/NCT00674817|[C4519138]|[batefenterol]
3966|GSK|A study to investigate the relative pharmacological activity of an inhaled B2-agonist/anticholinergic dual pharmacophore in healthy volunteers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MAB110553|http://clinicaltrials.gov/show/NCT00687700|[C4519138]|[batefenterol]
3967|GSK|A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115032|http://clinicaltrials.gov/show/NCT01319019|[C4519138]|[batefenterol]
3968|GSK|A randomised, double-blind, double-dummy, single dose, four way cross-over study to compare the pharmacokinetics and pharmacodynamics of GSK961081 and fluticasone propionate when administered alone, concurrently and as a combination blend in healthy subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113423|http://clinicaltrials.gov/show/NCT01449799|[C4519138]|[batefenterol]
3969|GSK|An Open-label, Randomized, Single Dose, Two-Period Crossover study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg.|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114694|http://clinicaltrials.gov/show/NCT01254071|[C0754659]|[dutasteride]
3970|GSK|An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride/0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry.|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115708|http://clinicaltrials.gov/show/NCT01495026|[C0754659]|[dutasteride]
3971|GSK|A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 micrograms in children aged 5 to 11 years with persistent asthma.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112777|http://clinicaltrials.gov/show/NCT01453023|[C1948374]|[fluticasone furoate]
3972|GSK|A randomized, double-blind, placebo controlled, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of levocabastine when administered once daily or twice daily on the symptoms of rhinitis in an allergen challenge chamber.|Rhinitis, Allergic, Perennial and Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200285|http://clinicaltrials.gov/show/NCT01949051|[C1948374, C0064870]|[fluticasone furoate, levocabastine]
3973|GSK|A randomised, double-blind, placebo-controlled, 3 way, incomplete block cross over study in subjects with allergic rhinitis to assess the effect of once daily single and repeat doses of intranasal Fluticasone furoate/Levocabastine fixed dose combination (FDC) relative to Levocabastine and Fluticasone furoate alone on the onset and magnitude of symptoms of rhinitis in an allergen challenge chamber.|Rhinitis, Allergic, Perennial and Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200286|http://clinicaltrials.gov/show/NCT01957202|[C1948374, C0064870]|[fluticasone furoate, levocabastine]
3974|GSK|A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.|Diabetes Mellitus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116378|http://clinicaltrials.gov/show/NCT01648153|[C4278474]|[GSK1070806]
3977|GSK|A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219).|Oesophagitis, Eosinophilic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MEE103219|http://clinicaltrials.gov/show/NCT00358449|[C0969324]|[mepolizumab]
3978|GSK|DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.|Diabetes Mellitus, Type 1|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115494|http://clinicaltrials.gov/show/NCT01123083|[C2935224]|[otelixizumab]
3979|GSK|A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects.|Therapeutic treatment of inhalation anthrax|Phase 3|nan|http://clinicaltrials.gov/show/NCT00639678|[C2717174]|[raxibacumab]
3980|GSK|A randomised, double blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and systemic pharmacokinetic profile of single inhaled doses of GW642444 in healthy male subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2C10001|nan|[C2935023]|[vilanterol]
3981|GSK|A multi-centre, randomised, double-blind, placebo controlled, dose ascending, four way crossover study to examine efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat doses of GW642444.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C101762|http://clinicaltrials.gov/show/NCT00354874|[C2935023]|[vilanterol]
3982|GSK|A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C104604|http://clinicaltrials.gov/show/NCT00381667|[C2935023]|[vilanterol]
3983|GSK|Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C106093|http://clinicaltrials.gov/show/NCT00347139|[C2935023]|[vilanterol]
3984|GSK|A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2C106180|http://clinicaltrials.gov/show/NCT00711126|[C2935023]|[vilanterol]
3985|GSK|An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106181|http://clinicaltrials.gov/show/NCT01286831|[C2935023]|[vilanterol]
3986|GSK|A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2C106996|http://clinicaltrials.gov/show/NCT00463697|[C2935023]|[vilanterol]
3987|GSK|A 2-wk study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C108562|http://clinicaltrials.gov/show/NCT00372112|[C2935023]|[vilanterol]
3988|GSK|A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2C108784|http://clinicaltrials.gov/show/NCT00469040|[C2935023]|[vilanterol]
3989|GSK|A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C110165|http://clinicaltrials.gov/show/NCT00519376|[C2935023]|[vilanterol]
3990|GSK|Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD.|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=B2C111045|http://clinicaltrials.gov/show/NCT00606684|[C2935023]|[vilanterol]
3991|GSK|A randomised, single-dose, dose-ascending, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M in asthmatic patients.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=B2C111401|http://clinicaltrials.gov/show/NCT00702910|[C2935023]|[vilanterol]
3992|GSK|A double-blind, placebo-controlled, randomised, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following co-administration of GW642444M with ketoconazole.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112205|http://clinicaltrials.gov/show/NCT00866515|[C2935023]|[vilanterol]
3993|GSK|A randomized, double-blind, placebo-controlled, two-way crossover 7-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled GW642444 25μg (micrograms) in children aged 5-11 years with persistent asthma.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112776|http://clinicaltrials.gov/show/NCT01453296|[C2935023]|[vilanterol]
3994|GSK|Phase I, Open-label Study To Evaluate Steady-State Serum and Pulmonary Pharmacokinetics following Intravenous Administration of Zanamivir in Healthy Adult Subjects.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106784|nan|[C0216660]|[zanamivir]
3995|GSK|An Open-Label, Non-Randomized, Single-Dose Study To Evaluate Serum Zanamivir Pharmacokinetics Following Intravenous Administration to Human Subjects With Renal Impairment Compared to Subjects Without Renal Impairment.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=108127|nan|[C0216660]|[zanamivir]
3996|GSK|An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection.|Influenza, Human|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113678|http://clinicaltrials.gov/show/NCT01014988|[C0216660]|[zanamivir]
3997|GSK|A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) with Moxifloxacin as a Positive Control in Healthy Volunteers.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114346|http://clinicaltrials.gov/show/NCT01353729|[C0216660]|[zanamivir]
3998|GSK|A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers.|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115096|http://clinicaltrials.gov/show/NCT01258530|[C0216660]|[zanamivir]
4005|GSK|An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects under Fasting Conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116798|http://clinicaltrials.gov/show/NCT01822639|[C0051696, C0014025]|[amlodipine, enalapril]
4006|GSK|An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200561|http://clinicaltrials.gov/show/NCT02075619|[C0051696, C0965129]|[amlodipine, rosuvastatin]
4007|GSK|An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116119|http://clinicaltrials.gov/show/NCT01516450|[C1723401]|[belimumab]
4008|GSK|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117326|http://clinicaltrials.gov/show/NCT02000804|[C2348075]|[darapladib]
4009|GSK|An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115707|http://clinicaltrials.gov/show/NCT01471678|[C0754659]|[dutasteride]
4010|GSK|A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects|Cancer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113581|http://clinicaltrials.gov/show/NCT00996671|[C2981865]|[GSK2256098]
4015|GSK|An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects|Therapeutic treatment of inhalation anthrax|Phase 2/3|https://www.gsk-studyregister.com/en/trial-details/?id=HGS1021-C1069|http://clinicaltrials.gov/show/NCT02016963|[C2717174]|[raxibacumab]
4016|GSK|A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers|Skin Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117151|http://clinicaltrials.gov/show/NCT01812382|[C1703334]|[retapamulin]
4017|GSK|A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MAB104954|http://clinicaltrials.gov/show/NCT00549120|[C0001927]|[albuterol]
4018|GSK|A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=106853|http://clinicaltrials.gov/show/NCT01573767|[C2935023]|[vilanterol]
4033|Astellas|A phase III, double-blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi.|Invasive aspergillosis / Invasive mucormycosis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0104|https://clinicaltrials.gov/ct2/show/NCT00412893|[C4018470]|[isavuconazonium sulfate]
4034|Astellas|Open-Label Study of Isavuconazole in the Treatment of Patients with Aspergillosis and Renal Impairment or of Patients with Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi|Invasive aspergillosis / Invasive mucormycosis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0103|https://clinicaltrials.gov/ct2/show/NCT00634049|[C4018470]|[isavuconazonium sulfate]
4035|Astellas|A Study to Evaluate the Overall Effect of Solifenacin 5 mg and 10 mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Overactivity – A Double-blind, Randomized, Placebo-controlled, Parallel-group, Multi-center Study|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=905-EC-007|https://clinicaltrials.gov/ct2/show/NCT01093534|[C1509436]|[solifenacin succinate]
4040|Novartis|Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension|Open-Angle Glaucoma; Ocular Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12971|https://clinicaltrials.gov/show/NCT01297517|[C0673966]|[brinzolamide]
4041|Novartis|A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension|Open-Angle Glaucoma; Ocular Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12972|https://clinicaltrials.gov/show/NCT01297920|[C0673966]|[brinzolamide]
4042|Novartis|Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Open-Angle Glaucoma; Ocular Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12973|https://clinicaltrials.gov/show/NCT01310777|[C0673966]|[brinzolamide]
4044|Novartis|A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy|Cancer, Advanced Gastric|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13505|https://clinicaltrials.gov/show/NCT00879333|[C0541315]|[everolimus]
4045|Novartis|A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2822|https://clinicaltrials.gov/show/NCT00620022|[C1722260]|[indacaterol]
4046|Novartis|A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7505|https://clinicaltrials.gov/show/NCT01294787|[C1722260, C0017970]|[indacaterol, glycopyrrolate]
4047|Novartis|An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.|Chronic Myelogenous Leukemia|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15067|https://www.clinicaltrials.gov/ct2/show/NCT00760877?term=CAMN107A2405&rank=1|[C1721377]|[nilotinib]
4048|Novartis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5183|https://clinicaltrials.gov/show/NCT01154127|[C3814772]|[glycopyrronium]
4050|Novartis|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)|Chronic Idiopathic Urticaria (CIU)|Phase 3|http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4881g|https://clinicaltrials.gov/show/NCT01287117|[C0966225]|[omalizumab]
4051|Novartis|A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)|Chronic Idiopathic Urticaria (CIU)|Phase 3|http://roche-trials.com/studyResultGet.action?studyResultNumber=Q4882g|https://clinicaltrials.gov/show/NCT01292473|[C0966225]|[omalizumab]
4053|Novartis|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures|Epilepsy|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1634|https://clinicaltrials.gov/show/NCT00050947|[C0069751]|[oxcarbazepine]
4054|Novartis|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures|Epilepsy|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1876|https://clinicaltrials.gov/show/NCT00050934|[C0069751]|[oxcarbazepine]
4061|Novartis|A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens|Heart Failure|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13984|https://clinicaltrials.gov/show/NCT01922089|[C4033447, C0216784]|[sacubitril, valsartan]
4062|Novartis|A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction|Heart Failure, Chronic (CHF)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13786|https://clinicaltrials.gov/show/NCT01035255|[C4033447, C0216784]|[sacubitril, valsartan]
4068|Novartis|A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13563|https://www.clinicaltrials.gov/ct2/show/NCT1406938?term=CAIN457A2304|[C3179547]|[secukinumab]
4069|Novartis|A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in patients with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11644|https://www.clinicaltrials.gov/ct2/show/NCT1412944?term=CAIN457A2307|[C3179547]|[secukinumab]
4070|Novartis|A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16807|https://www.clinicaltrials.gov/ct2/show/NCT1555125?term=CAIN457A2308&rank=1|[C3179547]|[secukinumab]
4071|Novartis|A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16808|https://www.clinicaltrials.gov/ct2/show/NCT1636687?term=CAIN457A2309&rank=1|[C3179547]|[secukinumab]
4074|Novartis|A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003 % Compared to Travatan in Patients with Open-Angle Glaucoma or Ocular Hypertension|Open-Angle Glaucoma; Ocular Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12951|https://clinicaltrials.gov/show/NCT01453855|[C0937916]|[travoprost]
4082|Novartis|Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction|Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1517|Not available|[C0216784]|[valsartan]
4083|Novartis|A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension|Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2612|https://clinicaltrials.gov/show/NCT00170950|[C0051696, C0770917]|[amlodipine, benazepril hydrochloride]
4084|Novartis|A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis|Multiple Sclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3147|https://clinicaltrials.gov/show/NCT00289978|[C1699926]|[fingolimod]
4085|Novartis|A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|Multiple Sclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6685|https://clinicaltrials.gov/show/NCT00340834|[C1699926]|[fingolimod]
4086|Novartis|A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)|Alzheimer's Disease|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4162|https://clinicaltrials.gov/show/NCT00423085|[C0649350]|[rivastigmine]
4087|Novartis|A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)|Diabetes Mellitus, Type 2|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3223|https://clinicaltrials.gov/show/NCT00097786|[C0216784]|[valsartan]
4089|Novartis|24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|Multiple Sclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6223|https://clinicaltrials.gov/show/NCT00355134|[C1699926]|[fingolimod]
4095|Novartis|A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma|Multiple myeloma (MM); Myelodysplastic syndrome (MDS)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13623|https://clinicaltrials.gov/show/NCT01023308|[C1998098]|[panobinostat]
4107|GSK|Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GlaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions|Healthy Subjects|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201529|http://clinicaltrials.gov/show/NCT02446496|[C0007538]|[cefadroxil]
4108|GSK|A randomised, repeat-dose, placebo-controlled, three-way crossover, double dummy study to evaluate and compare the efficacy of Fluticasone Furoate inhalation powder delivered via the single strip dry powder inhaler when administered either in the morning or in the evening, in male and female asthmatic subjects|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=117156|http://clinicaltrials.gov/show/NCT01808339|[C1948374]|[fluticasone furoate]
4109|GSK|A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113782|http://clinicaltrials.gov/show/NCT01313676|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4110|GSK|"""A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation. Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults with Chronic Obstructive Pulmonary Disease (COPD)"""|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116601|http://clinicaltrials.gov/show/NCT01691885|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4111|GSK|An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200260|http://clinicaltrials.gov/show/NCT01890863|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4112|GSK|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma|Solid Tumours|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112826|http://clinicaltrials.gov/show/NCT00972686|[C4519177]|[omipalisib]
4114|GSK|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults|Oesophagitis, Eosinophilic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MEE103226|http://clinicaltrials.gov/show/NCT00274703|[C0969324]|[mepolizumab]
4115|GSK|A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201315|http://clinicaltrials.gov/show/NCT02236611|[C3709474]|[umeclidinium bromide]
4116|GSK|A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201316|http://clinicaltrials.gov/show/NCT02207829|[C3709474]|[umeclidinium bromide]
4118|Novartis|Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Open-Angle Glaucoma; Ocular Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12974|https://clinicaltrials.gov/show/NCT01309204|[C0673966]|[brinzolamide]
4120|Novartis|A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)|Tumors Characterized by Genetic Abnormalities of ALK|Phase 1/2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12003|https://clinicaltrials.gov/show/NCT01283516|[C3818721]|[ceritinib]
4121|Novartis|A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib|Non-small cell lung carcinoma (NSCLC)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16109|https://clinicaltrials.gov/show/NCT01685060|[C3818721]|[ceritinib]
4123|Novartis|A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma|Melanoma|Phase 2|https://www.gsk-clinicalstudyregister.com/study/113710|https://www.clinicaltrials.gov/ct2/show/NCT01153763?term=BRF113710&rank=1|[C3467876]|[dabrafenib]
4124|Novartis|BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain|Melanoma|Phase 2|https://www.gsk-clinicalstudyregister.com/search/?study_ids=113929|https://clinicaltrials.gov/show/NCT01266967|[C3467876]|[dabrafenib]
4131|Novartis|Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures|Liver Diseases|Phase 3|http://www.gsk-clinicalstudyregister.com/study/TPL104054|http://clinicaltrials.gov/show/NCT00678587|[C1831905]|[eltrombopag]
4137|Novartis|Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients|Kidney Transplantation|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3401|https://clinicaltrials.gov/show/NCT00251004|[C0541315]|[everolimus]
4138|Novartis|An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.|Kidney Transplantation|Phase 3|nan|nan|[C0541315]|[everolimus]
4139|Novartis|An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.|Kidney Transplantation|Phase 3|nan|nan|[C0541315]|[everolimus]
4140|Novartis|Two-year randomized, multi-center, doubleblind, double-dummy study of the efficacy and safety of everolimus versus azathioprine (AZA) as part of a triple immunosuppressive therapy regimen in de novo heart transplant recipients.|Heart transplantation|Phase 3|nan|Not available|[C0541315]|[everolimus]
4141|Novartis|A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients|Liver Transplantation|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8503|https://clinicaltrials.gov/show/NCT00622869|[C0541315]|[everolimus]
4151|Novartis|An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens|Neoplasms, Breast|Phase 2|http://www.gsk-clinicalstudyregister.com/study/EGF20008|http://clinicaltrials.gov/show/NCT00062686|[C1506770]|[lapatinib]
4154|Novartis|A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens|Neoplasms, Breast|Phase 3|http://www.gsk-clinicalstudyregister.com/study/EGF104900|http://clinicaltrials.gov/show/NCT00320385|[C1506770]|[lapatinib]
4155|Novartis|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer|Neoplasms, Breast|Phase 3|http://www.gsk-clinicalstudyregister.com/study/EGF30001|http://clinicaltrials.gov/show/NCT00075270|[C1506770]|[lapatinib]
4163|Novartis|A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy|Sarcoma, Soft tissue|Phase 3|http://www.gsk-clinicalstudyregister.com/study/VEG110727|http://clinicaltrials.gov/show/NCT00753688|[C1831796]|[pazopanib]
4164|Novartis|A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma|Carcinoma, Renal Cell|Phase 3|http://www.gsk-clinicalstudyregister.com/study/VEG105192|http://clinicaltrials.gov/show/NCT00334282|[C1831796]|[pazopanib]
4165|Novartis|A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma|Carcinoma, Renal Cell|Phase 2|http://www.gsk-clinicalstudyregister.com/study/VEG102616|http://clinicaltrials.gov/show/NCT00244764|[C1831796]|[pazopanib]
4178|Novartis|Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma|Sarcoma, Soft tissue|Phase 2|https://www.gsk-clinicalstudyregister.com/study/VEG20002|https://clinicaltrials.gov/show/NCT00297258|[C1831796]|[pazopanib]
4179|Novartis|A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of Rivastigmine on the Time to Clinical Diagnosis of Alzheimer’s Disease in Subjects with Mild Cognitive Impairment (MCI)|Alzheimer's Disease|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1886|Not available|[C0649350]|[rivastigmine]
4180|Novartis|A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia|Parkinson's Disease Dementia|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1616|Not available|[C0649350]|[rivastigmine]
4183|Novartis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis|Psoriatic Arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14231|https://clinicaltrials.gov/show/NCT01392326|[C3179547]|[secukinumab]
4184|Novartis|Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)|Psoriatic Arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17573|https://www.clinicaltrials.gov/ct2/show/NCT01752634?term=CAIN457F2312&draw=2&rank=1|[C3179547]|[secukinumab]
4187|Novartis|An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor|Cancer|Phase 2|http://www.gsk-clinicalstudyregister.com/study/113583|http://clinicaltrials.gov/show/NCT01037127|[C2697961]|[trametinib]
4189|Novartis|Multinational, multicenter, double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture|Osteoporosis; Hip Fracture|Phase 3|nan|https://clinicaltrials.gov/show/NCT00046254|[C0257685]|[zoledronic acid]
4190|Novartis|A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking cal-cium and vitamin D|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2323|https://clinicaltrials.gov/show/NCT00049829|[C0257685]|[zoledronic acid]
4191|Novartis|A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3662|https://clinicaltrials.gov/show/NCT00145327|[C0257685]|[zoledronic acid]
4192|Novartis|A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10323|https://clinicaltrials.gov/show/NCT00718861|[C0257685]|[zoledronic acid]
4193|Novartis|A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2856|https://clinicaltrials.gov/show/NCT00439244|[C0257685]|[zoledronic acid]
4194|Novartis|Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2545|https://clinicaltrials.gov/ct2/show/NCT00097825?term=CZOL446M2308&rank=1|[C0257685]|[zoledronic acid]
4195|Novartis|A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men|Osteoporosis, Male|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4646|https://clinicaltrials.gov/show/NCT00439647|[C0257685]|[zoledronic acid]
4196|Novartis|Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis|Osteoporosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2456|https://clinicaltrials.gov/show/NCT00100620|[C0257685]|[zoledronic acid]
4204|Novartis|A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Neoplasms, Head and Neck|Phase 3|https://www.gsk-clinicalstudyregister.com/study/EGF102988|https://clinicaltrials.gov/show/NCT00424255|[C1506770]|[lapatinib]
4217|GSK|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113121|http://clinicaltrials.gov/show/NCT01733758|[C2607479]|[albiglutide]
4219|GSK|A Randomized, Parallel-Group, Open-Label Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Administered Subcutaneously to Healthy Subjects by Prefilled Syringe or Autoinjector|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117100|http://clinicaltrials.gov/show/NCT01894360|[C1723401]|[belimumab]
4220|GSK|A Multi-center, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=200398|http://clinicaltrials.gov/show/NCT02058628|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
4221|GSK|An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200254|http://clinicaltrials.gov/show/NCT01957189|[C0754659]|[dutasteride]
4222|GSK|An open label, randomised, six-way crossover, single dose study to determine the pharmacokinetics of GSK961081 and fluticasone furoate when administered alone or in combination|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201010|http://clinicaltrials.gov/show/NCT02064504|[C4519138, C1948374]|[batefenterol, fluticasone furoate]
4223|GSK|A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine with Levocabastine and Fluticasone Furoate Alone|Rhinitis, Allergic, Perennial and Seasonal|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200284|http://clinicaltrials.gov/show/NCT01962467|[C1948374, C0064870]|[fluticasone furoate, levocabastine]
4224|GSK|Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR)|Rhinitis, Allergic, Perennial and Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=200165|http://clinicaltrials.gov/show/NCT01916226|[C0117996]|[fluticasone propionate]
4225|GSK|A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of intravenously infused GSK1995057 in healthy subjects.|Respiratory Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110951|http://clinicaltrials.gov/show/NCT01476046|[C5196682]|[GSK1995057]
4237|GSK|DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study|Diabetes Mellitus, Type 1|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115496|nan|[C2935224]|[otelixizumab]
4238|GSK|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112810|http://clinicaltrials.gov/show/NCT00866294|[C0070122]|[paroxetine]
4241|GSK|A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116135|http://clinicaltrials.gov/show/NCT01772134|[C3709474]|[umeclidinium bromide]
4242|GSK|A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD.|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116136|http://clinicaltrials.gov/show/NCT01772147|[C3709474]|[umeclidinium bromide]
4243|GSK|DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116134|http://clinicaltrials.gov/show/NCT01822899|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
4244|GSK|A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201211|http://clinicaltrials.gov/show/NCT02152605|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
4286|GSK|Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment|Psoriasis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=117221|http://clinicaltrials.gov/show/NCT01245140|[C0281666]|[alitretinoin]
4287|GSK|A two-part crossover study to assess the pharmacokinetics of amoxicillin after administration with clavulanate of pharmacokinetically enhanced formulations of amoxicillin in healthy volunteers.|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/552|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
4288|GSK|An open, randomised, balanced, three period, single dose crossover study to investigate the effect of food on the bioavailability of pharmacokinetically enhanced (PE) oral Augmentin® in healthy male and female volunteers.|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=25000/553|nan|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
4290|GSK|A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201022|http://clinicaltrials.gov/show/NCT02169583|[C4519256]|[danirixin]
4291|GSK|A single-centre, double-blind, placebo-controlled study to evaluate the safety, tolerabilty, pharmacokinetics, and pharmacodynamics of single, oral, ascending doses and repeat oral doses of GSK1325756 in healthy male subjects.|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112483|http://clinicaltrials.gov/show/NCT01209052|[C4519256]|[danirixin]
4292|GSK|A single-dose, open, randomized, crossover investigation of age, gender, food-effect and proton-pump interaction on the pharmacokinetics of GSK1325756 in healthy adult subjects and a single-dose, double blind, parallel-group, placebo- controlled investigation of the pharmacokinetics of GSK1325756|Nutritional Status|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113722|http://clinicaltrials.gov/show/NCT01209104|[C4519256]|[danirixin]
4293|GSK|A randomized cross-over study to evaluate the pharmacokinetics and pharmacodynamics of twice daily oral administration of GSK1325756, compared to placebo, in healthy subjects; and the pharmacokinetic profile of twice daily oral administration of GSK1325756 in healthy fed and fasted elderly subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114922|http://clinicaltrials.gov/show/NCT01267006|[C4519256]|[danirixin]
4294|GSK|A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bio enhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115550|http://clinicaltrials.gov/show/NCT01453478|[C4519256]|[danirixin]
4295|GSK|Bioequivalence Study of Dutasteride Capsules-An evaluation of the bioequivalence of dutasteride capsule manufactured at GSK compared to dutasteride capsule manufactured at Catalent in healthy Japanese male subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204646|http://clinicaltrials.gov/show/NCT02578953|[C0754659]|[dutasteride]
4296|GSK|A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with low to mid-strength inhaled corticosteroid or low-strength combination therapy.|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113719|http://clinicaltrials.gov/show/NCT01498679|[C1948374, C3644419]|[fluticasone furoate, vilanterol trifenatate]
4297|GSK|A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and ADOAIR 50/250mcg alone) in the treatment of Japanese subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116572|http://clinicaltrials.gov/show/NCT01751113|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4298|GSK|SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115359|http://clinicaltrials.gov/show/NCT01475721|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4299|GSK|An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666)|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116666|http://clinicaltrials.gov/show/NCT01934205|[C4309999]|[gepotidacin]
4300|GSK|A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115198|http://clinicaltrials.gov/show/NCT01615796|[C4309999]|[gepotidacin]
4301|GSK|A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116778|http://clinicaltrials.gov/show/NCT01706315|[C4309999]|[gepotidacin]
4302|GSK|Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil)|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113634|http://clinicaltrials.gov/show/NCT01376232|[C4519188]|[daprodustat]
4303|GSK|A multi-center, placebo-controlled study to evaluate the safety and efficacy of GSK1278863 vs. placebo in subjects with peripheral artery disease (PAD).|Vascular Disease, Peripheral|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114272|http://clinicaltrials.gov/show/NCT02135848|[C4519188]|[daprodustat]
4304|GSK|A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114703|http://clinicaltrials.gov/show/NCT01319006|[C4519188]|[daprodustat]
4305|GSK|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115385|http://clinicaltrials.gov/show/NCT02348372|[C4519188]|[daprodustat]
4306|GSK|A randomized, placebo-controlled, study to evaluate the effects of GSK1278863A on pulmonary artery pressure in healthy volunteers|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116008|http://clinicaltrials.gov/show/NCT01673555|[C4519188]|[daprodustat]
4307|GSK|A four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116581|http://clinicaltrials.gov/show/NCT01587898|[C4519188]|[daprodustat]
4308|GSK|A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116582|http://clinicaltrials.gov/show/NCT01587924|[C4519188]|[daprodustat]
4309|GSK|Cancer immunotherapeutic GSK1572932A as adjuvant therapy for patients with MAGE-A3-positive Non-Small Cell Lung cancer|Lung Cancer, Non-Small Cell|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=107240|http://clinicaltrials.gov/show/NCT00455572|[C2984506]|[Immunotherapeutic GSK1572932A]
4310|GSK|A randomised, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and efficacy against allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies|Asthma and Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116392|http://clinicaltrials.gov/show/NCT01607372|[C4079591]|[GSK2245035]
4312|GSK|A First Time in Human study to assess the safety, tolerability and pharmacokinetics of GSK356278 (PDE4 inhibitor) in healthy volunteers|Depressive Disorder and Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113324|http://clinicaltrials.gov/show/NCT01031186|[C3886520]|[GSK356278]
4313|GSK|A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278|Huntington Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115719|http://clinicaltrials.gov/show/NCT01573819|[C3886520]|[GSK356278]
4314|GSK|An open label positron emission tomography study in healthy male subjects to investigate brain PDE4 engagement, pharmacokinetics and safety of single oral doses of GSK356278, using 11C-(R)-rolipram as a PET ligand(s)|Huntington Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116038|http://clinicaltrials.gov/show/NCT01602900|[C3886520]|[GSK356278]
4315|GSK|A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115207|http://clinicaltrials.gov/show/NCT01879423|[C0064636]|[lamotrigine]
4316|GSK|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects|Epilepsy|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200697|http://clinicaltrials.gov/show/NCT02064465|[C0064636]|[lamotrigine]
4317|GSK|A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115377|http://clinicaltrials.gov/show/NCT01431976|[C0064636]|[lamotrigine]
4318|GSK|A randomized, placebo-controlled, single-blind study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of otelixizumab in rheumatoid arthritis subjects|Arthritis, Rheumatoid|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111601|http://clinicaltrials.gov/show/NCT01077531|[C2935224]|[otelixizumab]
4322|GSK|An open label, randomized, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of the controlled-release paroxetine tablets at the dose levels of 12.5, 25 and 50mg in healthy Japanese male subjects|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112811|http://clinicaltrials.gov/show/NCT00938184|[C0070122]|[paroxetine]
4323|GSK|A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled-release paroxetine tablet (25 mg) with that of the standard immediate-release paroxetine tablet (20 mg) in healthy Japanese male subjects|Depressive Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112812|http://clinicaltrials.gov/show/NCT01000857|[C0070122]|[paroxetine]
4325|GSK|To evaluate the pharmacokinetics, safety and tolerability of Retosiban (GSK221149) co-administered with EFAVIRENZ|Obstetric Labour, Premature|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116073|http://clinicaltrials.gov/show/NCT01867996|[C2699069]|[Retosiban]
4326|GSK|A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, with Moxifloxacin as a Positive Control in Healthy Volunteers|Obstetric Labour, Premature|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113789|http://clinicaltrials.gov/show/NCT01702376|[C2699069]|[Retosiban]
4327|GSK|A two cohort, open-label study to evaluate the pharmacokinetics of GSK2847065, the metabolite of Retosiban (GSK221149) after single and repeat oral doses, the pharmacokinetics of GSK221149 coadministered with a high fat meal, and the pharmacokinetics of GSK221149 coadministered with an inhibitor of CYP3A4 (Ketoconazole)|Obstetric Labour, Premature|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115893|http://clinicaltrials.gov/show/NCT01627587|[C2699069]|[Retosiban]
4328|GSK|A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks’ gestation|Obstetric Labour, Premature|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=OTA105256|http://clinicaltrials.gov/show/NCT00404768|[C2699069]|[Retosiban]
4329|GSK|Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116961|http://clinicaltrials.gov/show/NCT02257385|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
4330|GSK|Phase I study of GW642444M- A randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112017|http://clinicaltrials.gov/show/NCT00964249|[C2935023]|[vilanterol]
4331|GSK|Phase1 study of GR121167- A double blind, placebo controlled, randomized, dose ascending, single and multiple dose study to investigate the safety and pharmacokinetics following intravenous administration of GR121167 in healthy Japanese males|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115070|http://clinicaltrials.gov/show/NCT01428479|[C0216660]|[zanamivir]
4332|GSK|An open-label, multi-center, single arm study to evaluate the safety and efficacy of intravenous zanamivir in the treatment of hospitalized patients with confirmed influenza infection (NAI115215)|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115215|http://clinicaltrials.gov/show/NCT01527110|[C0216660]|[zanamivir]
4372|Astellas|Phase III Study of YM178: A double-blind group comparison study in patients with overactive bladder|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-048|https://clinicaltrials.gov/ct2/show/NCT00966004|[C2983812]|[mirabegron]
4373|Astellas|A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder|Urinary Bladder, Overactive|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-008|https://clinicaltrials.gov/ct2/show/NCT01604928|[C2983812]|[mirabegron]
4374|Astellas|A randomized, double-blind, parallel-group, placebo and active controlled, multi-center dose ranging study with beta-3 agonist YM178 in patients with symptomatic overactive bladder (DRAGON)|Urinary Bladder, Overactive|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-044|https://clinicaltrials.gov/ct2/show/NCT00337090|[C2983812]|[mirabegron]
4399|GSK|A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients with Gastroparesis|Gastroparesis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111809|http://clinicaltrials.gov/show/NCT00861809|[C4519144]|[Camicinal]
4400|GSK|A double-blind, randomized, placebo controlled Phase II study to evaluate the pharmacodynamics, safety, tolerability, and pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in critically ill male and female patients with enteral feed intolerance|Gastroparesis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112571|http://clinicaltrials.gov/show/NCT01039805|[C4519144]|[Camicinal]
4401|GSK|A single dose, open label, nonrandomized, study to evaluate the pharmacokinetics and absolute bioavailability of GSK962040 given as an oral dose simultaneously with an intravenous micro tracer dose of [14C]-GSK962040 in healthy volunteers|Gastroparesis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114136|http://clinicaltrials.gov/show/NCT01267071|[C4519144]|[Camicinal]
4402|GSK|A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects|Gastroparesis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MOT107043|http://clinicaltrials.gov/show/NCT00562848|[C4519144]|[Camicinal]
4403|GSK|A randomized, double-blind, ascending dose trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, of repeat doses of motilin receptor agonist GSK962040 in male and female healthy volunteers|Gastroparesis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=MOT109681|http://clinicaltrials.gov/show/NCT00733551|[C4519144]|[Camicinal]
4404|GSK|A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis.|Cystic Fibrosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110399|http://clinicaltrials.gov/show/NCT00903201|[C4519321]|[Elubrixin]
4406|GSK|A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation|Premature Ejaculation|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=109059|http://clinicaltrials.gov/show/NCT01021553|[C3274566]|[epelsiban]
4407|GSK|A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers after Single and Repeat Dosing|Embryo Transfer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116741|http://clinicaltrials.gov/show/NCT01669083|[C3274566]|[epelsiban]
4408|GSK|A multi-center, randomized, double-blind, dose-ranging study to evaluate GSK573719 in combination with fluticasone furoate, fluticasone furoate alone, and an active control of fluticasone furoate/vilanterol combination in subjects with asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115938|http://clinicaltrials.gov/show/NCT01573624|[C1948374, C3709474]|[fluticasone furoate, umeclidinium bromide]
4409|GSK|A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116524|http://clinicaltrials.gov/show/NCT01725685|[C1948374, C3709474]|[fluticasone furoate, umeclidinium bromide]
4410|GSK|An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison with FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).|Pulmonary disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200587|http://clinicaltrials.gov/show/NCT01894386|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
4411|GSK|A randomized, double-blind, single dose, four way cross-over study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol following single inhaled doses of Umeclidinium/Vilanterol blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in healthy subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116415|http://clinicaltrials.gov/show/NCT01691547|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
4412|GSK|A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate from FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol from SERETIDE™ 250/25 HFA pMDI when given with the VENTOLIN Mini-Spacer Compared to the Aero chamber Plus Spacer in Healthy Subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201092|http://clinicaltrials.gov/show/NCT02045953|[C0117996]|[fluticasone propionate]
4413|GSK|A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200185|http://clinicaltrials.gov/show/NCT01929863|[C5238076]|[linerixibat]
4414|GSK|A first time in human, single blind, randomized, placebo-controlled, dose escalating crossover study to evaluate the safety,tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in healthy volunteers|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114985|http://clinicaltrials.gov/show/NCT01416324|[C5238076]|[linerixibat]
4415|GSK|A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients with Relapsing Remitting Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116702|http://clinicaltrials.gov/show/NCT01808482|[C5392354]|[GSK2618960]
4416|GSK|A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers|Respiratory Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116343|http://clinicaltrials.gov/show/NCT01818024|[C4279387]|[GSK2862277]
4420|GSK|A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|Acute Coronary Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116628|http://clinicaltrials.gov/show/NCT01756495|[C3272847]|[Losmapimod]
4421|GSK|A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation|Acute Coronary Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111810|http://clinicaltrials.gov/show/NCT00910962|[C3272847]|[Losmapimod]
4422|GSK|A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury|Pain, Neuropathic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112967|http://clinicaltrials.gov/show/NCT00969059|[C3272847]|[Losmapimod]
4423|GSK|A Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113006|http://clinicaltrials.gov/show/NCT01218126|[C3272847]|[Losmapimod]
4424|GSK|A six week randomized, double-blind, multi-center, placebo-controlled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113009|http://clinicaltrials.gov/show/NCT00976560|[C3272847]|[Losmapimod]
4425|GSK|Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous dose(s) and a single oral dose of GW856553 in healthy volunteers|Cardiovascular Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113022|http://clinicaltrials.gov/show/NCT01039961|[C3272847]|[Losmapimod]
4426|GSK|A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy|Pain, Neuropathic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113049|http://clinicaltrials.gov/show/NCT01110057|[C3272847]|[Losmapimod]
4427|GSK|A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects.|Acute Coronary Syndrome|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116681|http://clinicaltrials.gov/show/NCT01648192|[C3272847]|[Losmapimod]
4428|GSK|A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=MKI102428|http://clinicaltrials.gov/show/NCT00642148|[C3272847]|[Losmapimod]
4429|GSK|A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 month, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis|Atherosclerosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=PM1111138|http://clinicaltrials.gov/show/NCT00633022|[C3272847]|[Losmapimod]
4430|GSK|A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) Losmapimod to Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome (LATITUDE)-TIMI 60.|Acute Coronary Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116197|http://clinicaltrials.gov/show/NCT02145468|[C3272847]|[Losmapimod]
4431|GSK|An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg from Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions|Respiratory Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200107|http://clinicaltrials.gov/show/NCT02322671|[C0298130]|[montelukast]
4432|GSK|Characterization of Exposure from Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects|Hyperhidrosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117157|http://clinicaltrials.gov/show/NCT01934153|[C3709474]|[umeclidinium bromide]
4433|GSK|A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116402|http://clinicaltrials.gov/show/NCT01641692|[C3709474]|[umeclidinium bromide]
4436|Novartis|Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer|Cancer, Breast|Phase 2|http://www.gsk-clinicalstudyregister.com/search/?study_ids=lpt109096|https://clinicaltrials.gov/show/NCT00524303|[C1506770]|[lapatinib]
4437|Novartis|A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|Allergic conjunctivitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12984|https://clinicaltrials.gov/show/NCT01479374|[C0771892]|[olopatadine hydrochloride]
4438|Novartis|A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily|Allergic conjunctivitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12985|https://clinicaltrials.gov/show/NCT01698814|[C0771892]|[olopatadine hydrochloride]
4439|Novartis|Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|Allergic conjunctivitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12986|https://clinicaltrials.gov/show/NCT01743027|[C0771892]|[olopatadine hydrochloride]
4478|Astellas|A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron (YM178) in Asian Patients with Symptoms of Overactive Bladder|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-090|https://clinicaltrials.gov/ct2/show/NCT01043666|[C2983812]|[mirabegron]
4479|Astellas|YM178 Phase II study - A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder|Urinary Bladder, Overactive|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-045|https://clinicaltrials.gov/ct2/show/NCT00527033|[C2983812]|[mirabegron]
4494|GSK|An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 8mg tablet formulation of candesartan cilexetil (GW615775) relative to one 8mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200956|http://clinicaltrials.gov/show/NCT02006589|[C0717550]|[candesartan]
4495|GSK|An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200957|http://clinicaltrials.gov/show/NCT02094924|[C0527379, C0020261]|[candesartan cilexetil, hydrochlorothiazide]
4496|GSK|A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116592|http://clinicaltrials.gov/show/NCT01837316|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4497|GSK|A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115358|http://clinicaltrials.gov/show/NCT01462344|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4503|GSK|A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114068|http://clinicaltrials.gov/show/NCT01762774|[C3713989]|[GSK2256294]
4504|GSK|A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study will also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117023|http://clinicaltrials.gov/show/NCT02006537|[C3713989]|[GSK2256294]
4505|GSK|A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201402|http://clinicaltrials.gov/show/NCT02262689|[C3713989]|[GSK2256294]
4506|GSK|A single-centre double-blind, placebo controlled three part study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and repeat doses of nebulised GSK2269557 in healthy male subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115117|http://clinicaltrials.gov/show/NCT01462617|[C5197976]|[Nemiralisib]
4507|GSK|A Randomized, Placebo Controlled, Repeat Dose, Double Blind (sponsor unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered with Metformin to Type 2 Diabetes Patients|Diabetes Mellitus, Type 2|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201351|http://clinicaltrials.gov/show/NCT02202161|[C5238076]|[linerixibat]
4509|GSK|An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinated with Twinrix™ Adult following a two-dose schedule or Twinrix™ Junior following a three-dose schedule.|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=110699|http://clinicaltrials.gov/show/NCT00875485|[C0593953]|[Twinrix]
4514|GSK|MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects who participated in the MEA115588 or MEA115575 trials|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115661|http://clinicaltrials.gov/show/NCT01842607|[C0969324]|[mepolizumab]
4516|GSK|A Two-Period, Randomized, Open-Label, Parallel group, Multiple-Probe Drug Interaction Study to Determine the Effects of NCE on the metabolism of CYP450 Probe Substrates in Healthy Postmenopausal Female Subjects|Osteoarthritis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=462795/007|nan|[C1700101]|[relacatib]
4517|GSK|A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures.|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114855|http://clinicaltrials.gov/show/NCT01648101|[C0530684]|[ezogabine]
4518|GSK|A single-blind, randomized, placebo-controlled study to investigate the safety, tolerability, and potential effects on betamethasone pharmacokinetics of a co-administered infusion of the new chemical entity (NCE) in healthy female subjects.|Obstetric Labour, Premature|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=105036|nan|[C2699069]|[Retosiban]
4519|GSK|A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease|Alzheimer's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114458|http://clinicaltrials.gov/show/NCT01428453|[C2699087]|[rilapladib]
4520|GSK|A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) with Focus on Cardiac Repolarization (QTc duration) in Healthy Subjects|Malaria, Vivax|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114582|http://clinicaltrials.gov/show/NCT01928914|[C0903411]|[tafenoquine]
4553|Novartis|A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salbutamol (200 μg) and Salmeterol/Fluticasone (50/500 μg) as Active Controls|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2745|https://clinicaltrials.gov/show/NCT00669617|[C1722260]|[indacaterol]
4556|Novartis|A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)|Parkinson's Disease Dementia|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4686|https://clinicaltrials.gov/show/NCT00623103|[C0649350]|[rivastigmine]
4572|GSK|An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector that Administers Belimumab Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200339|http://clinicaltrials.gov/show/NCT02124798|[C1723401]|[belimumab]
4573|GSK|201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily with Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down from a Maintenance Therapy with RELVAR® inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201135|http://clinicaltrials.gov/show/NCT02094937|[C1948374]|[fluticasone furoate]
4574|GSK|A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis|Rhinitis, Allergic, Perennial and Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201474|http://clinicaltrials.gov/show/NCT02397915|[C1948374]|[fluticasone furoate]
4575|GSK|A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=106855|http://clinicaltrials.gov/show/NCT01563029|[C1948374]|[fluticasone furoate]
4576|GSK|An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=200301|http://clinicaltrials.gov/show/NCT02184624|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4577|GSK|A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115645|http://clinicaltrials.gov/show/NCT01978119|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4580|GSK|A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116511|http://clinicaltrials.gov/show/NCT01607385|[C5238076]|[linerixibat]
4588|GSK|An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus|Systemic Lupus Erythematosus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115919|http://clinicaltrials.gov/show/NCT01777256|[C4726763]|[Solcitinib]
4589|GSK|A multi-centre, double-blind, randomised, parallel-group, active controlled study to evaluate the efficacy, safety and tolerability of tafenoquine (SB-252263, WR238605) in subjects with Plasmodium vivax malaria.|Malaria, Vivax|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112582|http://clinicaltrials.gov/show/NCT01376167|[C0903411]|[tafenoquine]
4594|Novartis|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|Multiple Sclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15030|https://clinicaltrials.gov/show/NCT00731692|[C1699926]|[fingolimod]
4595|Novartis|A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14907|https://clinicaltrials.gov/show/NCT01782326|[C1722260, C0017970]|[indacaterol, glycopyrrolate]
4596|Novartis|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery|Cataract|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14887|https://clinicaltrials.gov/show/NCT01853072|[C0961209]|[nepafenac]
4597|Novartis|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery|Cataract|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14930|https://clinicaltrials.gov/show/NCT01872611|[C0961209]|[nepafenac]
4608|Astellas|Long-term Study of ASP1941 — Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) —|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0072|https://clinicaltrials.gov/ct2/show/NCT01316094|[C3492889]|[ipragliflozin]
4609|Astellas|Phase III Study of ASP1941 –A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus–|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0105|https://clinicaltrials.gov/ct2/show/NCT01057628|[C3492889]|[ipragliflozin]
4610|Astellas|A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0106|https://clinicaltrials.gov/ct2/show/NCT01135433|[C3492889]|[ipragliflozin]
4611|Astellas|A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0107|https://clinicaltrials.gov/ct2/show/NCT01225081|[C3492889]|[ipragliflozin]
4612|Astellas|Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an α-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an α-Glucosidase Inhibitor Alone|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0108|https://clinicaltrials.gov/ct2/show/NCT01242202|[C3492889]|[ipragliflozin]
4613|Astellas|A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Sulfonylurea in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0109|https://clinicaltrials.gov/ct2/show/NCT01242215|[C3492889]|[ipragliflozin]
4614|Astellas|Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with a Dipeptidyl Peptidase-4 Inhibitor Alone -|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0110|https://clinicaltrials.gov/ct2/show/NCT01242228|[C3492889]|[ipragliflozin]
4615|Astellas|Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with Nateglinide in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Nateglinide Alone -|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0111|https://clinicaltrials.gov/ct2/show/NCT01316107|[C3492889]|[ipragliflozin]
4616|Astellas|Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus -|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0121|https://clinicaltrials.gov/ct2/show/NCT01054092|[C3492889]|[ipragliflozin]
4617|Eisai|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures|Seizure Disorder Generalized Tonic Clonic|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01393743|[C2698764]|[perampanel]
4618|Eisai|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures|Seizure Disorder Generalized Tonic Clonic|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01393743|[C2698764]|[perampanel]
4630|GSK|A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)|Hepatitis B, Chronic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114957|http://clinicaltrials.gov/show/NCT01353742|[C0050175, C0209738]|[adefovir, lamivudine]
4631|GSK|A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116170|http://clinicaltrials.gov/show/NCT01777282|[C2607479]|[albiglutide]
4634|GSK|A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115151|http://clinicaltrials.gov/show/NCT01551758|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4635|GSK|A 24-week study to evaluate the effect of fluticasone furoate/vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol in subjects with Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113108|http://clinicaltrials.gov/show/NCT01336608|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4636|GSK|A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200820|http://clinicaltrials.gov/show/NCT02105974|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
4637|GSK|An open-label study investigating critical and overall errors following 14 days of treatment with SERETIDE Metered Dose Inhaler (EVOHALER) in adult subjects with controlled asthma currently using the SERETIDE DISKUS Inhaler|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201909|http://clinicaltrials.gov/show/NCT02416180|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4638|GSK|A randomized, double-blind, placebo-controlled, crossover study to evaluate the influence of the A118G polymorphism in the mu opioid receptor gene (OPRM1) on effects of GSK1521498 and naltrexone on physiological and behavioral markers of brain function in healthy social drinkers|Alcoholism|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116753|http://clinicaltrials.gov/show/NCT01738867|[C3253174]|[GSK-1521498]
4639|GSK|A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV|Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUC30935|nan|[C0209738]|[lamivudine]
4640|GSK|A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis|Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=NUCB4006|nan|[C0209738]|[lamivudine]
4654|Novartis|An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma|Asthma|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14396|https://clinicaltrials.gov/show/NCT00411567|[C0117996]|[fluticasone propionate]
4660|GSK|An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 with Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200229|http://clinicaltrials.gov/show/NCT02371603|[C4519188]|[daprodustat]
4661|GSK|Single-blind, randomised, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2647544 and its potential pharmacokinetic interaction with simvastatin in healthy volunteers|Alzheimer's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200592|http://clinicaltrials.gov/show/NCT01978327|[C4505911]|[GSK2647544]
4663|GSK|A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials.|Hepatitis B|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=NUCB3017|nan|[C0209738]|[lamivudine]
4664|GSK|An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment|Hepatitis B, Chronic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=NUC40040|nan|[C0209738]|[lamivudine]
4665|GSK|An Open-Label Extension Study to Study MHE100185, to Evaluate Long-term Safety, Efficacy and Optimal Dosing Frequency of 750 mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndromes|Hypereosinophilic Syndrome|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=100901|http://clinicaltrials.gov/show/NCT00097370|[C0969324]|[mepolizumab]
4666|GSK|A Multicenter, Double-blind, Placebo-controlled, Study to  Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES|Hypereosinophilic Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=100185|http://clinicaltrials.gov/show/NCT00086658|[C0969324]|[mepolizumab]
4668|GSK|A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease|Parkinson Disease|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111662|http://clinicaltrials.gov/show/NCT01485172|[C0244821]|[ropinirole]
4669|GSK|A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson’s disease|Parkinson Disease|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=111569|http://clinicaltrials.gov/show/NCT01494532|[C0244821]|[ropinirole]
4671|GSK|An open-label, randomised, cross-over, two cohort, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the delivery of salbutamol and to compare the pharmacokinetic profile with the MDI and Diskus presentations.|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200921|http://clinicaltrials.gov/show/NCT01984086|[C0001927]|[albuterol]
4687|Novartis|An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192|Carcinoma, Renal Cell|Phase 3|https://www.gsk-clinicalstudyregister.com/study/VEG107769|https://clinicaltrials.gov/show/NCT00387764|[C1831796]|[pazopanib]
4688|Novartis|Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|Alzheimer's Disease|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2255|https://clinicaltrials.gov/show/NCT00099242|[C0649350]|[rivastigmine]
4689|Novartis|A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase|Alzheimer's Disease|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6023|https://clinicaltrials.gov/show/NCT00506415|[C0649350]|[rivastigmine]
4731|GSK|Efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) two times a day compared to clindamycin (150mg) four times a day for 5-7 days in treatment of acute odontogenic infection with or without abscess|Focal Infection, Dental|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=117044|http://clinicaltrials.gov/show/NCT02141217|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
4732|GSK|A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis|Sinusitis, Acute|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117150|http://clinicaltrials.gov/show/NCT01934231|[C0002645, C0055860]|[amoxicillin, clavulanic acid]
4733|GSK|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, One-Year Study to Evaluate the Efficacy and Safety of Bupropion Hydrochloride (SR) (Sustained-Release Tablets) for the Treatment of Nicotine Dependence as an Aid to Smoking Cessation.|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40017|nan|[C0085208]|[bupropion]
4734|GSK|An open-label, single dose, randomized, two-period crossover study to investigate the bioavailability of a novel dosage form of dutasteride in healthy male subjects|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115148|http://clinicaltrials.gov/show/NCT01577693|[C0754659]|[dutasteride]
4735|GSK|A randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2330672 administration in patients with primary biliary cirrhosis (PBC) and symptoms of pruritus|Cholestasis, Intrahepatic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=117213|http://clinicaltrials.gov/show/NCT01899703|[C5238076]|[linerixibat]
4736|GSK|An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117191|http://clinicaltrials.gov/show/NCT01984775|[C4541381]|[tapinarof]
4737|GSK|A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B|Hepatitis B, Chronic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NUC20912|nan|[C0209738]|[lamivudine]
4738|GSK|A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=PKI108574|http://clinicaltrials.gov/show/NCT00569062|[C3272847]|[Losmapimod]
4739|GSK|DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a fixed combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects with COPD Who Continue To Have Symptoms on Tiotropium|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116960|http://clinicaltrials.gov/show/NCT01899742|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
4740|GSK|A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza|Influenza, Human|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114373|http://clinicaltrials.gov/show/NCT01231620|[C0216660]|[zanamivir]
4749|Novartis|A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44|Alzheimer's Disease|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7723|https://clinicaltrials.gov/show/NCT00948766|[C0649350]|[rivastigmine]
4753|Novartis|A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia|Osteopenia|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2621|https://clinicaltrials.gov/show/NCT00132808|[C0257685]|[zoledronic acid]
4774|GSK|An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fasting conditions|Ulcers, Duodenal and Gastric|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116480|http://clinicaltrials.gov/show/NCT01847404|[C0004057, C0081876]|[aspirin, pantoprazole]
4775|GSK|An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets by Bayer vital GmbH, and Protium® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fed conditions|Ulcers, Duodenal and Gastric|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116498|http://clinicaltrials.gov/show/NCT01847417|[C0004057, C0081876]|[aspirin, pantoprazole]
4776|GSK|A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure|Heart failure, Congestive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112670|http://clinicaltrials.gov/show/NCT01357850|[C2607479]|[albiglutide]
4777|GSK|An open-label, randomized, single sequence, two period study to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of GSK962040 in healthy volunteers|Gastroparesis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112648|http://clinicaltrials.gov/show/NCT01039974|[C4519144]|[Camicinal]
4778|GSK|A double blind randomised placebo controlled two way cross over study to determine the effect of GSK962040 on oesophageal function and gastric emptying in healthy male volunteers.|Gastrointestinal Motility|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114639|http://clinicaltrials.gov/show/NCT01366560|[C4519144]|[Camicinal]
4779|GSK|A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116099|http://clinicaltrials.gov/show/NCT02019719|[C4519188]|[daprodustat]
4781|GSK|An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).|Atherosclerosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115679|http://clinicaltrials.gov/show/NCT01852565|[C2348075]|[darapladib]
4782|GSK|A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115646|http://clinicaltrials.gov/show/NCT01978145|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4783|GSK|A comparative bioavailability study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Fluticasone propionate and Salmeterol delivered by Fluticasone propionate/ Salmeterol combination in a capsule-based inhaler and a multi-dose dry powder inhaler, in moderate asthma patients and moderate to severe Chronic obstructive pulmonary disease (COPD) patients.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114334|http://clinicaltrials.gov/show/NCT01494610|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4784|GSK|A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects with Hepatocellular Carcinoma|Carcinoma, Hepatocellular|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111645|http://clinicaltrials.gov/show/NCT00920192|[C2973987]|[Foretinib]
4785|GSK|An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115774|http://clinicaltrials.gov/show/NCT02000765|[C4309999]|[gepotidacin]
4786|GSK|A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115775|http://clinicaltrials.gov/show/NCT02257398|[C4309999]|[gepotidacin]
4787|GSK|A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction with Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117349|http://clinicaltrials.gov/show/NCT02045849|[C4309999]|[gepotidacin]
4788|GSK|A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116266|http://clinicaltrials.gov/show/NCT01818011|[C3711860]|[GSK1322322]
4790|GSK|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer|Lung Cancer, Non-Small Cell|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=109493|http://clinicaltrials.gov/show/NCT00480025|[C2984506]|[Immunotherapeutic GSK1572932A]
4791|GSK|A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects who Smoke Cigarettes|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116617|http://clinicaltrials.gov/show/NCT01762878|[C5197976]|[Nemiralisib]
4793|GSK|Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects|Dermatitis, Atopic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200920|http://clinicaltrials.gov/show/NCT02637206|[C4541381]|[tapinarof]
4794|GSK|A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine|Hepatitis B, Chronic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NUC20904|nan|[C0209738]|[lamivudine]
4795|GSK|A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904|Hepatitis B|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=NUC20917|nan|[C0209738]|[lamivudine]
4796|GSK|A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint|Hepatitis B, Chronic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=NUC40021|nan|[C0209738]|[lamivudine]
4798|GSK|Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients|Cerebrovascular Accident|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=104615|http://clinicaltrials.gov/show/NCT01808261|[C4726669]|[refanezumab]
4799|GSK|A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg when Co-administered with the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP)|Malaria, Vivax|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200951|http://clinicaltrials.gov/show/NCT02184637|[C0903411]|[tafenoquine]
4800|GSK|A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201314|http://clinicaltrials.gov/show/NCT02257372|[C3709474]|[umeclidinium bromide]
4810|Novartis|A multicenter, double-blind, randomized, placebo-controlled, crossover study evaluating the efficacy and safety of methylphenidate hydrocholoride in female adolescents diagnosed with attention deficit/hyperactivity disorder|Attention deficit hyperactivity disorder (ADHD)|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1624|Not available|[C0025810]|[methylphenidate]
4829|Astellas|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors|Rheumatoid Arthritis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=CDP870-275-11-001|https://clinicaltrials.gov/ct2/show/NCT01451203|[C1872109]|[certolizumab pegol]
4831|Astellas|Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 2 Diabetes Mellitus -|Diabetes Mellitus, Type 2|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0131|https://clinicaltrials.gov/ct2/show/NCT02175784|[C3492889]|[ipragliflozin]
4832|Astellas|A Phase 3b, Open-label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)|Myocardial Perfusion Imaging|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-3004|https://clinicaltrials.gov/ct2/show/NCT01618669|[C1698215]|[regadenoson]
4876|GSK|Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects with Androgenetic Alopecia|Alopecia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114264|http://clinicaltrials.gov/show/NCT01831791|[C0754659]|[dutasteride]
4877|GSK|A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid Tumors|Cancer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113517|http://clinicaltrials.gov/show/NCT01138033|[C2981865]|[GSK2256098]
4878|GSK|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200862|http://clinicaltrials.gov/show/NCT02281318|[C0969324]|[mepolizumab]
4879|GSK|Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects|Healthy Subjects|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=112684|http://clinicaltrials.gov/show/NCT00964106|[C0289313]|[rosiglitazone]
4880|GSK|A study in patients with Crohn's Disease to evaluate the effect of AVANDIA™ on inflammatory activity mediated by monocytes/macrophages.|Crohn's Disease|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=999910/150|nan|[C0289313]|[rosiglitazone]
4899|Novartis|A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis|Multiple Sclerosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3963|https://clinicaltrials.gov/show/NCT00537082|[C1699926]|[fingolimod]
4900|Novartis|An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis|Multiple Sclerosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8343|https://clinicaltrials.gov/show/NCT00670449|[C1699926]|[fingolimod]
4907|Astellas|A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects with Overactive Bladder (OAB)|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1001|https://clinicaltrials.gov/ct2/show/NCT02138747|[C2983812]|[mirabegron]
4908|Astellas|A multicenter, 2-arm, randomized, open-label clinical study investigating renal function in an Advagraf®-based immunosuppressive regimen with or without sirolimus in kidney transplant patients|Transplantation, Kidney|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1212|https://clinicaltrials.gov/ct2/show/NCT01363752|[C0085149]|[tacrolimus]
4909|Astellas|Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids – A Multicenter, Two Arm, Randomized, Open Label Clinical Study|Transplantation, Kidney|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1211|https://clinicaltrials.gov/ct2/show/NCT01304836|[C0085149]|[tacrolimus]
4913|GSK|A multicenter, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SeretideTM) at a dose of 50/100µg twice daily and fluticasone propionate (FlixotideTM) at a dose of 200µg twice daily, both delivered via a dry powder inhaler (DiskusTM) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM104926|http://clinicaltrials.gov/show/NCT00353873|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4914|GSK|A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections|Infections, Bacterial|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116704|http://clinicaltrials.gov/show/NCT02045797|[C4309999]|[gepotidacin]
4916|GSK|A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers|Alzheimer's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116698|http://clinicaltrials.gov/show/NCT01702467|[C4505911]|[GSK2647544]
4918|GSK|Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study|Epilepsy|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=200776|http://clinicaltrials.gov/show/NCT02100644|[C0064636]|[lamotrigine]
4919|GSK|A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/274|nan|[C0070122]|[paroxetine]
4920|GSK|Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions|Gastrointestinal Diseases|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201527|http://clinicaltrials.gov/show/NCT02446483|[C0378482]|[rabeprazole]
4921|GSK|Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Raperazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fed conditions|Gastrointestinal Diseases|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201528|http://clinicaltrials.gov/show/NCT02605395|[C0378482]|[rabeprazole]
4922|GSK|A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-304|http://clinicaltrials.gov/show/NCT00310388|[C0530684]|[ezogabine]
4923|GSK|A Study ROP116991, Clinical Evaluation of 18 to 24mg/day Ropinirole CR for Parkinson’s disease.|Parkinson Disease|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116991|http://clinicaltrials.gov/show/NCT01929317|[C0244821]|[ropinirole]
4952|GSK|An Open-label, Randomized, Single Dose, three-way Crossover study to determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg tablets in Healthy Male Subjects in the fed and fasted states|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117057|http://clinicaltrials.gov/show/NCT02184585|[C0754659]|[dutasteride]
4953|GSK|An Open-label, Randomized, Single Dose, Two-way Crossover study to Determine the Bioavailability of one Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of one Dutasteride 0.5 mg capsule and one Tamsulosin Hydrochloride 0.2 mg tablet in Healthy Male Subjects in the Fed and Fasted States|Prostatic Hyperplasia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201897|http://clinicaltrials.gov/show/NCT02509104|[C0754659]|[dutasteride]
4954|GSK|An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects|Obesity|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200016|http://clinicaltrials.gov/show/NCT01857895|[C0167117]|[exenatide]
4955|GSK|A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=107112|http://clinicaltrials.gov/show/NCT02502734|[C1948374]|[fluticasone furoate]
4956|GSK|A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (with an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning via a Dry Powder Inhaler with Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily via a Reservoir Inhaler in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116853|http://clinicaltrials.gov/show/NCT02345161|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
4957|GSK|Steroid-sparing management of the salmeterol/fluticasone 50/100µg b.i.d. combination compared to fluticasone 200µg b.i.d. in children and adolescents with moderate asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=102318|http://clinicaltrials.gov/show/NCT00315744|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
4962|GSK|GSK2132231A Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with unresectable metastatic melanoma|Melanoma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111476|http://clinicaltrials.gov/show/NCT00942162|[C4053638]|[MAGE-A3-specific Immunotherapeutic GSK 2132231A]
4966|GSK|A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma|Carcinoma, Hepatocellular|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200149|http://clinicaltrials.gov/show/NCT01258608|[C1665688]|[mapatumumab]
4967|GSK|TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)|Diabetes Mellitus, Type 1|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115493|http://clinicaltrials.gov/show/NCT00451321|[C2935224]|[otelixizumab]
4968|GSK|A single centre, single blind study to investigate the safety, tolerability and pharmacokinetics of single doses of oxytocin (GR121619) administered via an inhaled route in healthy female volunteers|Postpartum Hemorrhage|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201558|http://clinicaltrials.gov/show/NCT02542813|[C0030095]|[oxytocin]
4971|GSK|A multicenter, open-label Phase I/II trial of the safety and efficacy of the dHER2 recombinant protein combined with immunological adjuvant AS15 in patients with metastatic breast cancer overexpressing HER2/neu|Neoplasms, Breast|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=100633|http://clinicaltrials.gov/show/NCT00140738|[C5576950]|[SB719125]
4972|GSK|An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=112266|http://clinicaltrials.gov/show/NCT01037114|[C0593953]|[Twinrix]
4973|GSK|An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which healthy adults were vaccinated with Twinrix Adult following a three-dose schedule.|Hepatitis A; Hepatitis B|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=112267|http://clinicaltrials.gov/show/NCT01000324|[C0593953]|[Twinrix]
4993|GSK|An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 16mg tablet formulation of candesartan cilexetil (GW615775) relative to one 16mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions|Hypertension|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201011|http://clinicaltrials.gov/show/NCT02006602|[C0717550]|[candesartan]
4994|GSK|An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions|Respiratory Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201713|http://clinicaltrials.gov/show/NCT02254447|[C0717550]|[candesartan]
4996|GSK|A randomized, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and effect on allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies|Mild Asthma and Allergic Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116958|http://clinicaltrials.gov/show/NCT01788813|[C4079591]|[GSK2245035]
4997|GSK|A single-centre, follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects who completed treatment in study TL7116958 in 2014|Asthma and Rhinitis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=204509|http://clinicaltrials.gov/show/NCT02446613|[C4079591]|[GSK2245035]
4999|GSK|Efficacy and safety of long-term inhaled salmeterol and beclomethasone dipropionate in corticosteroid-naïve children with mild to moderate, chronic, stable asthma.|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40065|nan|[C0073992]|[salmeterol]
5006|Novartis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis|Ankylosing Spondylitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14387|https://clinicaltrials.gov/show/NCT01358175|[C3179547]|[secukinumab]
5021|GSK|A randomized, double-blind, single-dose, placebo controlled, 2-way cross-over study evaluating effect of albiglutide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201834|http://clinicaltrials.gov/show/NCT02496221|[C2607479]|[albiglutide]
5022|GSK|A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation|Smoking Cessation|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A405|nan|[C0085208]|[bupropion]
5023|GSK|A multicenter dose response evaluation of Wellbutrin† (Bupropion hydrochloride) sustained release versus placebo as an aid to smoking cessation|Smoking Cessation|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A403|nan|[C0085208]|[bupropion]
5024|GSK|A multicenter comparison of bupropion hydrochloride sustained-release versus placebo for the prevention of relapse in patients who quit smoking while taking bupropion sustained-release|Smoking Cessation|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A406|nan|[C0085208]|[bupropion]
5025|GSK|A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation|Smoking Cessation|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=SMK20001|nan|[C0085208]|[bupropion]
5026|GSK|A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor|Smoking Cessation|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB 30011|nan|[C0085208]|[bupropion]
5027|GSK|A multi-centre, randomised, double-blind, placebo controlled, 6 month study to evaluate the efficacy and tolerability of bupropion hydrochloride sustained release tablets for the treatment of nicotine dependence as an aid to smoking cessation in a healthcare professionals and hospital staff population at hospitals in Denmark|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB30009|nan|[C0085208]|[bupropion]
5028|GSK|A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40001|nan|[C0085208]|[bupropion]
5029|GSK|A multi-centre, randomised, double-blind, placebo-controlled, one-year study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in population of healthcare professionals|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40011|nan|[C0085208]|[bupropion]
5030|GSK|Evaluation of efficacy of safety of ZybanTM (bupropion hydrochloride extended release tablet) in smoking cessation aid in nicotine-dependent patients. Multicentre, randomized, double blind, placebo-controlled study, 6 months length|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYBF4001|nan|[C0085208]|[bupropion]
5034|GSK|GSK2302032A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer|Lung Cancer, Non-Small Cell|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116389|http://clinicaltrials.gov/show/NCT01853878|[C3896844]|[Anti-PRAME Immunotherapeutic GSK2302032A]
5036|GSK|A Two-Part, Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis|Polyps, Nasal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111782|http://clinicaltrials.gov/show/NCT01362244|[C0969324]|[mepolizumab]
5037|GSK|An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older|Herpes Zoster|Phase 3|nan|nan|[C0249458]|[valacyclovir]
5038|GSK|A multicenter, double-blind, placebo-controlled trial evaluating oral 256U87 for the treatment of herpes zoster in immunocompetent patients less than 50 years old|Herpes Zoster|Phase 3|nan|nan|[C0249458]|[valacyclovir]
5039|ViiV|A DOUBLE BLIND (3rd PARTY OPEN), PLACEBO CONTROLLED, DOSE ESCALATING, CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF SINGLE ORAL DOSES (SOLUTION) OF UK-427,857 IN HEALTHY MALE VOLUNTEERS IN THE FED AND FASTED STATES|Infection, Human Immunodeficiency Virus|Phase 1|nan|nan|[C1667052]|[maraviroc]
5040|ViiV|A DOUBLE BLIND (3RD PARTY OPEN), PARALLEL GROUP, PLACEBO CONTROLLED SINGLE DOSE AND MULTIPLE ESCALATING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND PHARMACOKINETICS OF UK-427,857 IN HEALTHY MALE SUBJECTS|Infection, Human Immunodeficiency Virus|Phase 1|nan|nan|[C1667052]|[maraviroc]
5047|Astellas|A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)|Coronary Artery Disease|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=3606-CL-2001|https://clinicaltrials.gov/ct2/show/NCT01334918|[C1698215]|[regadenoson]
5048|Eisai|A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma|Soft Tissue Sarcoma|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01327885|[C2608038]|[eribulin mesylate]
5049|Eisai|Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma|Soft Tissue Sarcoma|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT00413192|[C2608038]|[eribulin mesylate]
5050|Eisai|An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma|Soft Tissue Sarcoma|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT01458249|[C2608038]|[eribulin mesylate]
5051|Eisai|An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment|Metastatic Renal Cell Carcinoma|Phase 1|nan|https://clinicaltrials.gov/ct2/show/NCT01136733|[C2986924]|[lenvatinib]
5052|Eisai|An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment|Metastatic Renal Cell Carcinoma|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT01136733|[C2986924]|[lenvatinib]
5053|Eisai|A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome|Lennox-Gastaut Syndrome|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01405053|[C0213404]|[rufinamide]
5088|GSK|Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects|Acne Vulgaris|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201884|http://clinicaltrials.gov/show/NCT02557399|[C0005088, C0055881]|[benzoyl peroxide, clindamycin phosphate]
5089|GSK|A multi-centre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with Chronic Obstructive Pulmonary Disease.|Smoking Cessation|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=ZYB40030|nan|[C0085208]|[bupropion]
5090|GSK|A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402)|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ZYBAKIA402|nan|[C0085208]|[bupropion]
5091|GSK|A Single Centre, Open-label, 5-Period, Cross over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201037|http://clinicaltrials.gov/show/NCT02453022|[C4519256]|[danirixin]
5092|GSK|A randomized, open-label, parallel-group study, to assess the pharmocodynamic effect on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner, of 0.5mg and 3.5mg dutasteride administered orally once daily, for one year in men with symptomatic benign prostatic hyperplasia and during a two month period between baseline and radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=104274|http://clinicaltrials.gov/show/NCT00375765|[C0754659]|[dutasteride]
5093|GSK|An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V)|Alopecia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=106377|http://clinicaltrials.gov/show/NCT00441116|[C0754659]|[dutasteride]
5094|GSK|A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia|Alopecia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200209|http://clinicaltrials.gov/show/NCT02014584|[C0754659]|[dutasteride]
5095|GSK|A randomized, double-blind, placebo-controlled, six-month parallel-group study to assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH), followed by a 12-month open-label treatment phase|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ARI108898|http://clinicaltrials.gov/show/NCT00527605|[C0754659]|[dutasteride]
5096|GSK|A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemical Failure (PSA increase) after Radical Therapy with Curative Intent|Neoplasms, Prostate|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=ARI109924|http://clinicaltrials.gov/show/NCT00558363|[C0754659]|[dutasteride]
5097|GSK|A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism|Hypogonadism, Male|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=TDC106220|http://clinicaltrials.gov/show/NCT00398580|[C0754659]|[dutasteride]
5098|GSK|A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin (0.2mg) with tamsulosin (0.2mg) monotherapy, administered once daily for 2 years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia|Prostatic Hyperplasia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114265|http://clinicaltrials.gov/show/NCT02058368|[C0754659, C0257343]|[dutasteride, tamsulosin]
5099|GSK|A pivotal, open-label trial assessing the safety and efficacy of the 0.5 mg dutasteride and 0.4 mg tamsulosin combination once daily for six months in patients with benign prostatic hyperplasia|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114785|http://clinicaltrials.gov/show/NCT01673490|[C0754659, C0257343]|[dutasteride, tamsulosin]
5100|GSK|A prospective study of sexual function in sexually active men treated for BPH|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116115|http://clinicaltrials.gov/show/NCT01777269|[C0754659, C0257343]|[dutasteride, tamsulosin]
5101|GSK|Comparative efficacy of Dutasteride plus tamsulosin with lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men with moderately symptomatic benign prostatic hyperplasia and prostate enlargement.|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=114615|http://clinicaltrials.gov/show/NCT01294592|[C0754659, C0257343]|[dutasteride, tamsulosin]
5103|GSK|An open-label, randomised, cross-over, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) with four different formulations for the delivery of fluticasone fuorate and to compare the pharmacokinetic profile with the fluticasone fuorate ELLIPTA presentation|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200939|http://clinicaltrials.gov/show/NCT02218723|[C1948374]|[fluticasone furoate]
5104|GSK|200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200699|http://clinicaltrials.gov/show/NCT02164539|[C1948374, C3709474]|[fluticasone furoate, umeclidinium bromide]
5107|GSK|Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in patients with metastatic melanoma|Melanoma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113173|http://clinicaltrials.gov/show/NCT01149343|[C2985195]|[Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A]
5108|GSK|A Single Dose First in Human Study of GSK2398852 Co-Administered with GSK2315698 in Patients with Systemic Amyloidosis|Amyloidosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115570|http://clinicaltrials.gov/show/NCT01777243|[C4727783, C4727784]|[GSK2315698, GSK-2398852]
5110|GSK|A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects|Cachexia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200181|http://clinicaltrials.gov/show/NCT02045940|[C4705766]|[GSK2881078]
5122|GSK|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) When Added to Their Usual Treatment Regimen|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SMS40026|nan|[C0073992]|[salmeterol]
14488|GSK|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112341|http://clinicaltrials.gov/show/NCT01484496|[C1723401]|[belimumab]
14491|GSK|A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of Salmeterol/Fluticasone propionate combination product (Seretide®) 50/100 mcg with Fluticasone propionate (Flixotide® ) 200 mcg, both delivered twice daily via the DISKUS inhaler, in the treatment of children aged 6-12 years with symptomatic asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=SAM101667|http://clinicaltrials.gov/show/NCT00197106|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
14492|GSK|A Phase 1, Randomized, Double-Blind (sponsor open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (anti-CCL20 monoclonal antibody) in Healthy Male Volunteers|Colitis, Ulcerative|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200784|http://clinicaltrials.gov/show/NCT01984047|[C4705543]|[GSK3050002]
14493|GSK|Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin|Embryo Transfer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116828|http://clinicaltrials.gov/show/NCT02213029|[C3274566]|[epelsiban]
14494|GSK|A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency|Cancer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115717|http://clinicaltrials.gov/show/NCT01458067|[C3827123]|[GSK2636771]
14495|GSK|201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201496|http://clinicaltrials.gov/show/NCT02299375|[C3272847]|[Losmapimod]
14496|GSK|A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects with Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium vivax Malaria Patients with Glucose-6-phosphate Dehydrogenase Deficiency|Malaria|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=110027|http://clinicaltrials.gov/show/NCT01205178|[C0903411]|[tafenoquine]
14497|GSK|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Measure the Efficacy and Safety of Nicotine Lozenges (2 mg and 4 mg) in Smoking Cessation|Smoking Cessation|Phase 3|nan|nan|[C0068722]|[nicotine polacrilex]
14526|GSK|Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 3 and 4-year-old children|acellular pertussis; Diphtheria; Poliomyelitis; Tetanus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111763|http://clinicaltrials.gov/show/NCT01245049|[C5233092, C0305062, C0982332, C0718003]|[Reduced cysteine content, 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', 'Poliovirus Vaccine, Inactivated']
14530|GSK|A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113635|http://clinicaltrials.gov/show/NCT02293148|[C4519188]|[daprodustat]
14531|GSK|A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women|Obstetric Labour, Premature|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117168|http://clinicaltrials.gov/show/NCT02377414|[C2699069]|[Retosiban]
14532|GSK|A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (belimumab; HGS1006) on Vaccine Responses in Subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115470|http://clinicaltrials.gov/show/NCT01597492|[C1723401]|[belimumab]
14533|GSK|A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults|Hepatitis C, Chronic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116973|http://clinicaltrials.gov/show/NCT01879462|[C5565730]|[GSK2878175]
14534|GSK|A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects with Chronic Hepatitis C.|Hepatitis C, Chronic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116976|http://clinicaltrials.gov/show/NCT02014571|[C5565730]|[GSK2878175]
14535|GSK|Study MEA117106: Mepolizumab vs. placebo as add-on treatment for frequently exacerbating COPD patients|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117106|http://clinicaltrials.gov/show/NCT02105948|[C0969324]|[mepolizumab]
14536|GSK|Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117113|http://clinicaltrials.gov/show/NCT02105961|[C0969324]|[mepolizumab]
14537|GSK|A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115150|http://clinicaltrials.gov/show/NCT01706198|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
14539|GSK|A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=204990|http://clinicaltrials.gov/show/NCT02799784|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
14540|GSK|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects with COPD|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201317|http://clinicaltrials.gov/show/NCT02275052|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
14542|GSK|A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination with Methotrexate Therapy, in Japanese Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201789|http://clinicaltrials.gov/show/NCT03028467|[C4731002]|[Otilimab]
14543|GSK|An open-label study to evaluate the preference attributes of the ELLIPTA™ dry powder inhaler (DPI) compared to the HandiHaler™ DPI in subjects with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=204983|http://clinicaltrials.gov/show/NCT02786927|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
14544|GSK|A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects with Primary Axillary Hyperhidrosis|Hyperhidrosis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=202093|http://clinicaltrials.gov/show/NCT02563899|[C3709474]|[umeclidinium bromide]
14545|GSK|A multicenter, randomized, single blind, active controlled, parallel group study to determine efficacy and safety of nebulized fluticasone propionate 1mg BID compared with nebulized budesonide 2mg BID administered for 12 weeks in Chinese adult and adolescent patients with severe persistent asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114219|http://clinicaltrials.gov/show/NCT01687283|[C0082607]|[fluticasone]
14546|GSK|An open-label, fixed sequence study to evaluate pharmacokinetics, safety and tolerability of single and repeated dose of extended-release bupropion hydrochloride (bupropion XL) tablets 150 mg and 300 mg once daily in Chinese healthy volunteers|Depressive Disorder, Major|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114883|http://clinicaltrials.gov/show/NCT02698553|[C0085208]|[bupropion]
14548|GSK|A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200812|http://clinicaltrials.gov/show/NCT02729051|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
14549|GSK|An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 monoclonal Antibody (mAb) GSK2849330 and Characterize its Dose-receptor Occupancy Relationship in Subjects with Advanced HER3-Positive Solid Tumors|Cancer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200980|http://clinicaltrials.gov/show/NCT02345174|[C3827121]|[GSK2849330]
14550|GSK|A Phase 1 double-blind, randomised, placebo-controlled, dose escalating study to assess the safety and tolerability of single and multiple oral doses of CHR-5154 and the effect of the fasted and fed state on pharmacokinetics of CHR-5154 and CHR-5426 in healthy male volunteers|Arthritis, Rheumatoid|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201302|http://clinicaltrials.gov/show/NCT01934101|[C5139715]|[GSK-3117391]
14551|GSK|A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban|Embryo Transfer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201691|http://clinicaltrials.gov/show/NCT02257359|[C3274566]|[epelsiban]
14552|GSK|A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban|Embryo Transfer|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201752|http://clinicaltrials.gov/show/NCT02703181|[C3274566]|[epelsiban]
14554|GSK|A Microdose Study to Describe the Intravenous Pharmacokinetics of GSK3191607 in Healthy Male Subjects Following Administration of [14C]-GSK3191607|Malaria, Falciparum|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204853|http://clinicaltrials.gov/show/NCT02737007|[C5882503]|[GSK3191607]
14556|GSK|A randomised, open, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).|Rhinitis, Allergic, Seasonal|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=IPR109764|http://clinicaltrials.gov/show/NCT00464568|[C2934026]|[GSK-256066]
14557|GSK|Single-blind, placebo-controlled, randomized study testing single ascending doses of GSK369796 in healthy subjects|Malaria|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=ISO105774|http://clinicaltrials.gov/show/NCT00675064|[C3884469]|[GSK 369796]
14558|GSK|A Double-Blind (sponsor unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response using Sputum Biomarkers|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115119|http://clinicaltrials.gov/show/NCT02130635|[C5197976]|[Nemiralisib]
14559|GSK|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects|Urologic Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116897|http://clinicaltrials.gov/show/NCT02052713|[C0754659]|[dutasteride]
14560|GSK|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects|Urologic Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116108|http://clinicaltrials.gov/show/NCT02058576|[C0754659]|[dutasteride]
14561|GSK|Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in patients with resectable Non-Small Cell Lung Cancer|Lung Cancer, Non-Small Cell|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=113174|http://clinicaltrials.gov/show/NCT01159964|[C3896844]|[Anti-PRAME Immunotherapeutic GSK2302032A]
14567|Novartis|Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer|Breast Cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14105|https://www.clinicaltrials.gov/ct2/show/NCT00248170?term=CFEM345D2411&rank=1|[C0246421]|[letrozole]
14569|Novartis|A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research|Metastatic Breast Cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13063|https://www.clinicaltrials.gov/ct2/show/NCT01626222?term=CRAD001JDE49&rank=1|[C0541315]|[everolimus]
14570|Novartis|A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane|Advanced Breast Cancer|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15368|https://www.clinicaltrials.gov/ct2/show/NCT02069093?term=CRAD001JUS226&rank=1|[C0541315]|[everolimus]
14572|Astellas|A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain|Peripheral Neuropathic Pain|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=8477-CL-0020|https://clinicaltrials.gov/ct2/show/NCT02065349|[C5198241]|[ASP8477]
14583|ViiV|A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19533|http://clinicaltrials.gov/show/NCT01199731|[C4550352]|[Fosdevirine]
14584|ViiV|Phase 2b study to select a once daily oral dose of GSK2248761 administered with tenofovir/emtricitabine or abacavir/lamivudine in HIV-1 infected antiretroviral therapy naive adult subjects|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19534|http://clinicaltrials.gov/show/NCT01231555|[C4550352]|[Fosdevirine]
14587|Astellas|A randomized, double-blind, double-dummy, placebo-controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10 mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity|Neurogenic detrusor overactivity|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=905-EC-005|https://clinicaltrials.gov/ct2/show/NCT00629642|[C1509436]|[solifenacin succinate]
16026|GSK|A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia|Sleep Initiation and Maintenance Disorders|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=OXS107714|http://clinicaltrials.gov/show/NCT00426816|[C3180886]|[SB-649868]
16027|GSK|A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center study to Evaluate the Dose Response Relationship of GSK1278863 over the first 4 weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 over 24 weeks in Hemodialysis-Dependent Subjects with Anemia associated with Chronic Kidney Disease who Switch from Recombinant Human Erythropoietin|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113633|http://clinicaltrials.gov/show/NCT01977482|[C4519188]|[daprodustat]
16029|GSK|A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum|Smoking Cessation|Phase 2|nan|http://clinicaltrials.gov/show/NCT01476202|[C0028040]|[nicotine]
16038|GSK|GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma|Melanoma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=111482|http://clinicaltrials.gov/show/NCT00796445|[C4053638]|[MAGE-A3-specific Immunotherapeutic GSK 2132231A]
16043|GSK|Clinical activity, safety and immunogenic properties of cancer immunotherapeutic GSK2132231A in patients with unresectable and progressive metastatic cutaneous melanoma|Melanoma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111473|http://clinicaltrials.gov/show/NCT00896480|[C4053638]|[MAGE-A3-specific Immunotherapeutic GSK 2132231A]
16047|GSK|An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects with Pulmonary Arterial Hypertension (PAH)|Cardiovascular Disease|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201614|http://clinicaltrials.gov/show/NCT02705807|[C0033567]|[epoprostenol]
16058|ViiV|A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination with the Abacavir/Lamivudine Fixed Dose Combination Tablet over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19559|http://clinicaltrials.gov/show/NCT01499199|[C3253985]|[dolutegravir]
16059|ViiV|A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo over 7 Days in HIV-1-infected Subjects with RAL/ELV resistance, Followed by an Open-label Phase with an Optimized Background Regimen|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19567|http://clinicaltrials.gov/show/NCT01568892|[C3253985]|[dolutegravir]
16066|GSK|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in adult Acute Myeloid Leukemia patients with a suboptimal clinical response to induction chemotherapy|Leukaemia, Myelocytic, Acute|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111727|http://clinicaltrials.gov/show/NCT01051063|[C2700264]|[WT1-A10/AS01B Immunotherapeutic GSK2130579A]
16067|GSK|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as post-consolidation therapy in adult patients with Acute Myeloid Leukemia|Leukaemia, Myelocytic, Acute|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=111444|http://clinicaltrials.gov/show/NCT00725283|[C2700264]|[WT1-A10/AS01B Immunotherapeutic GSK2130579A]
16070|GSK|A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586184 following a single dose of 800mg and repeat oral tablet doses of 800mg b.d and the effect of food and gender on the pharmacokinetics of oralGSK2586184 in healthy subjects|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116439|http://clinicaltrials.gov/show/NCT01687309|[C4726763]|[Solcitinib]
16071|GSK|A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir after Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults|Influenza, Human|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117104|http://clinicaltrials.gov/show/NCT02377401|[C0216660]|[zanamivir]
16072|GSK|A comparison of the effects of AVANDIA® on arterial stiffness in obese subjects and healthy non-obese control subjects|Insulin Resistance|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=999910/189|nan|[C0289313]|[rosiglitazone]
16073|GSK|A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116855|http://clinicaltrials.gov/show/NCT02164513|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
16074|GSK|A Multicenter, Double–Blind, Placebo–Controlled, Flexible Dose (100–400mg) 10 Week Evaluation Of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Bipolar Disorder|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCAA2010|nan|[C0064636]|[lamotrigine]
16075|GSK|A Multicenter, Double–Blind, Placebo–Controlled, Fixed Dose (50 or 200mg per day) 7 Week Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar Disorder|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=SCAB2001|nan|[C0064636]|[lamotrigine]
16107|GSK|Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in association with chemotherapy in patients with unresectable and progressive metastatic cutaneous melanoma|Melanoma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=111714|http://clinicaltrials.gov/show/NCT00849875|[C4053638]|[MAGE-A3-specific Immunotherapeutic GSK 2132231A]
16116|GSK|A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease exhibiting delayed gastric emptying|Gastroparesis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=115816|http://clinicaltrials.gov/show/NCT01602549|[C4519144]|[Camicinal]
16117|GSK|A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically applied GSK2894512 Cream in Subjects with Atopic Dermatitis|Dermatitis, Atopic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201851|http://clinicaltrials.gov/show/NCT02466152|[C4541381]|[tapinarof]
16118|GSK|A FTIH study with GSK3008348 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis|Idiopathic Pulmonary Fibrosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200262|http://clinicaltrials.gov/show/NCT02612051|[C4742753]|[GSK3008348]
16119|GSK|A randomized, open-label, single-period, parallel-group study in healthy subjects to determine the effects of dissolution profile on the pharmacokinetics (via both venous and peripheral micro-samples) of single oral 300 mg doses of Tafenoquine (SB-252263) tablets + 30 mg Tafenoquine stable isotope labelled (SIL) solution|Malaria, Vivax|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201780|http://clinicaltrials.gov/show/NCT02751294|[C0903411]|[tafenoquine]
16120|GSK|A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test|Psoriasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201465|http://clinicaltrials.gov/show/NCT02548052|[C5227418]|[GSK2981278]
16128|Novartis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer|Breast Cancer|Phase 3|nan|https://www.clinicaltrials.gov/ct2/show/NCT00073528?term=EGF30008&rank=1|[C1506770]|[lapatinib]
16139|Astellas|A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis|Invasive Candidiasis|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=9463-CL-2101|https://clinicaltrials.gov/ct2/show/NCT00608335|[C1120386]|[micafungin]
16153|Novartis|Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)|Breast Neoplasms|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5783|https://www.clinicaltrials.gov/ct2/show/NCT00375752?term=CZOL446+GDE19&rank=1|[C0257685]|[zoledronic acid]
16158|Novartis|A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma|Renal cell carcinoma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15450|https://www.clinicaltrials.gov/ct2/show/NCT01064310?term=NCT01064310&rank=1|[C1831796]|[pazopanib]
16159|Novartis|A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole|Breast Cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6843|https://www.clinicaltrials.gov/ct2/show/NCT00863655?term=CRAD001Y2301&rank=1|[C0541315]|[everolimus]
16160|Novartis|A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma|Renal cell carcinoma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15450|https://www.clinicaltrials.gov/ct2/show/study/NCT01064310?term=113046&rank=1|[C1831796]|[pazopanib]
19523|Novartis|A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP|Idiopathic Thrombocytopenic Purpura|Phase 3|nan|https://www.clinicaltrials.gov/ct2/show/NCT01520909?term=115450&rank=2|[C1831905]|[eltrombopag]
19531|GSK|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF MELOXICAM GSK 15 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND MOBIC® 15 MG TABLETS OF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BINGER STR.173, 5521 INGELHEIM AM RHEIN, GERMANY, IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FED CONDITION.|Arthritis, Rheumatoid|nan|https://www.gsk-studyregister.com/en/trial-details/?id=117176|http://clinicaltrials.gov/show/NCT01750931|[C0083381]|[meloxicam]
19532|GSK|A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis|Skin Diseases|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=117291|http://clinicaltrials.gov/show/NCT01915914|[C0117996]|[fluticasone propionate]
19533|GSK|NUTRItional Adequacy Therapeutic Enhancement in the critically ill: A randomized double blind, placebo-controlled trial of the motilin receptor agonist GSK962040. The NUTRIATE Study|Gastroparesis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113445|http://clinicaltrials.gov/show/NCT01934192|[C4519144]|[Camicinal]
19534|GSK|A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae|Gonorrhea|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116576|http://clinicaltrials.gov/show/NCT02294682|[C4309999]|[gepotidacin]
19536|GSK|A randomized, open-label, cross-over, placebo-device study investigating critical and over all errors, training/teaching time, and preference attributes of the ELLIPTA dry powder Inhaler (DPI) as compared to HANDIHALER DPI used in combination with either DISKUS DPI or TURBUHALER DPI, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=206215|http://clinicaltrials.gov/show/NCT02982187|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
19537|GSK|A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler ELLIPTA™ compared with usual ICS/LABA maintenance therapy delivered by Dry Powder Inhaler in subjects with Persistent Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116492|http://clinicaltrials.gov/show/NCT02446418|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19538|GSK|BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation|Transplantation, Organ|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114424|http://clinicaltrials.gov/show/NCT01536379|[C1723401]|[belimumab]
19539|GSK|An open-label study to evaluate the pharmacokinetics, safety and tolerability of repeat dosing lamotrigine in healthy Chinese subjects|Bipolar Disorder|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114536|http://clinicaltrials.gov/show/NCT02513654|[C0064636]|[lamotrigine]
19540|GSK|A Glucose-6-Phosphate Dehydrogenase (G6PD) enzyme assay validation protocol|Malaria|nan|nan|nan|[C0903411]|[tafenoquine]
19557|GSK|A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201378|http://clinicaltrials.gov/show/NCT02301975|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19558|GSK|A single-centre, randomized, double-blind (sponsor unblinded), placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2982772, in single (in both fed and fasted states) and repeat oral doses in healthy male subjects|Inflammatory Bowel Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200975|http://clinicaltrials.gov/show/NCT02302404|[C5392621]|[GSK2982772]
19580|GSK|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects with Schizophrenia|Schizophrenia|Phase 2|nan|http://clinicaltrials.gov/show/NCT00103727|[C1701942]|[Talnetant]
19582|GSK|A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects with Mild to Moderate Airflow Limitation at Risk for Exacerbations|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200163|http://clinicaltrials.gov/show/NCT02130193|[C4519256]|[danirixin]
19583|GSK|Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50/250mcg twice daily alone or ADOAIR 50/250mcg plus tiotropium bromide 18mcg|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116717|http://clinicaltrials.gov/show/NCT01762800|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
19584|GSK|A multi-centre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, and tolerability of repeat doses of inhaled GSK2269557 in adults with persistent, uncontrolled asthma|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201543|http://clinicaltrials.gov/show/NCT02567708|[C5197976]|[Nemiralisib]
19585|GSK|Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers|Dermatitis, Atopic|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201661|http://clinicaltrials.gov/show/NCT02411162|[C4541381]|[tapinarof]
19586|GSK|A single centre, three part, randomised, study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to Healthy Subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201544|http://clinicaltrials.gov/show/NCT02691325|[C5197976]|[Nemiralisib]
19588|GSK|A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects|Diabetes Mellitus, Type 2|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201287|http://clinicaltrials.gov/show/NCT02660736|[C2607479]|[albiglutide]
19589|GSK|Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis|Dermatitis, Atopic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=203121|http://clinicaltrials.gov/show/NCT02564055|[C4541381]|[tapinarof]
19590|GSK|A Sponsor un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients|Oedema, Pulmonary|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=117387|http://clinicaltrials.gov/show/NCT02119260|[C5226839]|[GSK2798745]
19591|GSK|A double-blind, randomized, placebo controlled, dose escalating crossover study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in Japanese healthy male volunteers|Cholestasis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205808|http://clinicaltrials.gov/show/NCT02801981|[C5238076]|[linerixibat]
19592|GSK|Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers|Malaria|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=106491|http://clinicaltrials.gov/show/NCT00871156|[C0903411]|[tafenoquine]
19593|GSK|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects|Infections, Respiratory Tract|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114595|http://clinicaltrials.gov/show/NCT02202187|[C4309999]|[gepotidacin]
19594|GSK|A microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients using Positron Emission Tomography (PET)|Hypertension, Pulmonary|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204746|http://clinicaltrials.gov/show/NCT02551653|[C2981865]|[GSK2256098]
19595|GSK|A randomised, placebo-controlled, double-blind, two period crossover study to characterise the exhaled nitric oxide time profile as a biomarker of airway inflammation in adult asthma patients following repeat administration of inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201499|http://clinicaltrials.gov/show/NCT02712047|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19596|GSK|An open label, six-period cross-over, single and repeat dose study to determine the pharmacokinetics of fluticasone furoate and GSK961081 when administered alone, in combination, or concurrently via the ELLIPTA|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201958|http://clinicaltrials.gov/show/NCT02666287|[C4519138]|[batefenterol]
19597|GSK|An open-label study in healthy male subjects, to determine the excretion balance and pharmacokinetics of [14C]-GSK961081, administered as a single intravenous microtracer (concomitant with an inhaled non-radiolabelled dose) and a single oral dose|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201003|http://clinicaltrials.gov/show/NCT02663089|[C4519138]|[batefenterol]
19598|GSK|An Open Label, Randomized, Single Dose, Crossover study to determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects|Heart failure, Congestive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204725|http://clinicaltrials.gov/show/NCT02925546|[C5226839]|[GSK2798745]
19601|GSK|A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 protein with AS15 adjuvant in HER2-overexpressing patients with high-risk breast cancer|Neoplasms, Breast|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=719125/002|http://clinicaltrials.gov/show/NCT00058526|[C5576950]|[SB719125]
19602|GSK|A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 prot. with AS15 adj. in HER2-overexpressing patients with high-risk breast cancer.|Neoplasms, Breast|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=719125/002|http://clinicaltrials.gov/show/NCT00058526|[C5576950]|[SB719125]
19610|GSK|Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic combined with standard neoadjuvant treatment in patients with WT1-positive primary invasive breast cancer|Neoplasms, Breast|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113172|http://clinicaltrials.gov/show/NCT01220128|[C3896845]|[Recombinant Anti-WT1 Immunotherapeutic GSK2302024A]
19611|ViiV|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19595|http://clinicaltrials.gov/show/NCT02429791|[C3253985]|[dolutegravir]
19612|ViiV|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed (SWORD-2)|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19596|http://clinicaltrials.gov/show/NCT02422797|[C3253985]|[dolutegravir]
19613|ViiV|An Open-label Single-Center, 4-Period William’s Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects|Infection, Human Immunodeficiency Virus|Phase 4|https://www.viiv-studyregister.com/study/19607|http://clinicaltrials.gov/show/NCT02634073|[C0209738]|[lamivudine]
19614|Novartis|A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Breast Cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17258|https://www.clinicaltrials.gov/ct2/show/NCT00876395?term=CRAD001J2301&rank=1|[C0541315]|[everolimus]
19615|Novartis|A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer|HER2/Neu Over-expressing Locally Advanced Breast Cancer or Metastatic Breast Cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14989|https://www.clinicaltrials.gov/ct2/show/NCT01007942?term=CRAD001W2301&rank=1|[C0541315]|[everolimus]
19625|GSK|Subject Understanding of the Risks Associated with ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=205913|http://clinicaltrials.gov/show/NCT03001440|[C0085208]|[bupropion]
19638|Astellas|A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostridium difficile infection in an older population.|Clostridium difficile infection|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=2819-MA-1002|https://clinicaltrials.gov/ct2/show/NCT02254967|[C0065023]|[fidaxomicin]
19652|Eisai|A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma|Hepatocellular Carcinoma (HCC)|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01761266|[C2986924]|[lenvatinib]
19653|Eisai|Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)|Hepatocellular Carcinoma (HCC)|Phase 1/2|nan|https://clinicaltrials.gov/ct2/show/NCT00946153|[C2986924]|[lenvatinib]
19654|Eisai|A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures|Partial-onset Seizures|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT01618695|[C2698764]|[perampanel]
19655|Eisai|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Refractory Partial Seizures|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT00699972|[C2698764]|[perampanel]
19656|Eisai|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Refractory Partial Seizures|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT00699582|[C2698764]|[perampanel]
19657|Eisai|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Refractory Partial Seizures|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT00700310|[C2698764]|[perampanel]
19658|Eisai|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|Epilepsy|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT00144690|[C2698764]|[perampanel]
19659|Eisai|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures|Epilepsy|Phase 2|nan|https://clinicaltrials.gov/ct2/show/NCT01161524|[C2698764]|[perampanel]
19670|GSK|Immunogenicity and safety study of GSK Biologicals’ Infanrix hexa at 2, 4 and 6 months of age in healthy infants|acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117119|http://clinicaltrials.gov/show/NCT02096263|[C0545299, C0305062, C0982332, C1445761, C1743955]|['Immunization, diphtheria-tetanus combined', 'tetanus toxoid vaccine, inactivated', 'acellular pertussis vaccine, inactivated', Hepatitis B virus recombinant vaccine, DTP-IPV-Hib vaccine]
19671|GSK|A multi-center, randomized, active controlled, double-blind, parallel group comparison study and subsequent open-label study of GSK548470 in patients with compensated chronic hepatitis B untreated with nucleic acid analogue|Hepatitis B, Chronic|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115409|http://clinicaltrials.gov/show/NCT01480284|[C1099776]|[tenofovir disoproxil fumarate]
19672|GSK|An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications|Thrombosis, Venous|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=ART108053|http://clinicaltrials.gov/show/NCT00443053|[C1099664]|[fondaparinux sodium]
19673|GSK|A 24-week, Phase IIB, Randomized, Controlled, Parallel group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Diseases who are not on Dialysis.|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113747|http://clinicaltrials.gov/show/NCT01977573|[C4519188]|[daprodustat]
19674|GSK|A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with and without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200912|http://clinicaltrials.gov/show/NCT02289482|[C5196507]|[GSK-2838232]
19675|GSK|A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 with and without Ritonavir for 8-11 days in Healthy Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200207|http://clinicaltrials.gov/show/NCT02289495|[C5196507]|[GSK-2838232]
19676|GSK|A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with Ritonavir, in Healthy Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204953|http://clinicaltrials.gov/show/NCT02795754|[C5196507]|[GSK-2838232]
19677|GSK|A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116787|http://clinicaltrials.gov/show/NCT01802918|[C5196507]|[GSK-2838232]
19680|GSK|A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X, administered as single doses (12mg and 15mg), and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=SIG110405|http://clinicaltrials.gov/show/NCT00549497|[C3659427]|[GW870086X]
19681|GSK|A single center, double-blind, randomized, placebo-controlled, parallel, single and repeat, dose-ascending study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to healthy Japanese subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205759|http://clinicaltrials.gov/show/NCT02972905|[C5197976]|[Nemiralisib]
19682|GSK|Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis|Psoriasis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=203120|http://clinicaltrials.gov/show/NCT02564042|[C4541381]|[tapinarof]
19683|GSK|An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) after Single and Repeat Dose Administration from a Dry Powder Inhaler in Healthy Chinese Subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200558|http://clinicaltrials.gov/show/NCT02837380|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
19684|GSK|MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115666|http://clinicaltrials.gov/show/NCT01691859|[C0969324]|[mepolizumab]
19685|Novartis|A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy|Partial Onset Seizures|Phase 2/3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10103|https://www.clinicaltrials.gov/ct2/show/NCT00975715?term=CTRI476B1301&rank=2|[C0069751]|[oxcarbazepine]
19686|Novartis|A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients|Kidney Transplantation|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11223|https://www.clinicaltrials.gov/ct2/show/NCT01025817?term=CRAD001AUS92&rank=1|[C0541315]|[everolimus]
19687|Novartis|A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion.|Kidney Transplantation|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14245|https://www.clinicaltrials.gov/ct2/show/NCT01114529?term=CRAD001A2429&rank=1|[C0541315]|[everolimus]
19688|Novartis|A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active psoriatic arthritis (FUTURE 4)|Psoriatic arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17261|https://www.clinicaltrials.gov/ct2/show/NCT02294227?term=CAIN457F2336&rank=1|[C3179547]|[secukinumab]
19695|ViiV|A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once Daily in Healthy Adult Subjects (ING114005)|Infections, Human Immunodeficiency Virus and Herpesviridae|Phase 1|https://www.viiv-studyregister.com/study/19541|http://clinicaltrials.gov/show/NCT01098526|[C3253985]|[dolutegravir]
19696|ViiV|An Open-label, Randomized, Two-way Crossover, Single dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/study/19598|http://clinicaltrials.gov/show/NCT02741557|[C3253985, C1566826]|[dolutegravir, rilpivirine]
19758|GSK|An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of GR37547 ciprofloxacin 500 mg tablet versus ciprofloxacin 500 mg tablet reference product in healthy adult participants under fasting conditions|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205730|http://clinicaltrials.gov/show/NCT03150082|[C0008809]|[ciprofloxacin]
19761|GSK|A randomized double-blind (sponsor unblind) placebo controlled study in healthy subjects to evaluate: safety, tolerability, pharmacokinetics, and pharmacodynamics of the repeat doses of GSK2881078, the Selective Androgen Receptor Modulator with an open label dosing arm to evaluate the effect of CYP3A4 inhibition on pharmacokinetics of GSK2881078|Cachexia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204699|http://clinicaltrials.gov/show/NCT02567773|[C4705766]|[GSK2881078]
19762|GSK|Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=200860|http://clinicaltrials.gov/show/NCT02113436|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
19763|GSK|An open-label study of the correct use and ease of use of placebo ELLIPTA dry powder inhaler in subjects with chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201071|http://clinicaltrials.gov/show/NCT02586493|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19764|GSK|An open-label study of the ease of use and correct use of placebo ELLIPTA dry powder inhaler in subjects with asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201594|http://clinicaltrials.gov/show/NCT02586506|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19766|GSK|GSK1550188 A 52 week study of belimumab versus placebo in the treatment of subjects with systemic lupus erythematosus (SLE) located in Northeast Asia|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113750|http://clinicaltrials.gov/show/NCT01345253|[C1723401]|[belimumab]
19767|GSK|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112233|http://clinicaltrials.gov/show/NCT00724867|[C1723401]|[belimumab]
19790|Novartis|A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer|Neoplasms, Breast|Phase 3|nan|https://www.clinicaltrials.gov/ct2/show/NCT00374322?term=EGF105485&rank=1|[C1506770]|[lapatinib]
19797|ViiV|AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2-<18 YEARS OF AGE|Infection, Human Immunodeficiency Virus|Phase 2|https://www.viiv-studyregister.com/study/19684|http://clinicaltrials.gov/show/NCT02625207|[C1667052]|[maraviroc]
19798|ViiV|A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/study/19676|http://clinicaltrials.gov/show/NCT00791700|[C1667052]|[maraviroc]
19799|GSK|A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116174|http://clinicaltrials.gov/show/NCT02465515|[C2607479]|[albiglutide]
19800|GSK|A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis|Vasculitis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=115466|http://clinicaltrials.gov/show/NCT01663623|[C1723401]|[belimumab]
19811|GSK|A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamicsof single doses of inhaled GSK1995057 in healthy subjects|Respiratory Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116236|http://clinicaltrials.gov/show/NCT01587807|[C5196682]|[GSK1995057]
19812|GSK|A Randomized, Double-blind, Sponsor un-blinded, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients with Congestive Heart Failure|Heart Failure|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201881|http://clinicaltrials.gov/show/NCT02497937|[C5226839]|[GSK2798745]
19813|Novartis|A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase|Multiple Sclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17143|https://www.clinicaltrials.gov/ct2/show/NCT01892722?term=CFTY720D2311&rank=1|[C1699926]|[fingolimod]
19828|GSK|A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers|Autoimmune Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200902|http://clinicaltrials.gov/show/NCT02293161|[C5392354]|[GSK2618960]
19831|GSK|A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in normal subjects and subjects with impaired renal function|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115573|http://clinicaltrials.gov/show/NCT01406340|[C4519188]|[daprodustat]
19832|GSK|A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117225|http://clinicaltrials.gov/show/NCT01984801|[C5392505]|[GSK1940029]
19833|GSK|A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects|Acne Vulgaris|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117226|http://clinicaltrials.gov/show/NCT01938482|[C5392505]|[GSK1940029]
19834|GSK|Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer|Wound Healing|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115760|http://clinicaltrials.gov/show/NCT01831804|[C4519188]|[daprodustat]
19835|GSK|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) versus Primaquine in the Treatment of Subjects with Plasmodium vivax Malaria|Malaria, Vivax|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116564|http://clinicaltrials.gov/show/NCT02216123|[C0903411]|[tafenoquine]
19846|GSK|A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers|Tendon Injuries|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200884|http://clinicaltrials.gov/show/NCT02231190|[C4519188]|[daprodustat]
19847|Novartis|A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation|Kidney Transplantation|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17233|https://www.clinicaltrials.gov/ct2/show/NCT01950819?term=CRAD001A2433&rank=1|[C0541315]|[everolimus]
19878|GSK|204980: An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=204980|http://clinicaltrials.gov/show/NCT02794480|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19879|GSK|A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) who Completed the Phase 2 Protocol LBSL02|Systemic Lupus Erythematosus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112626|http://clinicaltrials.gov/show/NCT00583362|[C1723401]|[belimumab]
19881|GSK|201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects with Asthma and Exercise-Induced Bronchoconstriction|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201832|http://clinicaltrials.gov/show/NCT02730351|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
19882|GSK|Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201012|http://clinicaltrials.gov/show/NCT02570165|[C4519138]|[batefenterol]
19883|GSK|A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY OF MAPATUMUMAB ([HGS1012], A FULLY-HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH SORAFENIB AS A FIRST-LINE THERAPY IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA|Carcinoma, Hepatocellular|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200178|nan|[C1665688]|[mapatumumab]
19884|GSK|A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of administering multiple oral doses of GSK1292263 alone and with atorvastatin|Dyslipidaemias|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113779|http://clinicaltrials.gov/show/NCT01218204|[C3852542]|[GSK1292263]
19885|GSK|Effects of SB-649868 and Alprazolam on the Neuroendocrine and Sympathetic Responses to Insulin-Induced Hypoglycaemia in Healthy Male Subjects|Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115268|nan|[C3180886]|[SB-649868]
19888|Novartis|A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib|Chronic Myelogenous Leukemia|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13949|https://www.clinicaltrials.gov/ct2/show/NCT00802841?term=CAMN107A2404&rank=1|[C1721377]|[nilotinib]
19889|ViiV|A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR +DARUNAVIR/RITONAVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV INFECTED PATIENTS WITH CCR5 TROPIC HIV 1|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/study/19679|http://clinicaltrials.gov/show/NCT01345630|[C1667052]|[maraviroc]
19890|GSK|A Phase I, Randomized, Placebo-Controlled, Double-Blind (sponsor unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects|Healthy Volunteers|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204856|http://clinicaltrials.gov/show/NCT02742766|[C5433906]|[GSK3008356]
19892|GSK|A single-centre, double-blind (sponsor open), placebo controlled two part study to evaluate the safety, tolerability and pharmacokinetics of single and repeat doses of GSK2292767 as a dry powder in healthy participants who smoke cigarettes|Asthma|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=202062|http://clinicaltrials.gov/show/NCT03045887|[C4078791]|[GSK2292767]
19893|GSK|A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682)|Virus Diseases|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201682|http://clinicaltrials.gov/show/NCT02469298|[C4519256]|[danirixin]
19895|GSK|A Repeat-dose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200952|http://clinicaltrials.gov/show/NCT02683746|[C2607479]|[albiglutide]
19896|GSK|An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 205667)|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=205667|http://clinicaltrials.gov/show/NCT03021304|[C0969324]|[mepolizumab]
19897|GSK|A Phase 1b, multi-center, open-label, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=114746|http://clinicaltrials.gov/show/NCT01938443|[C2981865, C2697961]|[GSK2256098, trametinib]
19907|Novartis|A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)|Pulmonary Arterial Hypertension|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8543|https://clinicaltrials.gov/ct2/show/NCT00902174|[C0939537]|[imatinib mesylate]
19908|Novartis|An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer|Breast cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4346|https://clinicaltrials.gov/ct2/show/NCT00332709?term=CFEM345DDE09&rank=1|[C0246421]|[letrozole]
19909|Novartis|Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer|Solid Tumor cancer with Bone metastases|Phase 3|nan|https://clinicaltrials.gov/ct2/show/NCT00003884?term=NCT00003884&rank=1|[C0257685]|[zoledronic acid]
19917|GSK|Safety and tolerability of GSK 1557484A vaccine in adults at occupational risk for influenza A (H5N1) exposure|Influenza|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116861|http://clinicaltrials.gov/show/NCT01788228|[C3179804]|[GSK 1557484A]
19923|GSK|Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with paclitaxel and carboplatin, or docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117360|http://clinicaltrials.gov/show/NCT01868022|[C5442040]|[GSK3052230]
19925|GSK|A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=204471|http://clinicaltrials.gov/show/NCT02654145|[C0969324]|[mepolizumab]
19926|GSK|Evaluation of the nicotine lozenge in relief of provoked acute craving|Tobacco Use Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=S7120994|http://clinicaltrials.gov/show/NCT01466361|[C0068722]|[nicotine polacrilex]
19927|GSK|Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving|Tobacco Use Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=S7121359|http://clinicaltrials.gov/show/NCT01506908|[C0068722]|[nicotine polacrilex]
19928|GSK|A randomised, double-blind, parallel group study to evaluate the safety, tolerability and pharmacokinetics of a single dose of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to healthy participants|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207674|http://clinicaltrials.gov/show/NCT03189589|[C5197976]|[Nemiralisib]
19935|GSK|Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects with Age-Related Cognitive Decline|Alzheimer's Disease|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116713|http://clinicaltrials.gov/show/NCT01702480|[C5392405]|[GSK2981710]
19937|GSK|A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an open label, 2-way crossover to evaluate food effect on the pharmacokinetics of Danirixin (Part2)|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=206817|http://clinicaltrials.gov/show/NCT03136380|[C4519256]|[danirixin]
19938|GSK|A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers|Malaria, Vivax|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=201807|http://clinicaltrials.gov/show/NCT02658435|[C0903411]|[tafenoquine]
19939|GSK|An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 204959)|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=204959|http://clinicaltrials.gov/show/NCT03099096|[C0969324]|[mepolizumab]
19940|ViiV|ING117175: a Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir or efavirenz each administered with two NRTIs in HIV-1-infected antiretroviral therapy-naïve adults starting treatment for rifampicin-sensitive tuberculosis|Infection, Human Immunodeficiency Virus|Phase 3|http://www.viiv-clinicalstudyregister.com/study/117175|http://clinicaltrials.gov/show/NCT02178592|[C3253985]|[dolutegravir]
19941|ViiV|Phase 1, open label, two arm, fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers|Infection, Human Immunodeficiency Virus|Phase 1|http://www.viiv-clinicalstudyregister.com/study/113099|http://clinicaltrials.gov/show/NCT01231542|[C3253985]|[dolutegravir]
19970|Eisai|Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan.|Alzheimer's Disease|Phase 2/3|not available|not available|[C0527316]|[donepezil]
19971|Eisai|A Preliminary, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.|Alzheimer's Disease|Phase 2|not available|not available|[C0527316]|[donepezil]
19972|Eisai|A 15-week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.|Alzheimer's Disease|Phase 3|not available|not available|[C0527316]|[donepezil]
19973|Eisai|A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.|Alzheimer's Disease|Phase 3|not available|not available|[C0527316]|[donepezil]
19974|Eisai|A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer's Disease.|Alzheimer's Disease|Phase 3|not available|not available|[C0527316]|[donepezil]
19975|Eisai|A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020|Alzheimer's Disease|Phase 2|not available|https://clinicaltrials.gov/ct2/show/NCT00165659|[C0527316]|[donepezil]
19976|Eisai|A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period|Alzheimer's Disease|Phase 3|not available|https://clinicaltrials.gov/ct2/show/NCT00096473|[C0527316]|[donepezil]
19977|Eisai|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) in the Management of Patients with Alzheimer's Disease in a Nursing Home Facility.|Alzheimer's Disease|Phase 3|not available|not available|[C0527316]|[donepezil]
19978|Eisai|A 54-week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in Patients with Alzheimer's Disease.|Alzheimer's Disease|Phase 3|not available|not available|[C0527316]|[donepezil]
19979|Eisai|Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease|Alzheimer's Disease|Phase 3|not available|https://clinicaltrials.gov/ct2/show/NCT00478205|[C0527316]|[donepezil]
19980|Eisai|A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease|Alzheimer's Disease|Phase 3|not available|https://clinicaltrials.gov/ct2/show/NCT01404169|[C0527316]|[donepezil]
19986|Novartis|A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs|Hereditary Periodic Fevers|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16933|https://www.clinicaltrials.gov/ct2/show/NCT02059291?term=CACZ885N2301&rank=3|[C2718773]|[canakinumab]
19987|Novartis|A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation|Chronic Obstructive Pulmonary Disease (COPD)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14285|https://www.clinicaltrials.gov/ct2/show/NCT01697696?term=CNVA237A2319&rank=1|[C4082411]|[Glycopyrronium Bromide]
20036|Novartis|A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)|Chronic Lymphocytic Leukemia (CLL)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15449|https://www.clinicaltrials.gov/ct2/show/NCT01520922?term=NCT01520922&rank=1|[C1832027]|[ofatumumab]
20037|Novartis|Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients|Liver Transplantation|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10843|https://www.clinicaltrials.gov/ct2/show/NCT00378014?term=CRAD001HDE10&rank=1|[C0541315]|[everolimus]
20055|GSK|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects with Systemic Lupus Erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=112234|http://clinicaltrials.gov/show/NCT00712933|[C1723401]|[belimumab]
20056|GSK|A randomised, placebo-controlled, double-blind, repeat dose escalation study with GSK2126458 in patients with Idiopathic Pulmonary Fibrosis (IPF)|Idiopathic Pulmonary Fibrosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116711|http://clinicaltrials.gov/show/NCT01725139|[C4519177]|[omipalisib]
20057|GSK|An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200363|http://clinicaltrials.gov/show/NCT02377427|[C0969324]|[mepolizumab]
20058|GSK|A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma|Carcinoma, Small Cell|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200858|http://clinicaltrials.gov/show/NCT02034123|[C3827120]|[GSK2879552]
20059|GSK|A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201312|http://clinicaltrials.gov/show/NCT02135692|[C0969324]|[mepolizumab]
20060|GSK|An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an auto injector with a reconstituted lyophilised drug product from a vial|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=204958|http://clinicaltrials.gov/show/NCT03014674|[C0969324]|[mepolizumab]
20061|GSK|A two part, multicenter Phase IIa, placebo controlled study, to examine the safety, tolerability, and effects of GSK256073 on lipids in subjects with dyslipidemia|Dyslipidaemias|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=112795|http://clinicaltrials.gov/show/NCT00903617|[C4079835]|[GSK256073]
20062|GSK|A 24-week, Phase III, open-label, non-comparative, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese hemodialysis subjects with anemia associated with chronic kidney disease who are not taking erythropoiesis stimulating agents|Anaemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=204716|http://clinicaltrials.gov/show/NCT02829320|[C4519188]|[daprodustat]
20064|GSK|Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma|Lymphoma, Mantle-Cell|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=393229/005|http://clinicaltrials.gov/show/NCT00992992|[C0879399]|[tositumomab]
20065|GSK|Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/308|nan|[C0070122]|[paroxetine]
20066|GSK|Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/309|nan|[C0070122]|[paroxetine]
20067|GSK|Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/310|nan|[C0070122]|[paroxetine]
20068|GSK|Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/316|nan|[C0070122]|[paroxetine]
20069|GSK|Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/314|nan|[C0070122]|[paroxetine]
20070|GSK|A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/281|nan|[C0070122]|[paroxetine]
20071|GSK|A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/290|nan|[C0070122]|[paroxetine]
20072|GSK|A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/291|nan|[C0070122]|[paroxetine]
20073|GSK|A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age >60 years) with moderate depression according to feighner's criteria|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/070|nan|[C0070122]|[paroxetine]
20074|GSK|A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/069|nan|[C0070122]|[paroxetine]
20075|GSK|A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=MY-060/BRL-029060/1.|nan|[C0070122]|[paroxetine]
20076|GSK|A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/061|nan|[C0070122]|[paroxetine]
20077|GSK|A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mg Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/078|nan|[C0070122]|[paroxetine]
20078|GSK|A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression.|Depressive Disorder|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=29060/063|nan|[C0070122]|[paroxetine]
20079|GSK|A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/112|nan|[C0070122]|[paroxetine]
20080|GSK|A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/064|nan|[C0070122]|[paroxetine]
20081|GSK|A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/079|nan|[C0070122]|[paroxetine]
20082|GSK|A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/073|nan|[C0070122]|[paroxetine]
20083|GSK|A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/245|nan|[C0070122]|[paroxetine]
20084|GSK|A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/131|nan|[C0070122]|[paroxetine]
20085|GSK|The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/076|nan|[C0070122]|[paroxetine]
20087|GSK|Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=89|nan|[C0085208]|[bupropion]
20088|GSK|A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=WELL 203|nan|[C0085208]|[bupropion]
20089|GSK|The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=Well 209|nan|[C0085208]|[bupropion]
20090|GSK|A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=WELL 212|nan|[C0085208]|[bupropion]
20091|GSK|A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4002|nan|[C0085208]|[bupropion]
20092|GSK|A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression|Depressive Disorder|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4001|nan|[C0085208]|[bupropion]
20093|GSK|A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4007|nan|[C0085208]|[bupropion]
20094|GSK|A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients|Depressive Disorder, Major|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=WELL 205|nan|[C0085208]|[bupropion]
20095|GSK|A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK1A4006|nan|[C0085208]|[bupropion]
20099|GSK|Efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy|Eczema|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117183|http://clinicaltrials.gov/show/NCT00817063|[C0281666]|[alitretinoin]
20100|GSK|Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis|Dermatitis, Atopic|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205050|http://clinicaltrials.gov/show/NCT03055195|[C0969324]|[mepolizumab]
20101|GSK|A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other Non-Hodgkin’s lymphomas, solid tumors and multiple myeloma|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117208|http://clinicaltrials.gov/show/NCT02082977|[C3660728]|[GSK-2816126]
20102|GSK|A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (bupropion XL 300mg once daily), Escitalopram oxalate (escitalopram, 10mg-20mg once daily) in Subjects with Major Depressive Disorder|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114589|http://clinicaltrials.gov/show/NCT02191397|[C0085208]|[bupropion]
20171|Novartis|A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia with or without an Associated Hematological Clonal Non-Mast Cell Lineage Disease|Mastocytosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17203|https://www.clinicaltrials.gov/ct2/show/NCT782067?term=CPKC412d2201&rank=1|[C0526371]|[midostaurin]
20173|GSK|An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of SKF101804 Cefixime 200 mg/5 mL suspension versus Cefixime 200 mg/5 mL suspension reference product in healthy adult participants under fasting conditions|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205731|http://clinicaltrials.gov/show/NCT03408392|[C0060400]|[cefixime]
20174|GSK|A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are switched from a stable dose of an erythropoiesis-stimulating agent|Anaemia|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=204836|http://clinicaltrials.gov/show/NCT02689206|[C4519188]|[daprodustat]
20175|GSK|An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder|Depressive Disorder, Major|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=AK140016|nan|[C0085208, C0070122]|[bupropion, paroxetine]
20187|Novartis|A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naive adult patients with ALK-activated non-small cell lung cancer|Non-small cell lung carcinoma (NSCLC)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17324|https://www.clinicaltrials.gov/ct2/show/NCT1685138?term=CLDK378A2203&rank=1|[C3818721]|[ceritinib]
20188|Novartis|An open-label, phase II (Proof of Concept) trial of PKC412 monotherapy in patients with acute myeloid leukemia (AML) and patients with high risk myelodysplastic syndrome (MDS).|Myelodysplastic syndrome (MDS)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8663|https://www.clinicaltrials.gov/ct2/show/NCT45942?term=CPKC412A2104&rank=1|[C0526371]|[midostaurin]
20189|Astellas|A randomized, double-blind, factorial, parallel-group, active and placebo-controlled, multicenter dose-ranging study to evaluate the efficacy, safety and tolerability of six dose combinations of Solifenacin Succinate and Mirabegron compared to Mirabegron and Solifenacin Succinate monotherapies in the treatment of overactive bladder|Urinary Bladder, Overactive|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-100|https://clinicaltrials.gov/ct2/show/NCT01340027|[C2983812]|[mirabegron]
20259|Astellas|A randomized, double-blind, parallel-group, active-controlled, multicenter study to evaluate the long-term safety and efficacy of combination of Solifenacin Succinate with Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in patients with overactive bladder|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-102|https://clinicaltrials.gov/ct2/show/NCT02045862|[C2983812]|[mirabegron]
20260|Astellas|A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up|Prevention of rejection after organ transplant|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=PMR-EC-1206|https://clinicaltrials.gov/ct2/show/NCT01294020|[C0085149]|[tacrolimus]
20262|Astellas|An Open-Label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations|Non-small cell lung cancer|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0302|https://clinicaltrials.gov/ct2/show/NCT02588261|[C5237985]|[Naquotinib Mesylate]
20264|Novartis|A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLEAR)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16409|https://www.clinicaltrials.gov/ct2/show/NCT2074982?term=CAIN457A2317&rank=1|[C3179547]|[secukinumab]
20265|Novartis|A 52-week, randomized, double-blind study of secukinumab (300 mg) compared to ustekinumab in subjects with moderate to severe plaque psoriasis|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17439|https://www.clinicaltrials.gov/ct2/show/NCT2826603?term=CAIN457A2326&rank=1|[C3179547]|[secukinumab]
20266|Novartis|A randomized, double-blind, placebo-controlled, multicenter study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe palmoplantar psoriasis|Psoriasis, Palmoplantar|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16828|https://www.clinicaltrials.gov/ct2/show/NCT1806597?term=CAIN457A2312&rank=1|[C3179547]|[secukinumab]
20267|Novartis|A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe nail psoriasis|Psoriasis, nail|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16951|https://www.clinicaltrials.gov/ct2/show/NCT1807520?term=CAIN457A2313&rank=1|[C3179547]|[secukinumab]
20269|Astellas|A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in patients with relapsing or locally advanced prostate cancer who are responsive to such therapy|Prostate Cancer|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=EGD-EC-003|https://clinicaltrials.gov/ct2/show/NCT00378690|[C0700596]|[leuprolide acetate]
20270|Astellas|An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-CL-077|https://clinicaltrials.gov/ct2/show/NCT01655069|[C1509436]|[solifenacin succinate]
20271|Astellas|A randomized, double-blind, parallel-group, placebo- and active- controlled, multicenter study to evaluate the efficacy, safety and tolerability of combinations of Solifenacin Succinate and Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in the treatment of overactive bladder|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-101|https://clinicaltrials.gov/ct2/show/NCT01972841|[C2983812]|[mirabegron]
20272|Astellas|A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center, Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder (OAB)|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1005|https://clinicaltrials.gov/ct2/show/NCT02216214|[C2983812]|[mirabegron]
20273|ViiV|An evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen|Infection, Human Immunodeficiency Virus|Phase 3|http://www.viiv-clinicalstudyregister.com/study/202094|http://clinicaltrials.gov/show/NCT02478632|[C3253985]|[dolutegravir]
20277|GSK|A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201749|http://clinicaltrials.gov/show/NCT03034915|[C3709474, C2935023]|[umeclidinium bromide, vilanterol]
20278|GSK|An open-label study in healthy male subjects, to determine the excretion balance and pharmacokinetics of [14C]-GSK2269557, administered as a single intravenous microtracer (concomitant with an inhaled non-radiolabelled dose) and a single oral dose|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=206764|http://clinicaltrials.gov/show/NCT03315559|[C5197976]|[Nemiralisib]
20279|GSK|A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905)|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=113413|http://clinicaltrials.gov/show/NCT01336621|[C0530684]|[ezogabine]
20280|GSK|A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855)|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114873|http://clinicaltrials.gov/show/NCT01777139|[C0530684]|[ezogabine]
20281|GSK|A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults|Infection, Human Immunodeficiency Virus|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200911|http://clinicaltrials.gov/show/NCT03045861|[C5196507]|[GSK-2838232]
20286|Astellas|A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus Granules) in de Novo Paediatric Allograft Recipients|Prevention of rejection after organ transplant|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=F506-CL-0403|https://clinicaltrials.gov/ct2/show/NCT01371331|[C0085149]|[tacrolimus]
20287|Astellas|Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Acute myeloid leukemia|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=2215-CL-0101|https://clinicaltrials.gov/ct2/show/NCT02014558|[C3896946]|[gilteritinib fumarate]
20288|Astellas|A PHASE 3, DOUBLE-BLIND, RANDOMIZED, MULTI-CENTER, PLACEBO-CONTROLLED SEQUENTIAL DOSE TITRATION STUDY TO ASSESS EFFICACY, SAFETY AND POPULATION PHARMACOKINETICS OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH OVERACTIVE BLADDER (OAB)|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-CL-076|https://clinicaltrials.gov/ct2/show/NCT01565707|[C1509436]|[solifenacin succinate]
20289|Astellas|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma|Adrenocortical carcinoma|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-301|https://clinicaltrials.gov/ct2/show/NCT00924989|[C2987649]|[Linsitinib]
20290|Astellas|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment|Endometriosis|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=1707-CL-0011|https://clinicaltrials.gov/ct2/show/NCT01767090|[C5392742]|[ASP1707]
20291|Astellas|A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema|Diabetic macular edema|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=8232-CL-3001|https://clinicaltrials.gov/ct2/show/NCT02302079|[C5198358]|[ASP8232]
20294|Astellas|A Phase 2 Open-label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study|Rheumatoid Arthritis|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RA25|https://clinicaltrials.gov/ct2/show/NCT01711814|[C5418498]|[Peficitinib Hydrobromide]
20295|Novartis|β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Systemic Juvenile Idiopathic Arthritis (SJIA)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17206|https://www.clinicaltrials.gov/ct2/show/NCT02296424?term=CACZ885G2306&draw=2&rank=2|[C2718773]|[canakinumab]
20296|Novartis|A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis|Relapsing-remitting Multiple Sclerosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=6043|https://www.clinicaltrials.gov/ct2/show/NCT879658?term=CBAF312A2201|[C3657824]|[siponimod]
20297|Novartis|Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Iran.|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20298|Novartis|Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Chile.|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20299|Novartis|Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Cuba.|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20300|Novartis|Evaluation of Triclabendazole (CGP 23030) in the treatment of chronic human infection with Fasciola hepatica (liver fluke) in Bolivia.|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20301|Novartis|Dose finding trial with postprandial triclabendazole in Bolivian children infected with Fasciola hepatica (liver fluke).|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20302|Novartis|Combined clinicopharmacokinetic trial of triclabendazole in Peruvian patients  infected with Fasciola hepatica (liver fluke).|Fasciolasis|Phase 2|nan|nan|[C0077071]|[triclabendazole]
20303|GSK|Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome|Restless Legs Syndrome|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=999910/188|nan|[C0244821]|[ropinirole]
20304|GSK|A single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1550188 in Chinese subjects with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200909|http://clinicaltrials.gov/show/NCT02880852|[C1723401]|[belimumab]
20305|GSK|A single centre, open-label, parallel-group, single oral dose study to evaluate the pharmacokinetics, safety and tolerability of Pyrimethamine in healthy Japanese and Caucasian male subjects|Toxoplasmosis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204678|http://clinicaltrials.gov/show/NCT03258762|[C0034283]|[pyrimethamine]
20306|GSK|Randomized, open label, 2-way crossover, single dose bioequivalence study of Paroxetine IR tablets manufactured in GSKT and Mississauga sites in healthy Chinese participants under fasting and fed conditions|Anxiety Disorders|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207652|http://clinicaltrials.gov/show/NCT03329573|[C0070122]|[paroxetine]
20307|GSK|BEL114333, a Multicenter, Continuation Study of Belimumab in subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase III study BEL113750 in Northeast Asia or completed the open-label extension of HGS1006-C1115 in Japan|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114333|http://clinicaltrials.gov/show/NCT01597622|[C1723401]|[belimumab]
20308|Astellas|A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients|Prostate cancer|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0011|https://clinicaltrials.gov/ct2/show/NCT01650194|[C3496793]|[enzalutamide]
20309|Astellas|A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant Additional Relief for their OAB Symptoms|Urinary Bladder, Overactive|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-EC-012|https://clinicaltrials.gov/ct2/show/NCT01908829|[C1509436]|[solifenacin succinate]
20310|Astellas|A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuriain Patients with Type 2 Diabetes and Chronic Kidney Disease|Diabetic kidney disease|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=8232-CL-0004|https://clinicaltrials.gov/ct2/show/NCT02358096|[C5198358]|[ASP8232]
20311|Astellas|An open-label, phase 1 dose escalation study of oral ASP8273 in subjects with non-small-cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations|Non-small cell lung cancer|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0102|https://clinicaltrials.gov/ct2/show/NCT02113813|[C5237985]|[Naquotinib Mesylate]
20312|Astellas|A Phase 4, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-MA-1008|https://clinicaltrials.gov/ct2/show/NCT02757768|[C2983812]|[mirabegron]
20313|Astellas|Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)|Chronic constipation|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=0456-CL-1021|https://clinicaltrials.gov/ct2/show/NCT02425722|[C2000261]|[linaclotide]
20314|Astellas|Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -|Chronic constipation|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=0456-CL-1031|https://clinicaltrials.gov/ct2/show/NCT02809105|[C2000261]|[linaclotide]
20316|Novartis|Letrozole in the Treatment of Severe and Recurrent Endometriosis|Endometriosis|Phase 2|nan|https://clinicaltrials.gov/ct2/show/study/NCT00240942|[C0246421]|[letrozole]
20317|Novartis|An Extension Study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing- remitting multiple sclerosis|Relapsing Remitting Multiple Sclerosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16747|https://www.clinicaltrials.gov/ct2/show/NCT1185821?term=CBAF312A2201E1&rank=1|[C3657824]|[siponimod]
20318|Novartis|A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma|Renal cell carcinoma|Phase 1/2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17626|https://www.clinicaltrials.gov/ct2/show/NCT02014636|[C1831796]|[pazopanib]
20319|Novartis|A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney|Renal cell carcinoma|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11483|https://www.clinicaltrials.gov/ct2/show/NCT719264?term=CRAD001L2201&rank=1|[C1831796]|[pazopanib]
20320|Astellas|A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer|Prostate cancer|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0321|https://clinicaltrials.gov/ct2/show/NCT01302041|[C3496793]|[enzalutamide]
20321|Astellas|A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients from 5 to Less than 18 years of Age with Neurogenic Detrusor Overactivity (NDO)|Neurogenic detrusor overactivity|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=905-CL-047|https://clinicaltrials.gov/ct2/show/NCT01565694|[C1509436]|[solifenacin succinate]
20322|Astellas|A Phase 1 Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients with Advanced Solid Tumors|Solid tumors|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-102|https://clinicaltrials.gov/ct2/show/NCT00514306|[C2987649]|[Linsitinib]
20323|Astellas|A Phase 1 Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients with Advanced Solid Tumors|Solid tumors|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-101|https://clinicaltrials.gov/ct2/show/NCT00514007|[C2987649]|[Linsitinib]
20324|Astellas|A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination with Metformin Compared to Metformin Plus Placebo in Subjects in Russia with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-9001|https://clinicaltrials.gov/ct2/show/NCT02794792|[C3492889]|[ipragliflozin]
20325|Astellas|A phase 2, randomized, double-blind, placebo-controlled, parallel group, adaptive, combined proof of concept and dose-finding study to investigate efficacy, safety, pharmacodynamics and pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis|Bladder Pain|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=3652-CL-0018|https://clinicaltrials.gov/ct2/show/NCT01613586|[C5565723]|[ASP3652]
20326|Astellas|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis|Psoriasis|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-PS01|https://clinicaltrials.gov/ct2/show/NCT01096862|[C5418498]|[Peficitinib Hydrobromide]
20327|Astellas|A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors|Solid tumors|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-103|https://clinicaltrials.gov/ct2/show/NCT00739453|[C2987649]|[Linsitinib]
20328|Astellas|A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)|Ovarian cancer|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=OSI-906-202|https://clinicaltrials.gov/ct2/show/NCT00889382|[C2987649]|[Linsitinib]
20329|GSK|A randomized, double-blind, placebo-controlled, parallel group study of once-daily inhaled Fluticasone Furoate Inhalation Powder for six weeks on the hypothalamic-pituitary-adrenocortical axis of children aged 5-11 years with asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=107118|http://clinicaltrials.gov/show/NCT02483975|[C1948374]|[fluticasone furoate]
20330|GSK|A single centre, open label, one sequence, cross-over study to evaluate the effect of itraconazole on the pharmacokinetics of single inhaled doses of nemiralisib in healthy subjects|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=206874|http://clinicaltrials.gov/show/NCT03398421|[C5197976]|[Nemiralisib]
20343|GSK|A phase III study (a placebo controlled, randomized, double-blind comparative study and an open-label, uncontrolled study) to evaluate the efficacy and safety of GSK1358820 in patients with post-stroke upper limb spasticity|Spasticity, Post-Stroke|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207660|http://clinicaltrials.gov/show/NCT03261167|[C2719767]|[onabotulinumtoxinA]
20344|GSK|A single centre, single dose, open-label, randomized, 2-part, 2-way crossover study to determine the bioequivalence of levocetirizine oral disintegrating tablet given with water and without water compared to levocetirizine immediate release tablet in healthy Japanese male subjects|Rhinitis|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204706|http://clinicaltrials.gov/show/NCT03555890|[C1174893]|[levocetirizine]
20355|Novartis|A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma|Asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17395|https://www.clinicaltrials.gov/ct2/show/NCT02892344?term=CQVM149B2303&draw=2&rank=1|[C5433054, C0066700]|[Indacaterol acetate, mometasone furoate]
20356|Novartis|A multi-center, randomized, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma.|Asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17554|https://www.clinicaltrials.gov/ct2/show/NCT02554786?term=CQVM149B2301&draw=2&rank=1|[C5433054, C0066700]|[Indacaterol acetate, mometasone furoate]
20357|Novartis|A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma.|Asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15408|https://www.clinicaltrials.gov/ct2/show/NCT1845025?term=CFOR258D2416&rank=1|[C0771469]|[formoterol fumarate]
20359|Astellas|A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients with Overactive Bladder under Treatment with the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-MA-3016|https://clinicaltrials.gov/ct2/show/NCT02656173|[C2983812]|[mirabegron]
20360|Astellas|A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections|Invasive fungal infection|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=9766-CL-0105|https://clinicaltrials.gov/ct2/show/NCT00413218|[C4018470]|[isavuconazonium sulfate]
20361|ViiV|A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/en/study/?id=201479|http://clinicaltrials.gov/show/NCT02354950|[C4310385]|[cabotegravir]
20362|ViiV|A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Severe Renal Impairment and Healthy Matched Control Subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/en/study/?id=201480|http://clinicaltrials.gov/show/NCT02354937|[C4310385]|[cabotegravir]
20363|ViiV|Phase I, single-center, open label, fixed-sequence cross-over study to evaluate the effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/en/study/?id=205712|http://clinicaltrials.gov/show/NCT03149848|[C4310385]|[cabotegravir]
20364|ViiV|A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/en/study/?id=201584|http://clinicaltrials.gov/show/NCT02938520|[C4310385, C1566826]|[cabotegravir, rilpivirine]
20365|GSK|A randomized, examiner blind, crossover, in situ erosion study to investigate the efficacy of an experimental dentifrice in remineralization of previously softened enamel compared to a placebo dentifrice|Tooth Erosion|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=208166|http://clinicaltrials.gov/show/NCT03296072|[C0071772, C0037508]|[potassium nitrate, sodium fluoride]
20366|GSK|Study 110933: Albiglutide versus Placebo in insulin-treated Subjects with new-onset type 1 diabetes mellitus|Diabetes Mellitus, Type 1|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=110933|http://clinicaltrials.gov/show/NCT02284009|[C2607479]|[albiglutide]
20367|GSK|A 24 Week Randomised, Double blind and Placebo controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=117410|http://clinicaltrials.gov/show/NCT02184611|[C3709474]|[umeclidinium bromide]
20368|GSK|A Phase IIa Single-Center, Open-Label Study Evaluating the Pharmacokinetics of Repeat Oral Doses of Gepotidacin (GSK2140944) in Adult Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)|Infections, Bacterial|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=206899|http://clinicaltrials.gov/show/NCT03568942|[C4309999]|[gepotidacin]
20369|GSK|A single centre, single dose, open-label, randomised, 2-way crossover study in healthy Japanese male subjects to evaluate the bioequivalence of daprodustat tablets (2 mg tablet vs. 4 mg tablet) (Part 1) and the food effect on the pharmacokinetics of daprodustat (Part 2)|Anaemia|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207727|http://clinicaltrials.gov/show/NCT03493386|[C4519188]|[daprodustat]
20371|GSK|A double-blind (sponsor unblind), randomized, placebo-controlled, single and repeat escalating dose study to investigate the safety, tolerability, and pharmacokinetics of CCI15106 capsules for inhalation in healthy subjects and patients with moderate chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=202031|http://clinicaltrials.gov/show/NCT03243760|[C0035525]|[ribavirin]
20372|GSK|A randomized, open-label, cross-over, placebo inhaler study to evaluate the correct use of ELLIPTA™ dry powder inhaler (DPI) compared to DISKUS™ DPI used in combination with HandiHaler DPI in participants with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=206901|http://clinicaltrials.gov/show/NCT03227445|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20373|GSK|A double-blind (sponsor unblind), randomized, placebo-controlled, single and repeat escalating dose study to investigate the safety, tolerability, and pharmacokinetics of CCI15106 inhalation powder in healthy participants and participants with moderate chronic obstructive pulmonary disease (COPD) including evaluation of environmental and healthy by-stander exposure levels during dosing|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205822|http://clinicaltrials.gov/show/NCT03235726|[C0035525]|[ribavirin]
20374|GSK|A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled, repeat dose study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active plaque-type psoriasis|Psoriasis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=203167|http://clinicaltrials.gov/show/NCT02776033|[C5392621]|[GSK2982772]
20375|GSK|A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-303|http://clinicaltrials.gov/show/NCT00310375|[C0530684]|[ezogabine]
20377|Astellas|Safety and Efficacy of Mirabegron as Add-on Therapy in Patients with Overactive Bladder Treated with Solifenacin: A Postmarketing Open-label Study in Japan|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-110|https://clinicaltrials.gov/ct2/show/NCT01745094|[C2983812]|[mirabegron]
20378|Astellas|Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy with Antimuscarinics in Patients with Overactive Bladder Treated with Mirabegron|Urinary Bladder, Overactive|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-112|https://clinicaltrials.gov/ct2/show/NCT02294396|[C2983812]|[mirabegron]
20379|Novartis|A multi-national open-label phase II study of the JAK inhibitor INC424 in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis|Post-polycythemia vera myelofibrosis (PPV-MF)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17208|https://www.clinicaltrials.gov/ct2/show/NCT1392443?term=CINC424A2202&rank=1|[C2931926]|[ruxolitinib]
20380|Novartis|A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia|Postherpetic neuralgia (PHN)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17628|https://www.clinicaltrials.gov/ct2/show/NCT03094195?term=CEMA401A2201&rank=1|[C5420974]|[Olodanrigan]
20381|Novartis|A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE)|Diabetic Neuropathic Pain|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17613|https://www.clinicaltrials.gov/ct2/show/NCT03297294?term=CEMA401A2202&rank=1|[C5420974]|[Olodanrigan]
20382|ViiV|A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed|Infection, Human Immunodeficiency Virus|Phase 3|https://www.viiv-studyregister.com/en/study/?id=201585|http://clinicaltrials.gov/show/NCT02951052|[C4310385, C1566826]|[cabotegravir, rilpivirine]
20383|GSK|201546, A repeat-dose study of batefenterol/FF (GSK961081/GW685698) compared with placebo in the treatment of COPD|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201546|http://clinicaltrials.gov/show/NCT02573870|[C4519138, C1948374]|[batefenterol, fluticasone furoate]
20384|GSK|A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly with Raxibacumab (GSK3068483)|Infections, Bacterial|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201436|http://clinicaltrials.gov/show/NCT02339155|[C2717174]|[raxibacumab]
20385|GSK|A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects with Varying Degrees of Renal Impairment and in Matched Control Subjects with Normal Renal Function|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=116849|http://clinicaltrials.gov/show/NCT02729038|[C4309999]|[gepotidacin]
20386|GSK|An escalating dose, randomized, placebo-controlled, incomplete-block, 2-period cross-over study to assess the dose response for topical efficacy via airway responsiveness to adenosine-5'-monophosphate (AMP) challenge and the dose response for systemic activity via 24h plasma cortisol suppression and thereby the relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=203162|http://clinicaltrials.gov/show/NCT02991859|[C1948374, C0117996]|[fluticasone furoate, fluticasone propionate]
20387|GSK|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Obstetric Labour, Premature|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200719|http://clinicaltrials.gov/show/NCT02377466|[C2699069]|[Retosiban]
20388|GSK|A randomized, double-blind, Sponsor open, placebo-controlled, 52 week study evaluating the effect of danirixin (GSK1325756) on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205864|http://clinicaltrials.gov/show/NCT03170232|[C4519256]|[danirixin]
20389|GSK|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor|Obstetric Labour, Premature|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200721|http://clinicaltrials.gov/show/NCT02292771|[C2699069]|[Retosiban]
20390|GSK|An Exploratory Study to Measure the Effect of Two Dietary Fibers on Satiety and Glycemic Parameters|Nutritional supplement|nan|https://www.gsk-studyregister.com/en/trial-details/?id=W7781293|nan|[C0907858, C0070203]|[oligofructose, pectin]
20400|Astellas|A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate|Prostate cancer|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=9785-CL-0410|https://clinicaltrials.gov/ct2/show/NCT02116582|[C3496793]|[enzalutamide]
20565|Astellas|Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy|Diabetes Mellitus, Type 2|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=1941-MA-3054|https://clinicaltrials.gov/ct2/show/NCT02847091|[C3492889]|[ipragliflozin]
20566|Astellas|Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-0132|https://clinicaltrials.gov/ct2/show/NCT02291874|[C3492889]|[ipragliflozin]
20567|Astellas|Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 1 Diabetes Mellitus|Diabetes Mellitus, Type 1|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-6002|https://clinicaltrials.gov/ct2/show/NCT02897219|[C3492889]|[ipragliflozin]
20568|Astellas|Phase 2b Study of ASP015K – A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients –|Rheumatoid Arthritis|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ1|https://clinicaltrials.gov/ct2/show/NCT01649999|[C5418498]|[Peficitinib Hydrobromide]
20569|Astellas|Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs -|Rheumatoid Arthritis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ3|https://clinicaltrials.gov/ct2/show/NCT02308163|[C5418498]|[Peficitinib Hydrobromide]
20570|Astellas|Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX -|Rheumatoid Arthritis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ4|https://clinicaltrials.gov/ct2/show/NCT02305849|[C5418498]|[Peficitinib Hydrobromide]
20571|Astellas|A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea (The SUNSHINE Study)|Clostridium difficile infection|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=2819-CL-0202|https://clinicaltrials.gov/ct2/show/NCT02218372|[C0065023]|[fidaxomicin]
20572|Astellas|A randomized, placebo-controlled, double-blind, parallel group phase 2a study of ASP1707 in postmenopausal female patients with rheumatoid arthritis (RA) taking methotrexate (MTX)|Rheumatoid Arthritis|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=1707-CL-3001|https://clinicaltrials.gov/ct2/show/NCT02884635|[C5392742]|[ASP1707]
20573|Novartis|A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma|Melanoma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17627|https://clinicaltrials.gov/ct2/show/NCT01584648|[C3467876]|[dabrafenib]
20574|Novartis|A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|Melanoma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17634|https://www.clinicaltrials.gov/ct2/show/NCT01597908?term=CDRB436B2302&draw=2&rank=1|[C3467876]|[dabrafenib]
20575|Novartis|A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjoegren's syndrome|Sjoegren's syndrome|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17462|https://www.clinicaltrials.gov/ct2/show/NCT2291029?term=CCFZ533X2203&rank=1|[C4548814]|[CFZ533]
20588|GSK|A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery|Lung Injury, Acute and Respiratory Distress Syndrome, Adult|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116341|http://clinicaltrials.gov/show/NCT02221037|[C4279387]|[GSK2862277]
20589|GSK|A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232|Infection, Human Immunodeficiency Virus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205820|http://clinicaltrials.gov/show/NCT03234036|[C5196507]|[GSK-2838232]
20591|GSK|An open-label, low interventional clinical study investigating error rates (critical and overall) prior to any retraining in correct use of the ELLIPTA dry powder inhaler (DPI) compared to other DPIs including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a monotherapy or in combination, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=204981|http://clinicaltrials.gov/show/NCT03114969|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20592|GSK|A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powder inhaler, versus placebo, in participants with asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205832|http://clinicaltrials.gov/show/NCT03012061|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20593|GSK|Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205724|http://clinicaltrials.gov/show/NCT03034967|[C4519256]|[danirixin]
20594|GSK|A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=207608|http://clinicaltrials.gov/show/NCT03478683|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20595|GSK|A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=207609|http://clinicaltrials.gov/show/NCT03478696|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20601|Novartis|A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload|Myelodysplastic syndrome (MDS)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17377|https://www.clinicaltrials.gov/ct2/show/NCT940602?term=CICL670A2302&rank=1|[C1619629]|[deferasirox]
20602|Novartis|A phase IIIb, multi-center, open-label study of RAD001 in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer|Breast cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17560|https://www.clinicaltrials.gov/ct2/show/NCT03176238?term=CRAD001JIC06&rank=1|[C0541315]|[everolimus]
20603|Novartis|A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy|Breast cancer|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17400|https://www.clinicaltrials.gov/ct2/show/NCT00263588?term=CLAP016A2202&draw=2&rank=1|[C1506770]|[lapatinib]
20604|Novartis|A Phase IIIB open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving letrozole as adjuvant therapy.|Breast cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4424|https://www.clinicaltrials.gov/ct2/show/NCT171340?term=CFEM345D2405&rank=1|[C0246421]|[letrozole]
20605|Novartis|An open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy|Breast cancer|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4923|https://www.clinicaltrials.gov/ct2/show/NCT171314?term=CFEM345D2406&rank=1|[C0246421]|[letrozole]
20606|Novartis|A randomized study of the JAK inhibitor INC424 tablets compared to best available therapy in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)|Myelofibrosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4843|https://www.clinicaltrials.gov/ct2/show/NCT934544?term=CINC424A2352&rank=1|[C2931926]|[ruxolitinib]
20607|Novartis|Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase|Chronic myeloid leukemia (CML)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14265|https://www.clinicaltrials.gov/ct2/show/NCT1254188?term=CAMN107E2401&rank=1|[C1721377]|[nilotinib]
20608|Novartis|ENESTChina: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in Chinese adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)|Chronic myeloid leukemia (CML)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14123|https://www.clinicaltrials.gov/ct2/show/NCT1275196?term=CAMN107ECN02|[C1721377]|[nilotinib]
20609|Novartis|A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph positive) chronic myelogenous leukemia in chronic phase (CML-CP).|Chronic myeloid leukemia (CML)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8504|https://www.clinicaltrials.gov/ct2/show/NCT471497?term=CAMN107A2303&rank=1|[C1721377]|[nilotinib]
20610|Novartis|phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec® (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies.|Chronic myeloid leukemia (CML)|Phase 1/2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9963|https://www.clinicaltrials.gov/ct2/show/NCT109707?term=CAMN107A2101&rank=1|[C1721377]|[nilotinib]
20611|Novartis|An expanded access protocol of imatinib mesylate in patients with chronic myeloid leukemia who are hematologically or cytogenetically resistant or refractory to, or intolerant of interferon-alpha|Chronic myeloid leukemia (CML)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1653|https://www.clinicaltrials.gov/ct2/show/NCT00006053?term=CSTI5710113&lead=novartis&draw=2&rank=1|[C0939537]|[imatinib mesylate]
20620|Novartis|A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer|Breast cancer|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17179|https://www.clinicaltrials.gov/ct2/show/NCT1923168?term=CBYL719A2201&rank=1|[C4055478]|[alpelisib]
20621|Novartis|A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma|Uncontrolled asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17579|https://www.clinicaltrials.gov/ct2/show/NCT03215758?term=CQAW039A2316&rank=1|[C4076895]|[fevipiprant]
20622|Novartis|A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF¿ agents (CAIN457F2302) and a three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis (CAIN457F2302E1)|Rheumatoid arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14947|https://www.clinicaltrials.gov/ct2/show/NCT1377012?term=CAIN457F2302%2FCAIN457F2302E1&rank=1|[C3179547]|[secukinumab]
20722|GSK|Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study|Diabetes Mellitus, Type 2|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200977|http://clinicaltrials.gov/show/NCT02229227|[C2607479]|[albiglutide]
20724|GSK|A single center, two part, randomized, open label cross-over study to evaluate the effect of itraconazole and rifampicin on the pharmacokinetics of GSK525762 in healthy female subjects of non child bearing potential|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204946|http://clinicaltrials.gov/show/NCT02706535|[C4682384]|[molibresib]
20725|GSK|A 2-part randomized, double-blind (sponsor-unblinded), placebo-controlled, ascending dose and parallel group study of TLR4 agonist (GSK1795091) administered to healthy subjects|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204685|http://clinicaltrials.gov/show/NCT02798978|[C4287760]|[TLR4 agonist GSK1795091]
20727|Astellas|An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-blind Study|Mycoses|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=9463-EC-0002|https://clinicaltrials.gov/ct2/show/NCT01122368|[C1120386]|[micafungin]
20728|Astellas|An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|Non-small cell lung cancer|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=8273-CL-0101|https://clinicaltrials.gov/ct2/show/NCT02192697|[C5237985]|[Naquotinib Mesylate]
20729|Astellas|An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors|Solid tumors|Phase 1|https://www.clinicaltrials.astellas.com/study/?pid=5878-CL-0101|https://clinicaltrials.gov/ct2/show/NCT02038673|[C4053679]|[ASP5878]
20730|Astellas|A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin|Diabetes Mellitus, Type 2|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=1941-CL-2009|https://clinicaltrials.gov/ct2/show/NCT02452632|[C3492889]|[ipragliflozin]
20731|Astellas|A Randomized, Double-Blind, Placebo-Control, Multicenter Clinical Trial evaluating the Efficacy and Safety of Tacrolimus Capsules in the Treatment of Myasthenia Gravis Patients with Inadequate Response to Glucocorticoid Therapy|Myasthenia gravis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=F506-CL-0611|https://clinicaltrials.gov/ct2/show/NCT01325571|[C0085149]|[tacrolimus]
20736|Novartis|Assessment of Real-Life Care - Describing European Heart Failure Management|Heart Failure|Phase 4|nan|nan|[C4033447, C0216784]|[sacubitril, valsartan]
20737|GSK|A 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study to evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are currently ESA users|Anaemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201754|http://clinicaltrials.gov/show/NCT02969655|[C4519188]|[daprodustat]
20738|GSK|A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with overactive bladder|Urinary Bladder, Overactive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=204947|http://clinicaltrials.gov/show/NCT02820844|[C2719767]|[onabotulinumtoxinA]
20740|GSK|A Clinical Study to Assess the Local Cutaneous and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females with Sensitive Skin|Skin Care|nan|https://www.gsk-studyregister.com/en/trial-details/?id=209442|http://clinicaltrials.gov/show/NCT03640832|[C0017861]|[glycerin]
20741|Novartis|A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care|Heart Failure|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17381|https://www.clinicaltrials.gov/ct2/show/NCT02807857?term=CLCZ696B3402&draw=2&rank=1|[C4033447, C0216784]|[sacubitril, valsartan]
20742|GSK|Implementation of a screening tool for subjects with benign prostatic enlargement/obstruction to identify men >=50 years presenting in General Practice with other co-morbidities who should be assessed for BPH|Prostatic Hyperplasia|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=116114|http://clinicaltrials.gov/show/NCT02757963|[C0754659, C0257343]|[dutasteride, tamsulosin]
20743|GSK|A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years with Allergic Rhinitis|Rhinitis, Allergic, Perennial and Seasonal|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201492|http://clinicaltrials.gov/show/NCT02424539|[C1948374]|[fluticasone furoate]
20744|GSK|A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201755|http://clinicaltrials.gov/show/NCT02504671|[C4731002]|[Otilimab]
20745|GSK|A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205180|http://clinicaltrials.gov/show/NCT02799472|[C4731002]|[Otilimab]
20746|GSK|A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis|Osteoarthritis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=204851|http://clinicaltrials.gov/show/NCT02683785|[C4731002]|[Otilimab]
20747|GSK|A Multicenter, Placebo-Controlled, Parallel-Design, Dose-Response Evaluation of the Safety and Efficacy of Lamotrigine as Add-On Therapy in Epileptic Outpatients with Partial Seizures|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=P42-05|nan|[C0064636]|[lamotrigine]
20748|GSK|A Multicenter, Double-Blind, Placebo-Controlled, Add-On, Crossover Study of Lamotrigine in Epileptic Outpatients with Partial Seizures|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=P42-06|nan|[C0064636]|[lamotrigine]
20749|GSK|A Multicenter, Placebo-Controlled Parallel-Design, Phase III Evaluation of the Safety of Lamotrigine (LAMICTAL) as Add-On Therapy in Outpatients with Partial Seizures|Epilepsy|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=P42-16|nan|[C0064636]|[lamotrigine]
20752|Novartis|A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Concept1 or Twisthaler® in adult and adolescent patients with persistent asthma|Asthma|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12184|https://www.clinicaltrials.gov/ct2/show/NCT1555151?term=CQMF149E2201&rank=1|[C1722260, C0066700]|[indacaterol, mometasone furoate]
20756|Astellas|A multi-center, randomized, open-label, pilot and exploratory study investigating safety and efficacy in OPTIMIZEd dosing of Advagraf® kidney transplantation in Asia.|Prevention of rejection after organ transplant|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=506-MA-1001|https://clinicaltrials.gov/ct2/show/NCT02161237|[C0085149]|[tacrolimus]
20757|Astellas|An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg|Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=HAURO-1201-TW|https://clinicaltrials.gov/ct2/show/NCT02180789|[C0771774]|[tamsulosin hydrochloride]
20758|Novartis|Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion|SMA - Spinal Muscular Atrophy|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17657|https://www.clinicaltrials.gov/ct2/show/NCT03306277?term=AVXS101CL303&rank=1|[C5140521]|[onasemnogene abeparvovec-xioi]
20760|Novartis|A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy|Asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5323|https://www.clinicaltrials.gov/ct2/show/NCT01007149?term=NCT01007149&draw=2&rank=1|[C0966225]|[omalizumab]
20761|Novartis|A 24-week, Phase III randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of Xolair® (omalizumab) in patients with moderate to severe persistent allergic asthma who remain not adequately controlled despite GINA (2009) Step 4 therapy|Persistent Asthma|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT1202903?term=CIGE025A2313&rank=1|[C0966225]|[omalizumab]
20762|GSK|A randomised, double-blind, placebo-controlled, parallel group, 8-week treatment study to investigate the safety, pharmacodynamics, and effect of the TLR7 agonist, GSK2245035, on the allergen-induced asthmatic response in subjects with mild allergic asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=205540|http://clinicaltrials.gov/show/NCT02833974|[C4079591]|[GSK2245035]
20764|GSK|Randomized double blind (sponsor unblind) study evaluating the effect of 14 days of treatment with danirixin (GSK1325756) on neutrophil extracellular traps (NETs) formation in participants with stable chronic obstructive pulmonary disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=207551|http://clinicaltrials.gov/show/NCT03250689|[C4519256]|[danirixin]
20765|GSK|An open-label study to evaluate correct use and ease of use of the ELLIPTA Dry Powder Inhaler (DPI) in pediatric patients currently receiving inhaled therapy for treatment of their asthma|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=206924|http://clinicaltrials.gov/show/NCT03478657|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
20766|GSK|A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab|Systemic Lupus Erythematosus|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115467|http://clinicaltrials.gov/show/NCT01705977|[C1723401]|[belimumab]
20767|GSK|A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=205715|http://clinicaltrials.gov/show/NCT02924688|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20768|GSK|A randomised, placebo-controlled, double-blind (sponsor open), segmental LPS challenge study to investigate the pharmacodynamics of GSK2798745 in healthy participants|Healthy Volunteers|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207464|http://clinicaltrials.gov/show/NCT03511105|[C5226839]|[GSK2798745]
20773|Eisai|An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects|Epilepsy|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT02427607|[C2698764]|[perampanel]
20774|Eisai|A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients|Lennox-Gastaut Syndrome|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT01146951|[C0213404]|[rufinamide]
20775|Eisai|A Long Term Extension Study of E2080 in Lennox-Gastaut Patients|Lennox-Gastaut Syndrome|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT01151540|[C0213404]|[rufinamide]
20776|Eisai|Phase II Clinical Study of E7389 for Locally Advanced or Metastatic Breast Cancer|Breast Cancer|Phase 2|not available|not available|[C2608038]|[eribulin mesylate]
20777|Eisai|Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer|Breast Cancer|Phase 2|not available|https://www.clinicaltrials.gov/ct2/show/NCT00965523|[C2608038]|[eribulin mesylate]
20778|Eisai|A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|Breast Cancer|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT00337103|[C2608038]|[eribulin mesylate]
20779|Eisai|"The ""EMBRACE"" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus ""Treatment of Physician's Choice"" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane"|Breast Cancer|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT00388726|[C2608038]|[eribulin mesylate]
20780|Eisai|An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane|Breast Cancer|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT02225470|[C2608038]|[eribulin mesylate]
20781|Eisai|A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Phase 2|not available|https://www.clinicaltrials.gov/ct2/show/NCT02481050|[C2608038]|[eribulin mesylate]
20782|Eisai|The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia|Dementia With Parkinson’s Disease|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT00165815|[C0527316]|[donepezil]
20783|Eisai|Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II|Dementia with Lewy bodies|Phase 2|not available|https://www.clinicaltrials.gov/ct2/show/record/NCT00543855|[C0527316]|[donepezil]
20784|Eisai|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase|Dementia with Lewy bodies|Phase 3|not available|https://www.clinicaltrials.gov/ct2/show/NCT01278407|[C0527316]|[donepezil]
20785|Eisai|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures|Refractory Partial Seizures|Phase 2|not available|https://www.clinicaltrials.gov/ct2/show/NCT00416195|[C2698764]|[perampanel]
20788|Eisai|An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)|Metastatic Triple-Negative Breast Cancer|Phase 2|not available|https://www.clinicaltrials.gov/ct2/show/NCT02513472|[C2608038]|[eribulin mesylate]
20789|GSK|A double-blind (sponsor unblinded) study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in cutaneous lupus erythematosus patients|Lupus Erythematosus, Cutaneous|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=204860|http://clinicaltrials.gov/show/NCT02927457|[C5198173]|[GSK2646264]
20790|GSK|An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor control|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=207040|http://clinicaltrials.gov/show/NCT03380429|[C1948374, C2935023]|[fluticasone furoate, vilanterol]
20791|GSK|A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants with Varying Degrees of Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117352|http://clinicaltrials.gov/show/NCT03562117|[C4309999]|[gepotidacin]
20792|GSK|Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/03/019|nan|[C0070122]|[paroxetine]
20793|GSK|An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/028/184|nan|[C0070122]|[paroxetine]
20794|GSK|A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/032|nan|[C0070122]|[paroxetine]
20795|GSK|An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study).|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/043|nan|[C0070122]|[paroxetine]
20796|GSK|A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/049|nan|[C0070122]|[paroxetine]
20797|GSK|Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression|Depressive Disorder|Phase 3|nan|nan|[C0070122]|[paroxetine]
20798|GSK|Study comparing the effects of oral Paroxetine and Amitriptyline in adult patients with depression|Depressive Disorder|Phase 3|nan|nan|[C0070122]|[paroxetine]
20799|GSK|Paroxetine in the treatment of depression – a randomised comparison with amitriptyline.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/260|nan|[C0070122]|[paroxetine]
20800|GSK|A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline|Depressive Disorder, Major|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/292|nan|[C0070122]|[paroxetine]
20801|GSK|Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily|Depressive Disorder|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=29060/318|nan|[C0070122]|[paroxetine]
20804|GSK|A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent.|Depressive Disorder|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=29060/109|nan|[C0070122]|[paroxetine]
20805|GSK|A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease|Anaemia|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201753|http://clinicaltrials.gov/show/NCT02791763|[C4519188]|[daprodustat]
20808|GSK|A Two Part, Randomized, Open-label, Cross over Study in Healthy Elderly Participants to Evaluate the Relative Bioavailability of Hydrobromide Salt Tablet Formulations of Danirixin in the Fed and Fasted States, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets|Pulmonary Disease, Chronic Obstructive|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207573|http://clinicaltrials.gov/show/NCT03457727|[C4519256]|[danirixin]
20811|Novartis|A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (Extension 1: 2002-2004 and Extension 2: 2004-2013).|Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ ALL)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12844|https://www.clinicaltrials.gov/ct2/show/NCT00171223?term=CSTI571+0110&lead=novartis&draw=2&rank=1|[C0939537]|[imatinib mesylate]
20812|Novartis|A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (Extension 1: 2002-2004 and Extension 2: 2004-2013).|Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ ALL)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12844|nan|[C0939537]|[imatinib mesylate]
20813|Novartis|A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)|Chronic myeloid leukemia (CML)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12064|https://www.clinicaltrials.gov/ct2/show/NCT171249|[C0939537]|[imatinib mesylate]
20814|Novartis|A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)|Chronic myeloid leukemia (CML)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12064|https://www.clinicaltrials.gov/ct2/show/NCT171249|[C0939537]|[imatinib mesylate]
20815|Novartis|A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)|Chronic myeloid leukemia (CML)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11563|https://www.clinicaltrials.gov/ct2/show/NCT171158|[C0939537]|[imatinib mesylate]
20816|Novartis|A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)|Chronic myeloid leukemia (CML)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11563|https://www.clinicaltrials.gov/ct2/show/NCT171158|[C0939537]|[imatinib mesylate]
20817|Novartis|A phase III study of imatinib versus interferon-¿ (IFN-¿) combined with cytarabine (Ara-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).|Chronic myeloid leukemia (CML)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=8244|https://www.clinicaltrials.gov/ct2/show/NCT00333840?term=CSTI571A0106&rank=1|[C0939537]|[imatinib mesylate]
20818|Novartis|A randomized Phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment¿ the EVOLVE-1 Study|Hepatocellular carcinoma (HCC)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12664|https://www.clinicaltrials.gov/ct2/show/NCT1035229?term=CRAD001O2301&rank=1|[C0541315]|[everolimus]
20819|Novartis|BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain|Melanoma|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17326|https://clinicaltrials.gov/ct2/show/NCT02039947?term=BRF117277&draw=2&rank=1|[C3467876, C2697961]|[dabrafenib, trametinib]
20820|Novartis|An Open-Label, Dose-Escalation, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma|Metastatic melanoma|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17378|nan|[C3467876, C2697961]|[dabrafenib, trametinib]
20821|Novartis|Placebo-controlled prospective randomized study on the antiproliferative efficacy of octreotide in patients with metastasized neuroendocrine tumors of the midgut (PROMID).|Neuroendocrine Tumors (NET)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10003|https://www.clinicaltrials.gov/ct2/show/NCT171873?term=CSMS995ADE05&rank=1|[C0028833]|[octreotide]
20822|Novartis|Phase 3, Open Label, Single Arm, Single Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion|SMA - Spinal Muscular Atrophy|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17805|https://www.clinicaltrials.gov/ct2/show/NCT03461289?term=AVXS101CL302&rank=1|[C5140521]|[onasemnogene abeparvovec-xioi]
20826|ViiV|A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants|Infection, Human Immunodeficiency Virus|Phase 1|https://www.viiv-studyregister.com/en/study/?id=207187|http://clinicaltrials.gov/show/NCT03231943|[C5772748]|[GSK3640254]
20827|GSK|A multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis|Arthritis, Rheumatoid|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=203168|http://clinicaltrials.gov/show/NCT02858492|[C5392621]|[GSK2982772]
20829|Novartis|An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.|Renal cell carcinoma (RCC)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=14929|https://www.clinicaltrials.gov/ct2/show/NCT903175?term=CRAD001L2202&rank=1|[C0541315]|[everolimus]
20830|Novartis|Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration|Wet age related macular degeneration (AMD)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17631|https://www.clinicaltrials.gov/ct2/show/NCT01304693?term=C+10+083&rank=1|[C4550124]|[brolucizumab]
20831|Novartis|Efficacy and Safety Study of ESBA1008 Versus EYLEA|Wet age related macular degeneration (AMD)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17620|https://www.clinicaltrials.gov/ct2/show/NCT01796964?term=c-12-006&draw=2&rank=1|[C4550124]|[brolucizumab]
20832|Novartis|A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration|Wet age related macular degeneration (AMD)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17621|https://www.clinicaltrials.gov/ct2/show/NCT01849692?term=c+13+001|[C4550124]|[brolucizumab]
20833|Novartis|A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration|Neovascular Age-Related Macular Degeneration|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16628|https://www.clinicaltrials.gov/ct2/show/NCT02507388?term=RTH258E003&rank=1|[C4550124]|[brolucizumab]
20834|Novartis|A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration|Neovascular Age-Related Macular Degeneration|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17623|https://www.clinicaltrials.gov/ct2/show/NCT02307682?term=CRTH258A2301&draw=2&rank=2|[C4550124]|[brolucizumab]
20835|Novartis|A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in subjects with neovascular age-related macular degeneration who have completed the CRTH258A2301 study|Neovascular Age-Related Macular Degeneration|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17632|nan|[C4550124]|[brolucizumab]
20836|Novartis|A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration|Neovascular Age-Related Macular Degeneration|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17360|https://www.clinicaltrials.gov/ct2/show/NCT02434328?term=RTH258C002|[C4550124]|[brolucizumab]
20837|Novartis|A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises, (SUSTAIN)|Sickle cell disease|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17571|https://www.clinicaltrials.gov/ct2/show/NCT01895361|[C4524703]|[crizanlizumab]
20838|Novartis|A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma.|asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17650|https://www.clinicaltrials.gov/ct2/show/NCT02555683?term=CQAW039A2307&rank=1|[C4076895]|[fevipiprant]
20839|Novartis|A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe Asthma.|asthma|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17580|https://www.clinicaltrials.gov/ct2/show/NCT02563067?term=CQAW039A2314&rank=1|[C4076895]|[fevipiprant]
20843|GSK|The effectiveness of Asthma Control Test guided treatment compared with usual care in China adult asthma patients|Asthma|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=201097|http://clinicaltrials.gov/show/NCT02868281|[C0117996, C0073992]|[fluticasone propionate, salmeterol]
20844|GSK|The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=206854|http://clinicaltrials.gov/show/NCT03467425|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20845|GSK|A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps - SYNAPSE (StudY in NAsal Polyps patients to assess the Safety and Efficacy of mepolizumab)|Polyps, Nasal|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=205687|http://clinicaltrials.gov/show/NCT03085797|[C0969324]|[mepolizumab]
20846|GSK|A two-part healthy volunteer study to investigate both the interaction of GSK2586184 with rosuvastatin and simvastatin and to compare the pharmacokinetics of two different formulations of GSK2586184.|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117171|http://clinicaltrials.gov/show/NCT01953835|[C4726763]|[Solcitinib]
20849|GSK|A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with urinary incontinence due to neurogenic detrusor overactivity|Urinary Bladder, Overactive|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=204948|http://clinicaltrials.gov/show/NCT02849418|[C2719767]|[onabotulinumtoxinA]
20850|GSK|A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=200879|http://clinicaltrials.gov/show/NCT03345407|[C5197976]|[Nemiralisib]
20851|GSK|A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in participants with chronic obstructive pulmonary disease|Pulmonary Disease, Chronic Obstructive|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=207626|http://clinicaltrials.gov/show/NCT03474081|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20852|GSK|A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis|Gastroparesis|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=114479|http://clinicaltrials.gov/show/NCT01262898|[C4519144]|[Camicinal]
20853|Astellas|Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K|Rheumatoid Arthritis|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=015K-CL-RAJ2|https://clinicaltrials.gov/ct2/show/NCT01638013|[C5418498]|[Peficitinib Hydrobromide]
20854|Astellas|An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)|Neurogenic detrusor overactivity|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=178-CL-206A|https://clinicaltrials.gov/ct2/show/NCT02751931|[C2983812]|[mirabegron]
20855|Novartis|A three-arm, randomized, open label, Phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole|Breast Cancer|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17393|https://www.clinicaltrials.gov/ct2/show/NCT1783444?term=CRAD001Y2201&rank=1|[C0541315]|[everolimus]
20856|Novartis|An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancre-atic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy.|Pancreatic neuroendocrine tumor (PNET)|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4563|https://www.clinicaltrials.gov/ct2/show/NCT363051?term=CRAD001C2239&rank=1|[C0541315]|[everolimus]
20857|Novartis|A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or San-dostatin LAR® Depot and placebo|Carcinoid tumor|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4723|https://www.clinicaltrials.gov/ct2/show/NCT412061?term=CRAD001C2325&rank=1|[C0541315]|[everolimus]
20858|Novartis|A randomized double-blind phase III study of everolimus 10 mg/d plus best supportive care (BSC) versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuro-endocrine tumor (NET)|Pancreatic neuroendocrine tumor (PNET)|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4703|https://www.clinicaltrials.gov/ct2/show/NCT510068?term=CRAD001C2324&rank=1|[C0541315]|[everolimus]
20859|GSK|A randomised, double-blind (sponsor unblinded), placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116678|https://www.clinicaltrials.gov/ct2/show/NCT02294734|[C5197976]|[Nemiralisib]
20860|GSK|A randomised double blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneous urticaria subjects to investigate safety, tolerability, pharmacodynamics and pharmacokinetics of topically applied GSK2646264|Urticaria|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200196|https://www.clinicaltrials.gov/ct2/show/NCT02424799|[C5198173]|[GSK2646264]
20861|GSK|A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).|Pulmonary Disease, Chronic Obstructive|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=201928|https://www.clinicaltrials.gov/ct2/show/NCT02522299|[C5197976]|[Nemiralisib]
20862|GSK|A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=115471|https://www.clinicaltrials.gov/ct2/show/NCT01632241|[C1723401]|[belimumab]
20863|GSK|A three part, non-randomised, open label study designed to assess the pharmacokinetics of GSK2982772 following administration of minitab modified release formulations in a capsule relative to an immediate release reference tablet formulation (Part A), the pharmacokinetics of escalating, repeat doses of a selected minitab modified release prototype (Part B), and the pharmacokinetics of GSK2982772 following administration of modified release tablet formulations in the fed and fasted state (Part C) in healthy participants|Autoimmune Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=205017|https://www.clinicaltrials.gov/ct2/show/NCT03266172|[C5392621]|[GSK2982772]
20867|GSK|A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects with Advanced Her3-Positive Solid Tumors|"Cancer|Neoplasms"|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117158|http://clinicaltrials.gov/show/NCT01966445|[C3827121]|[GSK2849330]
20868|GSK|A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma (201810)|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=201810|http://clinicaltrials.gov/show/NCT02555371|[C0969324]|[mepolizumab]
20869|GSK|An observer-blind, dose ranging safety and immunogenicity study of GSK Biologicals’ GSK1557484A vaccine in children 6 to less than 36 months of age|Influenza|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=116938|http://clinicaltrials.gov/show/NCT02719743|[C3179804]|[GSK 1557484A]
20870|GSK|A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients with Asthma|Asthma|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=207236|http://clinicaltrials.gov/show/NCT03184987|[C1948374, C2935023, C3709474]|[fluticasone furoate, vilanterol, umeclidinium bromide]
20877|Novartis|A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of secukinumab monotherapy compared with adalimumab monotherapy in patients with active psoriatic arthritis|Psoriatic arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17780|https://www.clinicaltrials.gov/ct2/show/NCT02745080?term=CAIN457F2366&rank=1|[C3179547]|[secukinumab]
20878|Novartis|A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer|Cancer|Phase 2|nan|https://www.clinicaltrials.gov/ct2/show/NCT01336634?term=cdrb436e2201&draw=2&rank=1|[C3467876]|[dabrafenib]
20880|Novartis|A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma|Melanoma|Phase 3|nan|https://www.clinicaltrials.gov/ct2/show/NCT01245062?term=114267&draw=2&rank=1|[C2703095]|[GSK 1120212]
20882|Novartis|A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab 300 mg as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis|Moderate to severe scalp psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15507|https://www.clinicaltrials.gov/ct2/show/NCT2267135?term=CAIN457AUS01&rank=1|[C3179547]|[secukinumab]
20883|Novartis|A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients  70 years (drug-naïve or inadequately controlled on oral agents)|Type 2 Diabetes|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT1257451?term=CLAF237A23150&rank=1|[C1570906]|[vildagliptin]
20884|Novartis|A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus|Type 2 Diabetes|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT1224366?term=CLAF237A23135&rank=1|[C1570906]|[vildagliptin]
20885|Novartis|A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure|Type 2 Diabetes|Phase 4|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT894868?term=CLAF237A23118&rank=1|[C1570906]|[vildagliptin]
20886|Novartis|A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes|Type 2 Diabetes|Phase 2/3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT860288?term=CLAF237B2224&rank=1|[C1570906]|[vildagliptin]
20887|Novartis|A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency|Type 2 Diabetes|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT765830?term=CLAF237A23137E1&rank=1|[C1570906]|[vildagliptin]
20888|Novartis|A multi-center, randomized, double-blind, clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency|Type 2 Diabetes|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT646542?term=CLAF237A23137&rank=1|[C1570906]|[vildagliptin]
20889|Novartis|A Multi-center, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients with Type 2 Diabetes|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2652|https://www.clinicaltrials.gov/ct2/show/NCT383578?term=CLAF237A2398&rank=1|[C1570906]|[vildagliptin]
20891|Novartis|A multicenter, randomized, double-blind, active controlled study to compare the long-term effect of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2649|https://www.clinicaltrials.gov/ct2/show/NCT106340?term=CLAF237A2308&rank=1|[C1570906]|[vildagliptin]
20892|Novartis|A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type 2 diabetes|Type 2 Diabetes|Phase 3|https://www.novctrd.com/|https://www.clinicaltrials.gov/ct2/show/NCT102388?term=CLAF237A2310&rank=1|[C1570906]|[vildagliptin]
20893|Novartis|A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2274|https://www.clinicaltrials.gov/ct2/show/NCT99944?term=CLAF237A2305&rank=1|[C1570906]|[vildagliptin]
20894|Novartis|A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug-naive patients with type 2 diabetes|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2282|https://www.clinicaltrials.gov/ct2/show/NCT99918?term=CLAF237A2327&rank=1|[C1570906]|[vildagliptin]
20895|Novartis|A multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetes.|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2275|https://www.clinicaltrials.gov/ct2/show/NCT99866?term=CLAF237A2309&rank=1|[C1570906]|[vildagliptin]
20896|Novartis|A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy|Type 2 Diabetes|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2851|https://www.clinicaltrials.gov/ct2/show/NCT102466?term=CLAF237A2338&rank=1|[C1570906]|[vildagliptin]
20902|GSK|A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi^TM ) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Neoplasms|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200331|http://clinicaltrials.gov/show/NCT02215096|[C3827123]|[GSK2636771]
20903|GSK|Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies|Obstetric Labour, Premature|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200722|http://clinicaltrials.gov/show/NCT02292784|[C2699069]|[Retosiban]
20904|GSK|A placebo-controlled, double-blind (sponsor open), randomized, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough|Cough|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=207702|http://clinicaltrials.gov/show/NCT03372603|[C5226839]|[GSK2798745]
20906|GSK|A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis.|Colitis, Ulcerative|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=202152|http://clinicaltrials.gov/show/NCT02903966|[C5392621]|[GSK2982772]
20908|GSK|A Phase IIa, open-label, non-randomized, controlled, mono-center study to evaluate the efficacy, immunogenicity and safety of a fractional (Fx) booster dose of GlaxoSmithKline Biologicals’ malaria candidate vaccine RTS,S/AS01E when given to healthy adults subjects previously receiving various primary dose schedules in a sporozoite challenge model.|Malaria|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=209003|http://clinicaltrials.gov/show/NCT03824236|[C5565453]|[SB257049]
20909|GSK|An open-label, randomized, parallel group, single dose study to investigate the PK and safety of belimumab 200 mg intravenous and 200 mg subcutaneous via auto-injector in Chinese healthy participants.|Systemic Lupus Erythematosus|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=209629|http://clinicaltrials.gov/show/NCT04136145|[C1723401]|[belimumab]
20919|GSK|A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=117351|http://clinicaltrials.gov/show/NCT02853435|[C4309999]|[gepotidacin]
20920|GSK|A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants|Infections, Bacterial|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=209611|http://clinicaltrials.gov/show/NCT04079790|[C4309999]|[gepotidacin]
20925|Grunenthal|Open-label evaluation of the population pharmacokinetic profile, safety,  tolerability, and efficacy of intravenous tapentadol solution for injection for the  treatment of post-surgical pain in children aged from birth to less than  2 years, including preterm neonates.|Moderate to severe acute post-operative pain|Phase 2|https://www.grunenthal.com/en/research-and-development/clinical-trials/data-clinical-trials|nan|[C2001271]|[tapentadol]
20926|Grunenthal|Open-label investigation of the pharmacokinetic profile, safety, tolerability, and efficacy of multiple administrations of tapentadol oral solution used for treatment of acute pain in children aged 2 years to less than 7 years.|Moderate to severe acute pain|Phase 2|https://www.grunenthal.com/en/research-and-development/clinical-trials/data-clinical-trials|nan|[C2001271]|[tapentadol]
20927|Novartis|A Multi-centre 3-year Follow-up Study to Assess the Viral Activity in Patients Who Failed to Achieve Sustained Virologic Response in Novartis-sponsored Alisporivir-studies for Chronic Hepatitis C Patients|Hepatitis C, Chronic|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13785|https://www.clinicaltrials.gov/ct2/show/NCT2465203?term=CDEB025A2313&rank=1|[C1567950]|[alisporivir]
20929|Astellas|ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients with Prostate Cancer -|Prostate Cancer|Phase 2|https://www.clinicaltrials.astellas.com/study/?pid=3550-CL-0009|https://clinicaltrials.gov/ct2/show/NCT01261572|[C2718533]|[degarelix acetate]
20930|Astellas|Phase III Study of ASP3550 – An Open-label, Goserelin Acetate-controlled, Parallel Group Study in Patients with Prostate Cancer –|Prostate Cancer|Phase 3|https://www.clinicaltrials.astellas.com/study/?pid=3550-CL-0010|https://clinicaltrials.gov/ct2/show/NCT01964170|[C2718533]|[degarelix acetate]
20940|Novartis|A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)|Alzheimers Disease|Phase 2/3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17821|https://www.clinicaltrials.gov/ct2/show/NCT02565511?term=CAPI015A2201J&draw=2&rank=1|[C4305639]|[CAD106]
20941|Novartis|A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)|Alzheimers Disease|Phase 2/3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17811|https://www.clinicaltrials.gov/ct2/show/NCT03131453?term=CCNP520A2202J&draw=2&rank=1|[C4742765]|[CNP520]
20942|Astellas|Postmarketing clinical study on enzalutamide —a randomized phase 4 study comparing enzalutamide versus flutamide in castration-resistant prostate cancer patients who have failed combined androgen blockade therapy with bicalutamide plus androgen deprivation therapy—|Prostate Cancer|Phase 4|https://www.clinicaltrials.astellas.com/study/?pid=9785-MA-3051|https://clinicaltrials.gov/ct2/show/NCT02918968|[C3496793]|[enzalutamide]
20943|GSK|A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and other cancers|Carcinoma, Midline|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=115521|http://clinicaltrials.gov/show/NCT01587703|[C4682384]|[molibresib]
20944|GSK|An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects with Plasmodium vivax Malaria|Malaria, Vivax|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=113577|http://clinicaltrials.gov/show/NCT02563496|[C0903411]|[tafenoquine]
20945|GSK|A multi-centre, one-arm prospective study to evaluate efficacy and safety of switching from Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese chronic hepatitis B HBeAg-positive and HBV-DNA undetectable subjects|Hepatitis B, Chronic|Phase 4|https://www.gsk-studyregister.com/en/trial-details/?id=205883|http://clinicaltrials.gov/show/NCT03258710|[C1099776]|[tenofovir disoproxil fumarate]
20988|GSK|A randomised, double-blind (sponsor open), placebo-controlled, three part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (in both fed and fasted states) or repeat doses of GSK3358699 in healthy male participants|Arthritis, Rheumatoid|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=207546|http://clinicaltrials.gov/show/NCT03426995|[C0216231]|[sargramostim]
20990|GSK|A two part, non-randomised, open label study designed to assess the pharmacokinetic profile of modified release prototype coated tablet formulations of GSK2982772 relative to an immediate release reference tablet formulation at a fixed strength (Part A) and the pharmacokinetic profile of alternative tablet strengths of the selected modified release prototype coated tablet formulation (Part B, optional) in healthy participants|Autoimmune Diseases|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=209261|http://clinicaltrials.gov/show/NCT03649412|[C5392621]|[GSK2982772]
20991|GSK|An open label, randomized, balanced, three treatment, three period, three sequence, single dose, crossover study to evaluate the bioequivalence of test Griseofulvin tablets, 500 mg versus reference Griseofulvin tablets, 500 mg as well as dose proportionality of test Griseofulvin tablets, 250 mg and 500 mg, in healthy, adult participants under fed conditions|Antifungal Agents|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=212504|http://clinicaltrials.gov/show/NCT04318535|[C0018242]|[griseofulvin]
20993|ViiV|A Phase 3b multi-center, open label, single arm, 52-week study, evaluating the feasibility, efficacy and safety of rapid Test and Treat intervention in newly diagnosed HIV-1 infected adults using a fixed dose combination of dolutegravir plus lamivudine (DOVATO) as a first line regimen|HIV Infections|Phase 3|https://www.viiv-studyregister.com/en/study/?id=212355|http://clinicaltrials.gov/show/NCT03945981|[C3253985, C0209738]|[dolutegravir, lamivudine]
20994|ViiV|An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=209712|http://clinicaltrials.gov/show/NCT03816696|[C5772748]|[GSK3640254]
20995|ViiV|An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=208134|http://clinicaltrials.gov/show/NCT03836729|[C5772748]|[GSK3640254]
20996|ViiV|The Effect of Coadministration of GSK3640254 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=208135|http://clinicaltrials.gov/show/NCT03984825|[C5772748]|[GSK3640254]
21004|Novartis|Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)|Psoriatic Arthritis|Phase 3|https://www.clinicaltrials.gov/ct2/show/NCT02404350?term=CAIN457F2342&draw=2&rank=1|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17160|[C3179547]|[secukinumab]
21005|ViiV|An Open-label, Randomized, Single dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine versus Dolutegravir and Lamivudine single entities and Food Effect Assessment in Healthy Volunteers|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=204994|http://clinicaltrials.gov/show/NCT03078556|[C3253985, C0209738]|[dolutegravir, lamivudine]
21006|ViiV|A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability Study of Both TIVICAY 10 mg Conventional Tablets and 5 mg Dispersible Tablets Compared to Conventional TIVICAY Tablets in Healthy Adult Subjects|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=205893|http://clinicaltrials.gov/show/NCT03095638|[C3253985]|[dolutegravir]
21007|ViiV|A Phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=204993|http://clinicaltrials.gov/show/NCT02738931|[C3253985, C0209738]|[dolutegravir, lamivudine]
21008|ViiV|A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=205894|http://clinicaltrials.gov/show/NCT03441984|[C3253985, C0663655, C0209738]|[dolutegravir, abacavir, lamivudine]
21009|GSK|An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects|Systemic Lupus Erythematosus|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=116027|http://clinicaltrials.gov/show/NCT02119156|[C1723401]|[belimumab]
21018|Novartis|Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16967|https://www.clinicaltrials.gov/ct2/show/NCT01961609?term=CAIN457AGB01&draw=2&rank=1|[C3179547]|[secukinumab]
21019|Novartis|Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis|Chronic Plaque Psoriasis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5686|https://www.clinicaltrials.gov/ct2/show/NCT00805480?term=CAIN457A2212&draw=2&rank=1|[C3179547]|[secukinumab]
21020|Novartis|Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16207|https://www.clinicaltrials.gov/ct2/show/NCT02559622?term=CAIN457ADE02&draw=2&rank=1|[C3179547]|[secukinumab]
21021|Novartis|Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)|Chronic Plaque Psoriasis|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17337|https://www.clinicaltrials.gov/ct2/show/NCT02690701?term=CAIN457AUS02&draw=2&rank=1|[C3179547]|[secukinumab]
21022|Novartis|Study of Secukinumab With 2 mL Pre-filled Syringes (ALLURE)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17438|https://www.clinicaltrials.gov/ct2/show/NCT02748863?term=CAIN457A2323&draw=2&rank=1|[C3179547]|[secukinumab]
21023|Novartis|Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Plaque Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17567|https://www.clinicaltrials.gov/ct2/show/NCT03066609?term=CAIN457A2318&draw=2&rank=1|[C3179547]|[secukinumab]
21024|Novartis|Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)|Plaque Psoriasis|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17605|https://www.clinicaltrials.gov/ct2/show/NCT03055494?term=CAIN457AUS07&draw=2&rank=1|[C3179547]|[secukinumab]
21025|Novartis|Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque-type Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17825|https://www.clinicaltrials.gov/ct2/show/NCT03504852?term=CAIN457A2324&draw=2&rank=1|[C3179547]|[secukinumab]
21026|Novartis|Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)|Plaque Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17850|https://www.clinicaltrials.gov/ct2/show/NCT03589885?term=CAIN457A2325&draw=2&rank=1|[C3179547]|[secukinumab]
21027|Novartis|Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)|Psoriasis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16347|https://www.clinicaltrials.gov/ct2/show/NCT02474082?term=CAIN457ADE06&draw=2&rank=1|[C3179547]|[secukinumab]
21028|Novartis|Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)|Carcinoma, Renal Cell|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17919|https://www.clinicaltrials.gov/ct2/show/NCT00720941?term=CPZP034A2301&draw=2&rank=1|[C1831796]|[pazopanib]
21029|GSK|Phase III randomized, open controlled, multicenter study to evaluate the immunogenicity and safety of the RTS,S/AS01E candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9 months of age with or without co-administration of measles and rubella and yellow fever vaccines to children living in sub-Saharan Africa|Malaria|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=200596|http://clinicaltrials.gov/show/NCT02699099|[C5565453]|[SB257049]
21031|GSK|A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia|Leukaemia, Myelocytic, Acute|Phase 1|https://www.gsk-studyregister.com/en/trial-details/?id=200200|http://clinicaltrials.gov/show/NCT02177812|[C3827120]|[GSK2879552]
21033|Teva|A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine|Episodic Migraine Headache|Phase 2|Not available|https://clinicaltrials.gov/ct2/show/NCT02025556|[C4549503]|[fremanezumab]
21034|Teva|Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine|Migraine|Phase 3|Not available|https://ClinicalTrials.gov/show/NCT02629861|[C4549503]|[fremanezumab]
21035|Teva|Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine|Migraine|Phase 3|Not available|https://ClinicalTrials.gov/show/NCT02638103|[C4549503]|[fremanezumab]
21036|Teva|A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose|Relapse-Remitting Multiple Sclerosis|Phase 2|Not available|https://clinicaltrials.gov/ct2/show/NCT00202982|[C0289884]|[glatiramer acetate]
21037|Teva|Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA)|Relapsing Remitting Multiple Sclerosis|Phase 3|Not available|https://www.clinicaltrials.gov/ct2/show/NCT00337779?term=NCT00337779&draw=2&rank=1|[C0289884]|[glatiramer acetate]
21038|Teva|Safety and Tolerability of Glatiramer Acetate (GLACIER)|Relapsing-Remitting Multiple Sclerosis|Phase 3|Not available|https://www.clinicaltrials.gov/ct2/show/NCT01874145?term=NCT01874145&draw=2&rank=1|[C0289884]|[glatiramer acetate]
21039|Teva|A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)|Relapsing Remitting Multiple Sclerosis|Phase 3|Not available|https://www.clinicaltrials.gov/ct2/show/NCT01067521?term=NCT01067521&draw=2&rank=1|[C0289884]|[glatiramer acetate]
21040|Teva|Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)|Multiple Sclerosis|Phase 4|Not available|https://www.clinicaltrials.gov/ct2/show/NCT02499900?term=NCT02499900&draw=2&rank=1|[C0289884]|[glatiramer acetate]
21041|Teva|Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma|Eosinophilic Asthma|Phase 3|Not available|https://clinicaltrials.gov/ct2/show/NCT01508936|[C1869620]|[reslizumab]
21042|Novartis|Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)|Non-radiographic Spondyloarthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17673|https://www.clinicaltrials.gov/ct2/show/NCT02696031?term=CAIN457H2315&draw=2&rank=1|[C3179547]|[secukinumab]
21043|Novartis|SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (SKIPPAIN)|Spondyloarthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17563|https://www.clinicaltrials.gov/ct2/show/NCT03136861?term=CAIN457H3301&draw=2&rank=1|[C3179547]|[secukinumab]
21044|Novartis|A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)|Hypercholesterolemia|Phase 1|nan|https://www.clinicaltrials.gov/ct2/show/NCT02314442?term=ALN-PCSSC-001&draw=2&rank=1|[C4307388]|[inclisiran]
21045|Novartis|Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)|Atherosclerosis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17575|https://www.clinicaltrials.gov/ct2/show/NCT01327846?term=CACZ885M2301&draw=2&rank=2|[C2718773]|[canakinumab]
21047|Novartis|An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder|Bipolar I Disorder|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2549|https://www.clinicaltrials.gov/ct2/show/NCT00238485?term=CLIC477D2302E1&draw=2&rank=1|[C1567854]|[Licarbazepine]
21048|Novartis|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|Bipolar Disorder|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2471|https://www.clinicaltrials.gov/ct2/show/NCT00107939?term=CLIC477D2302&draw=2&rank=2|[C1567854]|[Licarbazepine]
21053|Novartis|A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma|Melanoma|Phase 3|https://www.gsk-clinicalstudyregister.com/study/113683?search=study&search_terms=BRF113683|https://www.clinicaltrials.gov/ct2/show/NCT01227889?term=BRF113683&rank=1|[C3467876]|[dabrafenib]
21056|ViiV|An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men|HIV Infections|Phase 1|https://www.viiv-studyregister.com/en/study/?id=206898|http://clinicaltrials.gov/show/NCT03422172|[C4310385]|[cabotegravir]
21057|Novartis|Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD|Chronic Obstructive Pulmonary Disease (COPD)|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17180|https://www.clinicaltrials.gov/ct2/show/NCT02603393?term=CQVA149A2316&draw=2&rank=1|[C2920417, C4082411]|[indacaterol maleate, Glycopyrronium Bromide]
21058|Novartis|Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)|Chronic Obstructive Pulmonary Disease (COPD)|Phase 4|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13550|https://www.clinicaltrials.gov/ct2/show/NCT01555138?term=CQAB149B2401&draw=2&rank=1|[C1722260]|[indacaterol]
21059|Novartis|Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer|Metastases, Brain|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17404|https://www.clinicaltrials.gov/ct2/show/NCT00820222?term=111438&draw=2&rank=1|[C1506770, C0671970]|[lapatinib, capecitabine]
21064|Novartis|RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)|Retinopathy of Prematurity|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17138|https://www.clinicaltrials.gov/ct2/show/NCT02375971?term=CRFB002H2301&draw=2&rank=2|[C1566537]|[ranibizumab]
21065|Novartis|Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)|Heart Failure With Preserved Ejection Fraction|Phase 3|Microsoft Word - Clinical_Trials_Results_Word_Form-CLCZ696D2301_02Jun2020.doc (novctrd.com)|https://www.clinicaltrials.gov/ct2/show/NCT01920711?term=CLCZ696D2301&draw=2&rank=2|[C4033447, C0216784]|[sacubitril, valsartan]
21066|ViiV|A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy|HIV Infections|Phase 3|https://www.viiv-studyregister.com/en/study/?id=200304|http://clinicaltrials.gov/show/NCT02227238|[C3253985]|[dolutegravir]
21068|Novartis|16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)|Anklyosing Spondylitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17535|https://www.clinicaltrials.gov/ct2/show/NCT01649375?term=CAIN457F2310&draw=2&rank=1|[C3179547]|[secukinumab]
21069|Novartis|16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)|Spondylitis, Ankylosing|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17263|https://www.clinicaltrials.gov/ct2/show/NCT02008916?term=CAIN457F2314&draw=2&rank=1|[C3179547]|[secukinumab]
21070|Novartis|Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)|Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17822|https://www.clinicaltrials.gov/ct2/show/NCT03031782?term=CAIN457F2304&draw=2&rank=1|[C3179547]|[secukinumab]
21071|ViiV|A qualitative hybrid III implementation study to identify and evaluate strategies for successful implementation of the cabotegravir + rilpivirine long-acting injectable regimen in the US|HIV Infections|Phase 3|https://www.viiv-studyregister.com/en/study/?id=209493|http://clinicaltrials.gov/show/NCT04001803|[C4310385]|[cabotegravir]
21073|ViiV|A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed|HIV Infections|Phase 3|https://www.viiv-studyregister.com/en/study/?id=204862|https://clinicaltrials.gov/ct2/show/NCT03446573|[C3253985, C0209738]|[dolutegravir, lamivudine]
21074|GSK|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis|Lupus Nephritis|Phase 3|https://www.gsk-studyregister.com/en/trial-details/?id=114054|https://clinicaltrials.gov/ct2/show/NCT01639339|[C1723401]|[belimumab]
21075|GSK|A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma|Asthma|Phase 2|https://www.gsk-studyregister.com/en/trial-details/?id=207597|https://clinicaltrials.gov/ct2/show/NCT03207243|[C5421171]|[melrilimab]
21084|Novartis|A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients|Multiple Sclerosis|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17710|https://www.clinicaltrials.gov/ct2/show/NCT03560739?term=COMB157G2102&draw=2&rank=1|[C1832027]|[ofatumumab]
21085|Novartis|Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)|Relapsing Multiple Sclerosis|Phase 3|Microsoft Word - COMB157G2301_NovCTR_20Jul2021_Final_for_Approval 1 (novctrd.com)|https://www.clinicaltrials.gov/ct2/show/NCT02792218?term=COMB157G2301&draw=2&rank=1|[C1832027]|[ofatumumab]
21086|Novartis|Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)|Relapsing Multiple Sclerosis|Phase 3|Microsoft Word - COMB157G2302_NovCTR_Final_21_Oct_2021 final version (novctrd.com)|https://www.clinicaltrials.gov/ct2/show/NCT02792231?term=COMB157G2302&draw=2&rank=1|[C1832027]|[ofatumumab]
21087|Novartis|Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)|Corticosteroid Refractory Acute Graft vs Host Disease|Phase 3|Microsoft Word - CTR_CINC424C2301_Final_22Oct2021 (003).docx (novctrd.com)|https://www.clinicaltrials.gov/ct2/show/NCT02913261?term=CINC424C2301&draw=2&rank=1|[C2931926]|[ruxolitinib]
21088|Novartis|Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)|B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia|Phase 2|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=16690|https://www.clinicaltrials.gov/ct2/show/NCT02228096?term=CCTL019B2205J&draw=2&rank=1|[C3640939]|[tisagenlecleucel]
21090|Astellas|Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation|Prevention of rejection after organ transplant|Phase 4|https://www.clinicaltrials.astellas.com/study/IDTX-MA-3004/|https://clinicaltrials.gov/ct2/show/NCT02723591|[C0085149]|[tacrolimus]
21100|Novartis|16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)|Anklyosing Spondylitis|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17259|https://www.clinicaltrials.gov/ct2/show/NCT02159053?term=CAIN457F2320&draw=2&rank=1|[C3179547]|[secukinumab]
21103|Novartis|A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease|Alzheimer's Disease|Phase 3|https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11845|https://www.clinicaltrials.gov/ct2/show/NCT01399125?term=CENA713D2344&draw=2&rank=1|[C0649350]|[rivastigmine]
21104|Ono|A multicenter, randomized, open-label, docetaxel- or paclitaxel-controlled study to evaluate the efficacy and safety of ONO-4538 in patients with esophageal cancer refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs.|Esophageal cancer|Phase 3|Not available|https://clinicaltrials.gov/show/NCT02569242|[C3657270]|[nivolumab]
